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General Introduction 
The use of cytotoxic agents (i.e. chemical compounds capable of killing cells) is a core 
component of pharmacological approaches for the therapy of cancer. Ideally, cytotoxic agents 
should preferentially kill tumor cells while sparing healthy tissue. In practice, the scenario is 
much more complex: many anticancer drugs inhibit cells in rapid proliferation and thus act 
against healthy tissues, in which they accumulate. This drawback typically results in severe 
side-effects, limiting therapeutic benefits. 
Different approaches to overcome the drawbacks of traditional chemotherapy have been 
investigated so far, pointing at the selective delivery of cytotoxic agents to cancer cells. This 
goal has been pursued by improving the tumor accumulation of anticancer drugs through their 
covalent conjugation to specific ligands (antibodies or ‘small molecules’) of tumor-associated 
receptors. While Antibody-Drug Conjugates (ADCs) represent a mature technology, which has 
already reached the market, increasing research efforts have been recently put into Small 
Molecule-Drug Conjugates (SMDCs), which have the potential advantage of better 
pharmacokinetic properties and more sustainable preparation. 
One of the tumor receptors that has been studied as target for SMDCs is integrin αVβ3 (a 
heterodimeric transmembrane glycoprotein), owing to its high expression in the tumor 
neovasculature as well as on the surface of several tumor cells. Thus, in this PhD thesis, the 
synthesis of new SMDCs targeting αvβ3 integrin is described. The structure of such SMDCs 
consists in the connection of three core components: i) LIGAND - the cyclo[DKP-RGD] 
peptidomimetic, developed by the Gennari and Piarulli group, has been used as integrin-
targeting moiety in all the new constructs; ii) CYTOTOXIC PAYLOAD - three different cytotoxic 
agents (i.e. paclitaxel, monomethyl auristatin E and monomethyl auristatin F) have been 
included as anticancer drugs; iii) LINKER - specific functional groups (i.e. peptides) have been 
used to connect the drug and ligand, aiming at the selective drug release in the intra or 
extracellular tumor environment. 
These new SMDCs have been subjected to a panel of biochemical and biological assays, for 
the assessment of both their structural features (e.g. stability, cleavage experiments of the 
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linkers, kinetics of drug release, etc.) and biological activity (e.g. affinity for the purified integrin 
αVβ3 receptor, selective cytotoxicity against αvβ3-expressing or non-expressing cells, etc.). 
Thus, the main structure of the present PhD thesis is reported here: 
• Chapter I provides a general overview of the tumor-targeting research area through an 
in-depth survey of the most relevant and recent literature in the field. The contribution 
of our group in the field is also reported here.  
• Chapter II describes the development of a new library of multimeric cyclo[DKP-RGD]-
PTX conjugates (monomeric, dimeric, trimeric and tetrameric conjugates) bearing 
lysosomally-cleavable linkers and their full biological in vitro evaluation. The results 
achieved with these first compounds prompted the design of next-generation 
cyclo[DKP-RGD]-PTX conjugates, reported in the following chapters. 
• Chapter III describes the synthesis and in vitro evaluation of cyclo[DKP-RGD]-PTX 
conjugates bearing extracellularly-cleavable peptide linkers, capable of releasing the 
payload in the tumor microenvironment, rather than inside cancer cells: this mechanism 
can be promoted by tumor-associated enzymes present in the tumor stroma (e.g. 
elastase), which can efficiently cleave the linker and set the drug free to diffuse within 
the tumor mass. 
• Chapter IV consists in the development of a small library of conjugates containing the 
cyclo[DKP-RGD] ligand, a lysosomally-cleavable peptide linker and the highly potent 
toxins monomethyl auristatin E or F (MMAE and MMAF) as the cytotoxic payloads, 
which are state-of-the-art tools for targeted anticancer therapy. 
• Finally, all the experimental details of synthetic and biological procedures are included 
in Experimental Section, together with spectroscopic data and HPLC profiles of the 
newly synthesized compounds. 
   
 
 
Chapter I 
Drug Targeting to Cancer 
 
  
 
DRUG TARGETING TO CANCER 
1.1 General Introduction 
Cancer is one of the main causes of human mortality and morbidity in both developed and 
developing countries.[1] As stated by the World Health Organization (WHO), approximately 14 
million new incidences and 8.2 million cancer-related deaths were reported in 2014, affecting 
populations in all continents (Figure 1). The number of incidences is expected to increase to 
22 million within the next two decades. Among the world population, the most common 
identified cancer types were lung, breast, colon/rectum, liver, prostate and stomach (Figure 
1).[2] Cancer is triggered by complex processes, which are directly connected to the alteration 
of a fundamental process of life, i.e. cell division (mitosis). Cancer might be induced by down 
and/or upregulation of endogenous molecules, being characterized by uncontrolled cell growth 
and fast proliferation properties leading to tumor formation. 
 
Figure 1. Estimated world cancer incidences and mortality proportions by WHO, in both genders, 2014.[1] 
Treatment of cancer has been one of the key goals of medicine and medicinal chemistry 
research. Combinations of surgery, radiotherapy and chemotherapy interventions remain the 
backbone of cancer treatment. The traditional pharmaceutical approaches consist on the 
administration of small cytotoxic molecules aimed at stopping the rapid cell proliferation and 
inducing apoptosis by interfering with fundamental cellular functions (e.g. DNA replication, cell 
division).[3] 
Cytotoxic agents are commonly classified on the basis of their biological targets:[4,5] 
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• DNA-targeting groups:[6] these class of compounds are divided into DNA-alkylating agents 
(e.g. mechlorethamine, chlorambucil, Figure 2) and DNA metalating agents (e.g. cisplatin, 
oxaliplatin, picoplatin, Figure 2). DNA-alkylating agents are known as a class of compounds 
that directly modify DNA bases, forming crosslinks in DNA or intercalating between bases. 
Developed as a derivative of nitrogen mustard gas, Mechlorethamine (1, Figure 2) can be 
considered the first compound of such class to be evaluated as anticancer agent: it is a 
bifunctional alkylating agent, containing electrophilic residues, which react with guanine 
bases on the DNA sequence.  
On the other hand, DNA-metalating agents are described as a panel of molecules 
containing Pt(II)-complexes, capable of irreversibly crosslink DNA strands, upon reaction 
with N7-position of guanine bases. 
• Antimetabolites and Nucleoside analogs: this group of anticancer drugs consists on 
synthetic variants of endogenous fundamental building blocks, which interfere with the 
elongation of DNA strands (e.g. thioguanine, 5-fluoruracil, gemcitabine, Figure 2). 
• Anti-folates:[6,7] This class consists of inhibitors of crucial enzymes involved in the synthesis 
of DNA and its precursors. Methotrexate and pemetrexed (see Figure 2) are the most 
representative examples of this class. Their mechanism of action involves the inhibition of 
DHFR (dihydrofolate reductase) preventing the formation of tetrahydrofolate, an essential 
intermediate of purine and pyrimidine biosynthesis. Particularly, interferences with FH4 
(tetrahydrofolate cofactors - series of the reduced form of folate) metabolism hamper 
important biochemical processes, such as methylation reactions, that essential for the 
biosynthesis of purine ribonucleotides and thymidine monophosphate (TMP). 
• Topoisomerase Inhibitors:[6] this class of anticancer drugs interferes with DNA synthesis 
by inhibiting topoisomerase I and II. These enzymes are involved in crucial steps of the 
DNA structure organization. Topoisomerase I permits the passage of single DNA strands 
through a temporary single-strand break, originated in the complementary strand of the 
double helix. Topoisomerase II cleaves both double helix strands to allow the passage of a 
complete helix to the supercoiled DNA (unwind form). For example, camptothecin (11, 
Figure 2) and its analogs stabilize the DNA-topoisomerase I cleavable complex, thus 
inhibiting the rejoin step of DNA. On the other hand, topoisomerase II is one of the targets 
of Anthracyclines antibiotics (e.g. doxorubicin, daunorubicin, epirubicin and idarubicin, 
Figure 2), which are known to intercalate DNA leading to cell death.[8] 
• Antimitotic drugs:[9] this class of cytotoxic agents interfere with microtubule dynamics, 
which are crucial in the mitosis process. Microtubule destabilizing agents, such as Vinca 
Alkaloids (e.g. Vinblastine and Vincristine, Figure 2), inhibit tubulin polymerization, thus 
blocking the formation of microtubules. By contrast, Taxanes (e.g. Paclitaxel and Docetaxel, 
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Figure 2) are the most known microtubule-stabilizing agents, which also trigger apoptosis 
in highly-proliferating cells. These drugs, inhibit tubulin depolymerization, thus blocking the 
formation of free tubulin. 
 
Figure 2. Molecular structures of selected conventional chemotherapeutics divided by different groups. 
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In general, the systemic administration of traditional anticancer agents does not result in the 
selective drug accumulation to the diseased tissue. In fact, these compounds can interact with 
healthy cells, leading to considerable side effects (low molecular-weight cytotoxic drugs do not 
preferentially accumulate in solid tumors)[10] and preventing the administration of anticancer 
drugs to doses that are high enough to be effective.[11] This low accumulation of 
chemotherapeutics at the tumor site can be ascribed to different factors, such as the increased 
interstitial pressure in several solid tumors and the rapid elimination from systemic circulation 
of small molecule drugs, which eventually accumulate in excreting organs (e.g. liver and 
kidney).[12] 
Studies in mice have shown that injection of paclitaxel (PTX),[13] or doxorubicin (DOX)[14] led to 
poor tumor accumulation compared to the amount of injected drug detected in healthy organs 
such as liver and lung (1:10 – 1:20, after organ weight normalization). The same trend has 
been observed in human patients treated with a bolus injection of 11C-docetaxel: the product 
did not show any significant accumulation in the hepatic tumor.[15] 
Another drawback is the so-called drug resistance, which heavily affects the chemotherapy 
efficacy. In particular, due to their high heterogenicity and mutation rates, tumor cells can be 
considered as rapidly changing targets. A certain population of cancer cells may be less 
affected by the treatment and it can then overgrow, leading to a drug-resistant tumor mass.[16]  
 
Figure 3. Molecular structures and mechanism of action of some potent cytotoxic agents used in chemotherapy. 
As consequence of all these facts, traditional anticancer agents are characterized by a small 
“therapeutic window”, which is commonly described as the difference between the lowest 
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administered dose resulting to clinical benefits (minimum effective dose, MED) and the highest 
dose found to be free of undesired toxicities (maximum tolerated dose, MTD). To overcome 
the drawbacks mentioned above, multidrug therapy was one of the first approaches tried by 
the clinic.[12] Unlikely, severe side-effects were observed in patients. During the past three 
decades, efforts have been done to discover new more potent small anticancer agents with 
improved anticancer efficacy. A wide range of new anticancer drugs have been discovered 
from natural sources and developed as anticancer agents (Figure 3). New DNA- and RNA-
targeting agents (e.g. derivatives of calicheamicin, indolinobenzodiazepines and α-amanitin) 
and tubulin-targeting molecules (e.g. cryptophycins, maytansinoids, dolastatins) were found to 
inhibit cell proliferation at the picomolar and subnanomolar range.[17,18,19,20,21,22] However, most 
of these new cytotoxic molecules showed harsh side effects at low administration doses, 
indicating that the increased potency does not extend the therapeutic window of systemic 
cytotoxics. As a result, these ultrapotent cytotoxic agents were discontinued from the clinic at 
early stages, unveiling the need for new pharmacologic approaches. 
1.2. Targeted Therapies for Cancer 
The selective delivery of cytotoxic agents at the tumor site is still a major concern to improve 
current chemotherapy outcome. Regarding this issue, targeted delivery approaches rely on 
the ability of specific molecular constructs to selectively accumulate at the diseased site, 
improving the therapeutic window of cytotoxic agents. A particular group of such molecules 
(e.g. micelles, liposomes, polymers, nanoparticles and macromolecules) can have tumor-topic 
activity (i.e. the ability to passively accumulate into solid tumors).[12] The so-called EPR 
(Enhanced Permeability and Retention) effect has been described as the main mechanism of 
action of these large molecules , which take advantage of the absence of lymphatic drainage 
and the leakage of tumor vasculature.[23] For example, different types of nanoparticles have 
been used to encapsulate cytotoxic agents, with the aim to force drug accumulation within the 
tumor vasculature, following different mechanisms of action.[24] However, clinical success of 
nanomedicine has been limited so far to pegylated (Doxil™) and non-pegylated (Myocet™) 
liposomal forms of doxorubicin for the treatment of metastatic ovarian cancer, liposome-
encapsulated daunorubicin (DaunoXome™) for the treatment of leukemia, and albumin-based 
paclitaxel (Abraxane™) for the treatments of breast cancer.[25]  
On the contrary, active drug targeting systems use ligands (e.g. monoclonal antibodies, small 
molecule ligands such as vitamins, peptides or peptidomimetics) directed against specific 
tumor antigens (i.e. particular proteins showing predominant expression in tumors, located 
either on the surface of cancer cells, or in the tumor stroma or vasculature, see Fig. 4).[26] 
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Typically, one or more cytotoxic drugs are 
covalently attached to the targeting ligand through 
a specific linkers. Such systems will be hereafter 
referred to as ligand-drug conjugates. These 
conjugates are generally administered 
systemically to patients and the efficient 
extravasation (i.e. the migration from the 
circulation to the tissues) is fundamental for the 
conjugate to reach and bind the tumor antigen. 
Ideally, the binding leads to the selective 
conjugate accumulation in the diseased tissue 
expressing the target antigen, (Fig. 4), whereas in 
healthy tissues, binding does not occur and the 
conjugate is cleared quickly. Upon ligand binding, 
it has previously been described that target 
antigen-conjugate complexes must internalize into 
the diseased cells (i.e. internalization of the conjugate through receptor-mediated 
endocytosis).[20,27] The modified intracellular environment (e.g. lysosomal proteases, 
endosomal reducing agents, lowered pH) would then trigger the linker cleavage and the 
release of the cytotoxic cargo.[28] By contrast, other approaches have been investigated, where 
the drug release takes place in the extracellular space (i.e. “non-internalizing” tumor targeting). 
In this strategy, the drug can later act against tumor cells and other cellular targets (e.g. tumor 
endothelial cells or tumor cells with low antigen expression) by passive diffusion.[29] 
 
Figure 5. Strategy for the optimization of the therapeutic index of anticancer ligand-drug constructs.[30] 
A variety of ligand-drug conjugates have been successfully developed to treat cancer 
according to these strategies. Generally, by combining a homing device (e.g. antibodies or 
small molecule ligands) with an active drug, it is possible to locally increase the concentration 
of the anticancer drug, thus decreasing the dose-limiting toxicities and improving the overall 
Figure 4. Active drug targeting approach. A 
ligand-drug conjugate (green-yellow-red) diffuses 
to the tumor stroma and interacts with its tumor-
associated antigen. After internalization, the smart 
linker (yellow) between the ligand (green) and 
drug (red) is intracellularly cleaved, releasing its 
cytotoxic drug. Adapted from[20]  
  
11 Drug Targeting to Cancer 
therapeutic index of the drug (Figure 5).[30] As a result, while some of these constructs have 
already reached the market, others can be considered as promising technologies for future 
oncology. 
1.3 Antibody-Drug Conjugates (ADCs) 
1.3.1. Antibodies – an overview 
Antibodies, also known as immunoglobulins (Igs), are endogenous-occurring proteins 
biosynthesized by plasma cells and B-lymphocytes in mammals.[31] Antibodies can bind with 
high affinity and selectivity to virtually any kind of antigen, expressed in viruses, bacteria, 
cancer cells or other disease-causing organisms. In the context of immune response, 
antibodies play two main functions: 1) recognition (i.e. specific binding and blockade of 
pathogen molecules), and 2) recruitment of humoral immune components (e.g. complement 
proteins) and cellular immune components (e.g. cytotoxic T-lymphocytes or phagocytes 
activation for the release of cytokines and interaction with the antigen of interest) with the goal 
of destroying the pathogen.[31] 
1.3.2. From Discovery to Development 
In 1890, Emil von Behring and Kitasato Shibasaburo described a “molecule” that could 
neutralize diphtheria infection in the blood stream. Hence, rats, rabbits and pigs were 
immunized with attenuated forms of the infectious molecules causing diphtheria. Then, the 
serum produced by these animals was later injected in non-immunized animals that had 
previously been infected with diphtheria bacterium: all animals recovered from the infection.[32] 
Some years after, in 1987, Paul Ehrlich developed the concept of “magic bullets” (i.e. 
antibodies), being secreted on the cell membrane surface of immune system in response to 
“strange” antigens.[33] Such “magic bullets” would only attack specific pathogens (e.g. viruses, 
bacteria). During the decade of 1940, Linus Pauling proved that the theory of Paul Ehrlich was 
correct, fully describing the way of interaction between an antibody and the recognized antigen 
(i.e. lock-and-key theory). In 1976, Susumu Tonegawa showed the first rearrangement of Ig 
genes, being the key role for the development of sequence diversity in antibodies.[34] In 1975, 
Georges Köhler and César Milstein developed the hybridoma technology,[35] which allowed the 
synthesis of large amounts of a single-purified monoclonal antibody (mAb). The hybridoma 
technology made possible the specific targeting of a single epitope of the antigen of interest, 
which was then a springboard to the clinical use of mAbs as therapeutic agents for cancer and 
other indications. Therefore, antibody-based constructs are one of the largest and fastest 
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growing family of drugs, putting pressure on the development of new targeted anticancer 
molecules. 
1.3.3. Antibody Engineering and Structure 
A typical mAb molecule features a Y-shaped structure, which carries two similar peptidic heavy 
(H) and light (L) chains (Figure 6A). Both heavy (~50 kDa) and light (~25 kDa) chains are 
connected by an intramolecular disulfide bond and heterodimerized by non-covalent 
interactions. Two copies of heterodimers are covalently linked at the level of the heavy chains 
by two extra disulfide bonds at the hinge region, leading to a full antibody structure of ~150 
kDa. Each chain is known to be composed by a variable domain at its N-terminus (VL and VH 
for the light and heavy chain, respectively), which is responsible for antigen biding, and one or 
more C-terminus constant domains (CL and CH for the light and heavy chain, respectively). 
Finally, the general Y-shape of mAbs is divided into Fab (antigen recognition) and Fc (effector) 
domains. The latter is glycosylated at a conserved Asn 297 amino acid residue.[26] 
 
Figure 6. Antibody general structure and evolution of antibody engineering. A. Mouse antibody; B. Chimeric 
antibody; C. Humanized antibody; D. Human antibody. The mAb subdomains are reported. Fab: Fragment antigen-
binding; Fc: fragment crystallizable domain; VH: heavy-chain variable; VL: light-chain variable; CH: heavy-chain 
constant; CL: light-chain constant.[26] 
While the enormous therapeutic potential of mAbs became evident since the early discovery, 
a considerable limitation was identified when murine antibodies showed severe 
immunogenicity in humans. Moreover, murine mAbs show low binding to human Fc receptors 
(i.e. receptor found on the cell surface of, for example, B-lymphocytes and macrophages), 
resulting in inefficient effector functions and leading to fast clearance (Figure 6A). To overcome 
these limitations, advances in recombinant DNA techniques made possible the modification of 
the mAb structure, allowing the generation of engineered mAbs containing human sequences. 
In other words, the variable domains of a murine mAb are installed onto the constant domains 
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of a human mAb, forming the “chimeric antibodies” (Figure 6B). Thus, immunogenic response 
is reduced and stronger binding affinity is allowed for its target antigen (e.g. Fc receptors). 
Later on, “humanized antibodies” were developed, where only the murine complementary 
determining regions (CDRs) are grafted on human antibodies (Figure 6C). The origin of fully 
human antibodies (Figure 6D) was achieved in the 1990s after the development of phage 
display techniques by George P. Smith and the revolutionary work of Sir Gregory Winter on 
mAbs field. Other techniques including the use of transgenic mice (bearing the immunized 
gene loci of human mAb with the antigen of interest) or ribosome and yeast display, have also 
been developed as valuable tools to produces fully human antibodies.[30] 
1.3.4. mAbs as Carriers for the Tumor Targeted Delivery of Anticancer Agents 
Due to the success achieved by the development of “chimeric”, “humanized” and “fully human” 
mAbs (i.e. the half-life of 21 days in humans[36] and 6-8 days in mice[37] is way longer than the 
half-life of murine mAbs), pharmaceutical industry have been using such macromolecules as 
single agents, for cancer treatment. The first mAb to receive marketing authorization for cancer 
treatment was the chimeric mAb Rituxan™ (rituximab, Biogen-Idec in 1997): approved for 
treatment of patients with non-Hodgkin’s lymphoma, it became rapidly a blockbuster.[30] On the 
contrary, the development of antibodies for the treatment of solid tumors is generally more 
cumbersome.[38] Accordingly, mAbs are usually given in combination with traditional anticancer 
drugs or other mAbs. For instance, Roche/Genentech’s Herceptin™ (trastuzumab) was 
approved for the treatment of Her/neu positive metastatic breast cancer in combination with 
doxorubicin or paclitaxel.[30] Moreover, the use of mAbs to stimulate the immune system to 
attack cancer cells should be mentioned here: the success of the so-called checkpoint 
inhibitors (e.g. Nivolumab and Ipilimumab) is now established and the products are receiving 
marketing authorization for an increasing number of indications.[39] 
Over the past two decades, antibodies have been studied as interesting tools to carry several 
cytotoxic agents at the tumor site.[20,30] Since traditional cytotoxic drugs exhibit their action 
inside the cell, the observation that specific antibodies can enter cells upon binding to a 
transmembrane antigen (i.e. receptor-mediated endocytosis) stimulated the mAb 
functionalization with cytotoxic drugs through specific linkers, giving rise to the so-called 
antibody-drug conjugates (ADCs).[20,40] The release of the payload inside the targeted cancer 
cell would increase the selectivity and therapeutic efficacy of these constructs and it is made 
possible either by the linker cleavage or after intracellular degradation of the antibody structure 
– Figure 7A.[20,40] 
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By contrast, it has been recently understood that mAb internalization may not be essential for 
selective drug release (e.g. ADCs specific to extracellular matrix proteins have been showing 
strong anti-tumor activity) if equipped with extracellularly cleavable linkers – Figure 7B.[27,29,41] 
Considering the mechanism of action of ADCs, it is conceivable that the linker plays a key role: 
ideally, this moiety should be stable in circulation for days and be efficiently cleaved during the 
receptor-mediated endocytosis (Fig. 7A) or in the tumor microenvironment (Fig. 7B). In fact, 
premature release of the drug in the blood circulation would lead to systemic toxicity and a 
lower therapeutic index.[29,30] 
 
Figure 7. Structure and different drug delivery mechanisms of ADCs. A) Upon binding to tumor cell surface 
antigens, the ADC-receptor complex is internalized into the cell. This receptor-mediated endocytosis leads to drug 
release in intracellular compartments (e.g. endosomes and lysosomes). B) In case of non-internalizing antigens, 
the ADC remains bound to the receptor on the cell surface. Here, depending on the linker, the cytotoxic drug may 
be released in the extracellular environment and enter the cell by passive diffusion.[29,30] 
In the development of 1st-generation ADCs, the chimeric mAb (BR96), targeting the LewisY 
tetrasaccharide (LeY) tumor antigen, was linked to eight unities of doxorubicin (14, Fig. 2) 
through an acid-labile hydrazone linker.[42] Low anti-tumor activity and undesired cytotoxicity 
were observed. Whereas the non-human form of the mAb structure was associated to 
significant immunogenicity, the occurrence of severe toxicity was probably due to the short 
half-life of the hydrazone linker (t1/2 = 43 h), which was not compatible with the long circulation 
time of the BR96 mAb (t1/2 = 12 days).[43] Another 1st-generation ADC was the K1S/4 mAb, 
which was connected to desacetylvinblastine (a vinca alkaloid), through an esterase-labile 
hemisuccinate or an acid-labile hydrazone linkers. Also in these two cases, no considerable 
anti-tumor activity emerged from clinical trials.[44] 
Following these clinical failures, it was proved that a rational linker development would play an 
essential role in the evolution of the next generations of ADCs, as well as the use of more 
potent cytotoxic drugs. Moreover, “humanized” and “fully human” antibodies were used to 
reduce immunogenicity and the rapid clearance of the ADCs from circulation. 
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New generations of ADCs were developed accordingly and, so far, four ADCs have been 
approved by the FDA for cancer therapy: the CD30-targeting brentuximab vedotin (Adcetris™ 
from Seattle Genetics, compound 30 – Figure 8) is used for the treatment of Hodgkin 
lymphoma and anaplastic large cell lymphoma, and HER2-targeting ado-trastuzumab 
emtansine (Kadcyla™ from Roche, compound 31 – Figure 8) for the treatment of metastatic 
breast cancer. More recently, the CD33-targeting gemtuzumab ozogamicin (Mylotarg™ from 
Pfizer, compound 32 – Figure 8) was approved for treatment of acute myeloid leukemia. This 
ADC had been withdrawn in 2010, due to an inadequate efficacy/side effect relationship, but 
a dose-treatment revision led to the re-approval of the biotherapeutic (FDA news release, 
2017). [45] Lastly, the newly CD22-targeting inotuzumab ozogamicin (Besponsa™ from Pfizer, 
compound 33 – Figure 8) was approved during the previous year for treatment of acute 
lymphoblastic leukemia.[45] Moreover, around 60 ADCs are now running the clinical trials, while 
many drug candidates are being investigated at preclinical level.[46] 
 
Figure 8. Molecular structures and mAb/linker/drug system of ADCs that were, so far, approved for cancer therapy. 
DM1: mertansine (i.e. a thiol-bearing maytansinoid); MMAE: monomethyl auristatin E.[45]  
1.3.5. Drawbacks of Antibodies 
As already mentioned, mAbs have been chosen as selective targeted delivery vehicles of 
cytotoxic agents, due to their strong binding affinity properties and accumulation at the tumor 
site in patients. Although ADCs show a variety of benefits over traditional anticancer 
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approaches, the in vivo pharmacodelivery of the cytotoxic agent by an antibody is limited by a 
number of factors:[47] 
• the large size of antibodies delays the ADC extravasation and the diffusion into the tissues. 
Moreover, only a little fraction of the conjugates penetrates into the tumor mass, being 
immediately trapped by antigens located on perivascular tumor cells (i.e. the so-called 
antigen barrier effect). This particular feature may prevent the drug to reach all cells in the 
tumor mass; to circumvent this limitation, smaller formats of ADCs (SIP, diabody etc.) have 
been proposed, but this approach is currently being investigated only at the preclinical level. 
• As mentioned above, the ADC efficacy can be substantially affected by the occurrence of 
anti-mAb immune response, not only depending on the type (i.e. chimeric, humanized or 
fully humanized) but also on the format (i.e. diabody, miniantibody or small immune 
proteins) of the mAb structure. 
• From the manufactory point of view, the large-scale assembly of ADCs is an expensive 
process, requiring providers to simultaneously handle biologic materials in sterile conditions 
and manipulate highly potent cytotoxic compounds. As a result, the high manufacturing 
costs limit the clinical evaluation of new ADCs and, importantly, they impact dramatically on 
the final costs of the treatment. 
Considering these drawbacks of the ADC technology, the development of other active 
targeting devices, is now gaining high interest among the pharmaceutical industry. 
1.4. Small Molecule-Drug Conjugates (SMDCs) 
1.4.1. Why SMDCs? – an overview 
The development of low-molecular-weight compounds (i.e. small organic ligands) may 
represent an alternative to antibodies for pharmacodelivery applications.[47] However, while it 
is now possible to develop antibodies against virtually any protein antigen, the development of 
potent small molecular binders is not a general process and so far only few ligands have been 
investigated for drug delivery purposes.[48] Small molecule-drug conjugates (SMDCs) that bind 
with high affinity to tumor-overexpressed receptors are now designed to rapidly extravasate, 
accumulate in the tumor mass homogeneously, without being immunogenic.[48] Moreover, in 
case of absence of good binding (e.g. recognition of extracellular matrix proteins or membrane 
antigens) lower molecular weight compounds quickly diffuse back to blood stream for 
excretion.[48] Furthermore, due to their synthetic accessibility, the large-scale production of 
SMDCs is more sustainable at the industrial level.[48] 
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Similarly to ADCs, the mechanism of drug release for SMDCs depends on the targeted 
receptor (Figure 9).[17] Usually, most of the SMDCs are internalized into the cell through 
receptor-mediated endocytosis. The drug is then released upon linker cleavage by specific 
mechanisms in intracellular compartments. By contrast, in the case of SMDCs bearing a linker 
which can be cleaved in the extracellular milieu, the cytotoxic drug can be released in the tumor 
microenvironment and it can then penetrate the cancer cell by passive diffusion.[49,50] 
 
Figure 9. General structure of small molecule-drug conjugates (SMDCs). Ligand (green) for targeting, Spacer 1 
and Spacer 2 (blue), to modify the conjugate’s physicochemical properties (e.g. solubility) or to improve the kinetic 
of drug release, linker (yellow) to achieve intra or extracellular cytotoxic drug release, and drug (red) to get 
therapeutic effect after release. Adapted from [49] 
Ideally, the cytotoxic payload should be stably connected to the targeting moiety while the 
SMDC is in circulation. On the contrary, the drug should be efficiently released at the tumor 
site in its unmodified form. 
1.4.2. Linkers and Spacers 
The nature of the linker shows direct impact on the efficacy and stability of the SMDC construct. 
Several parameters, such as type of connection bond on the targeting ligand (e.g. ester, 
carbonate, carbamate, oxime), polarity, hydrophobicity and drug release mechanisms, may 
contribute to the SMDC performance.[17,51] Depending on the chemical bonds lability on the 
linker structure, linkers can be divided into two categories: cleavable and uncleavable. The 
latter rely on the complete stability of the whole conjugate, being usually exploited for diagnosis 
purposes (i.e. connection of fluorophores to the targeting ligand). On the other hand, 
environmental factors such as the acidic or reductive conditions of cytoplasm and extracellular 
matrix or the presence of specific enzymes in lysosomes are some of the exploited intra- and 
extracellular promoters of drug release from cleavable linkers.[50,52] 
Regarding that, a variety of chemical structures have been used as linkers to release the drug 
under different conditions at the tumor site: 
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• Reductively cleavable linkers: the high intracellular concentration of reduced glutathione 
(~2-10 mM) and other reductants (e.g. cysteine, thioredoxin, peroxiredoxins, and 
nicotinamide adenine dinucleotides) in cancer cells inspired the development of delivery 
systems containing reducible moieties, such as disulfide linkers. The drug release from 
disulfide bonds mainly occurs in the cytoplasm upon endocytosis, through disulfide 
exchange reactions with glutathione and other cysteine-containing proteins. However, it has 
been claimed that the high reducible environment at the tumor stroma can cleave the 
disulfide bond extracellularly and the drug can be taken up, passively, by the cancer cell. 
Upon S-S bond cleavage, the resulting reduced thiol group triggers the drug release through 
a cyclization onto electrophilic functional groups (e.g. carbonates and carbamates, Scheme 
1).[17,52] 
 
Scheme 1. Drug release mechanism of SMDCs bearing reductively cleavable linkers. After cleavage by 
glutathione, the free drug is released leading to the formation of different byproducts: A) thiirane; B) thioquinone 
methide; C) thiolactone; D) thiirane, 1,3-oxathiolan-2-one, and 1,3-dimethyl-2-imidazolidinone. GSH = 
glutathione; X=NH or O.[52] 
• Acid-labile linkers: the receptor-mediated endocytic process is known to proceed through 
a progressive acidification of the intracellular compartments (i.e. pH 4.5-5.0 in lysosomes 
and 5.0-6.5 in endosomes). Moreover, tumors are often characterized by a remarkable 
acidity of their extracellular milieu, as a result of the high metabolic rates of aggressive 
tumors. Therefore, linkers that are rapidly hydrolyzed under acidic conditions can be 
exploited for delivery of anticancer drugs. An example, in addition to esters, is the acidic 
hydrolysis of the para-alkoxybenzylidene methoxy (Scheme 2A), where the electron-
donating effect of the para-alkoxy functional group in the aromatic ring gives increasing 
stability to a para-alkoxybenzylonium cation, facilitating the cleavage and consecutive drug 
release. Hydrazones are also acid-labile linkers, especially when connected by direct 
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coupling of a carbonyl-containing drug to hydrazide linker. This approach relies on the linker 
hydrolysis within the endosomes (Scheme 2B), but the poor stability of such linker avoids 
significant drug accumulation at the tumor site and negligible release of the payload into the 
blood stream.[17,52] 
 
Scheme 2. Examples of drug release mechanism, upon hydrolysis, of SMDCs bearing acid-labile linkers. A) 
para-alkoxybenzylidene acetal; B) hydrazones; X=NH or O.[52] 
• Enzyme-cleavable linkers: the abundance of hydrolytic enzymes inside cancer cells and 
within the tumor stroma differs from their presence in the blood stream. As a consequence, 
linkers composed by specific peptide sequences or sugar moieties can be selectively 
recognized and cleaved by a variety of enzymes (i.e. proteases or glycosidases). 
Depending on the location of these effectors, the linker cleavage can take place at different 
sites of the cancer cell (e.g. tumor stroma, cell membrane, lysosomes and endosomes). 
Being composed by peptide bonds, enzymatically labile linkers show high stability under 
different pH conditions. In these drug-delivery systems, a self-immolative spacer is often 
present to decrease the steric hindrance around the peptide sequence, thus allowing a more 
efficient enzymatic action. The proteolytic cleavage generates a nucleophilic functional 
groups (e.g. hydroxy, amino, or thiol groups) which reacts intramolecularly through different 
mechanisms (mainly cyclization and electronic cascade over conjugated double bonds), 
releasing the free drug (see Scheme 3).[52] 
• Uncleavable linkers: unlike uncleavable linkers in ADCs (where the mAb structure is 
proteolytically degraded inside the cell, eventually releasing the cytotoxic agent), 
uncleavable linkers in SMDCs are generally stable both in circulation and inside the cell (i.e. 
blood stream and tumor site). The typical functional groups used for these linkers are 
triazoles, carbamates, and amides. Due to this high stability, these bonds are typically not 
indicated for drug delivery purpose, whereas they can be used for diagnosis, conjugating a 
fluorophore to the targeting ligand (i.e. SMDCs for cancer diagnosis).[52] 
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Scheme 3. Examples of enzyme-cleavable linkers bearing a self-immolative spacer. The cleavage by different 
located enzymes (intracellular for cathepsin B, extracellular for MMP-2/9 and intra/extracellular for β-glucuronidase) 
gives rise to liberation of the free drug after 1,6-elimination of the p-amino or p-hydroxy benzoxycarbonyl spacers. 
X= O or NH.[17] 
The choice of the linker is normally dependent on the target protein and its biological features 
(e.g. location in the tumor mass, internalization pathway etc.), as intra- or extracellular 
processes contribute to the fully active drug release.[50,52]  
From the structural point of view, the linker moiety is often functionalized at both sides with 
different kinds of spacers (see Figure 9). As mentioned above, self-immolative spacers 
between linker and payload (spacer 2, Figure 9) are important to release the drug in the active 
form upon linker cleavage (e.g. most common in literature is the 1,6-elimination of the para-
amino benzoxycarbonyl spacers, Scheme 3). Many other self-immolative spacers are reported 
in literature, considering different connection bonds (e.g. 1,8-elimination concerning 
chromanone rings and 1,4-elimination concerning phenyl rings). Moreover, additional chemical 
structures between linker and ligand are often included for different reasons. 
For instance, as linkers and cytotoxic agents are usually highly lipophilic, the spacer between 
the cleavable linker and targeting ligand is often included to improve the solubility in aqueous 
media of the entire SMDC (e.g. through the use of PEG chains or short peptide sequences 
bearing hydrophilic residues - spacer 1, Figure 9).[52] In some cases, the spacer minimizes 
possible steric hindrance from the cytotoxic drug that can interfere with the ligand affinity for 
its receptor. Moreover, modifications of the spacer structure have been used to modulate the 
pharmacokinetic properties of the SMDC, as well as to allow multipresentation of ligands and 
drug moieties.[53] 
It is now established that cancer cells express specific receptors on their surface which are 
present in a higher number of copies compared to healthy cells. In the case of SMDCs, a 
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variety of antigens have been investigated as targeted receptors: among all, some of the most 
studied targeted receptors will be described in the following sections [e.g. folate receptor (FR), 
prostate-specific membrane antigen (PSMA), somatostatin receptor (SSTR), carbonic 
anhydrase IX and integrin receptor]. Moreover, other receptors have been also described [e.g. 
cholecystokin receptor (CCKR), sigma-2 receptor, tropomyosin receptor kinase (Trk), 
hormones receptors (androgen, estrogen and progesterone), biotin receptor, CD13 receptor] 
but they will not be debated here in detail.[56] 
1.4.3. SMDCs Targeting Folate Receptors (FRs) 
Among all vitamin receptors, FRs are the most studied as cancer biomarkers. Vitamins are 
required for the survival of all living cells, and especially tumor cells require them in large 
quantities to sustain fast growth.[54] Folic acid is a crucial dietary factor that is converted by 
enzymatic reduction to a series of tetrahydrofolate (FH4) cofactors, providing methyl groups for 
the synthesis of DNA precursors (e.g. thymines and purines) and RNA (e.g. purines). Due to 
the importance of folic acid for fast-growing cells, FR is overexpressed on the surface of 
different cancer cells.[55] For this reason, folic acid (folate, Figure 10 in green) is considered the 
first small molecule to be used as ligand in SMDCs and the research activity done on folate-
drug conjugates represents a milestone in the development of tumor-targeting cytotoxic 
agents. Impressive work by Philip Low and co-workers at Endocyte, has been done in the 
applications of folate conjugates for tumor targeting.[56] The most studied SMDCs from 
Endocyte are EC145 (vintafolide, Vynfinit™ compound 34, Figure 10) and the analog, 
peptidoglycan-based, EC0489 (compound 35, Figure 10). Both compounds are known to enter 
the cell by FR-mediated endocytosis and, during this internalization pathway, the compounds 
are carried to the endosome.[52] From the structural point of view, both compounds are folate-
desacetylvinblastine hydrazide (DAVBH) conjugates, bearing a disulfide linker and hydrophilic 
spacers. EC145 showed considerable efficacy in preclinical mouse models and it is now being 
evaluated in Phase II clinical trials for solid tumors (i.e. ovarian, neck and colorectal). However, 
the clinical reports of EC145 highlighted side effects such as fatigue and constipation 
ascribable to the hepatic clearance and metabolism of the conjugate, which leads to the 
release of free drug (i.e. vinca alkaloid) to gastrointestinal organs. Subsequently, EC0489 (35), 
containing a peptidoglycan-based spacer was developed to reduce hepatic clearance and 
metabolism. Here, the hydrophilic spacer that connects the drug to the folate (Figure 10) was 
found to allow better affinity for the receptor (i.e. without any further data, authors stated that 
a rigid hydrophilic spacer might avoid the decrease of affinity) which prevents unspecific uptake 
by healthy cells. This conjugate is now undergoing Phase I clinical trials.[52] Other drugs have 
been conjugated to folate ligand by Endocyte, as cryptophycin, through a carbonate bond. 
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Compound 36 (Figure 10) displayed cell cytotoxicity in vitro at low nanomolar concentrations, 
while data of in vivo antitumor activity are currently not available.[57] 
Besides FRs, other vitamin-targeted receptors have been explored.[54] For example, the 
conjugation of potent drugs to biotin has been investigated, due to the overexpression of biotin 
receptors (BR) in tumor cells.[58] 
 
Figure 10. Molecular structures of three examples of FR-targeted SMDCs. 
1.4.4. SMDCs Targeting Prostate-Specific Membrane Antigen (PSMA) 
PSMA (also known as folate hydrolase I or glutamate carboxypeptidase II) is a plasma 
membrane protein, and it is the second most upregulated protein in prostate cancer (PCa).[59] 
This antigen represents an ideal cell surface protein for tumor-specific targeting. In addition to 
its expression on both prostate cancer cells and on the neovascular tissue of other solid 
tumors, PSMA is present at low concentrations in healthy tissues. Physiologically, this 
transmembrane glycoprotein cleaves glutamate residues from biological substrates (e.g. N-
acetylaspartyl glutamate) and, upon ligand binding, this cell-surface receptor undergoes 
endocytosis through clathrin-coated pits, recycling then to the cell surface.[60] 
Also in this case, Endocyte has been doing considerable efforts in PSMA-targeting SMDCs 
field. A variety of analogs of N-acetylaspartyl glutamate have been prepared and linked to 
cytotoxic agents or radioisotopes. For example, in EC0652 (compound 37, Figure 11) the 
ligand 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA, Fig. 11) was conjugated to 
the radioisotope technetium Tc-99m (99mTc), that can potentially be used as a radio-imaging 
agent for PSMA-overexpressing tumor cells. After cell uptake and SPECT (i.e. single-photon 
emission computed tomography) imaging, PSMA-positive tumor cells can be observed and 
identified. Furthermore, PSMA-overexpression has been correlated to the targeting skills and 
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the efficacy of certain PSMA-targeting cytotoxic agents. Compound 37 showed remarkable 
tumor accumulation in seven patients without reported toxicities, being now in phase I/II trials 
with a larger number of patients.[56] Another example of successful radioligand is 177Lu-PSMA-
617 (compound 38, Figure 11) developed by Endocyte and now in Phase III clinical trials.[61] 
The DUPA ligand in 177Lu-PSMA-617, is chemically attached to a therapeutic radioactive 
isotope called Lutetium-177 (177Lu), which releases an energetically active β- particle as a 
cytotoxic radiation at the site of disease (i.e. PSMA-positive cells). DUPA ligand was also 
conjugated to a potent antimitotic agent tubulysin hydrazide through a disulfide linker (EC1169, 
compound 39). Treatment of compound 39 in a in vivo model (i.e. nude mice bearing 
subcutaneous LNCaP tumor) showed regression in all treated animals, with 2/7 achieving 
complete tumor eradication (i.e. no tumor regrowth until 90 days), with no apparent toxicities. 
Compound 39 is now being evaluated in phase I clinical trials.[56] 
 
Figure 11. Molecular structures of three examples of PSMA-targeted SMDCs. DUPA ligand is represented in 
green. 
 
1.4.5. SMDCs Targeting Somatostatin Receptors (SSTRs) 
Specific hormone receptors are considered suitable targets for anticancer therapy, due to their 
high expression in different cancer cells. Among different hormone receptors (e.g. 
gonadotropin-releasing hormone or GnRH, steroid hormones, etc.), hormone somatostatin 
receptors (SSTRs, in particular subtypes 2, 3 and 5) are widely expressed in cancer cells, in 
particular in neuroendocrine tumors.[62] The most studied subtypes are SSTR2 and SSTR5. In 
particular, synthetic cyclic peptides such as octreotide and seglitide have been developed as 
somatostatin analogs. These compounds are particularly selective for SSTR2, rather than 
SSTR5 (14-fold and 130-fold higher affinity for SSTR2 isolated receptor, respectively).[63] 
Interestingly, a correlation was observed between somatostatin and its analogs to bind to the 
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SSTR2 subtype and its capability to constrain angiogenesis (i.e. the growth of new ramified 
blood vessels, which is significantly faster in aggressive and metastatic tumors).[63] For 
instance, somatostatin analog octreotide has been coupled through a labile ester bond at the 
2’-O position of paclitaxel (PTX, 20, Fig. 2), showing considerable antitumor efﬁcacy in mouse 
models, with potent inhibition of tumor growth and lower systemic toxicity compared to PTX 
alone.[64,65,66]  
Moreover, ligands consisting of octreotide analogs have been also used to improve the 
anticancer efficacy of octreotide-DM1 SMDC, through a disulfide cleavable linker, against 
SSTR2-expressing tumor model (Fig. 12). A recent work from Tarveda Therapeutics showed 
the significant in vivo antitumor efficacy of compound 40 (Figure 12) in several SSTR2-positive 
lung xenograft models with. Antitumor activity was superior to that observed with standard of 
cytotoxic agents, cisplatin/etoposide. Remarkably, compound 40 showed no antitumor effect 
in a SSTR2-negative xenograft model.[67] 
 
Figure 12. Molecular structure of PEN-221 conjugate (40) developed by Tarveda Therapeutics and effect on the 
growth of small cell lung cancer NCI-H69 xenograft model in comparison with standard cytotoxic agents.[67] 
1.4.6. SMDCs Targeting Carbonic Anhydrases (CA) 
Carbonic anhydrase is described as a zinc metalloprotein located in cervical cancer cells. This 
metalloenzyme catalyzes the reversible hydration of carbon dioxide to hydrogen carbonate 
and H+ (CO2 + H2O ↔ H+ + HCO3−), being responsible by physiological pH homeostasis. In 
humans, this enzyme is expressed in 16 known isoforms varying their catalytic activities, 
cellular localizations, and vulnerability to different inhibitors. Among these isoforms, carbonic 
anhydrase IX (CAIX) is considered an excellent tumor antigen, being overexpressed in 
different cancer types (e.g. glioblastoma, colorectal and breast cancer) as a marker of 
hypoxia.[68] 
Due to its high and localized expression, a group of highly specific SMDCs based on CAIX 
ligands has been developed. Although it is now clear that CAIX-targeting ligands do not enter 
the cell through receptor-mediated endocytosis, different CAIX-targeted SMDCs have been 
developed, and their antitumor properties were evaluated in vivo.[69] Over the past decade, 
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Neri and co-workers, have synthesized several SMDCs bearing a CAIX inhibitor 
acetalozamide (AAZ, Figure 13 in green). A first fluorescent conjugate carrying the AAZ CAIX-
targeting ligand, allowed the confirmation of the high affinity of AAZ ligand, which showed 
nanomolar Kd values (Kd = 12.6 nM) for the receptor, while exhibiting good tumor accumulation 
in vivo, 1 hour post-administration (the tumor accumulation was 22-fold higher than the 
negative control ligand confirming the selectivity of the ligand).[69] The development of SMDC 
compounds based on AAZ ligand showed that the combination of a disulfide linker and 
duocarmycin drug led to modest tumor volume inhibition. On the contrary, the use of a 
maytansinoid payload (in compound 41, Fig. 13) resulted in a potent antitumor effect.[69] 
 
Figure 13. Molecular structures of SMDCs bearing CAIX as targeting ligand (41-44), developed by Neri and co-
workers. CAIX ligands are represented in green. Compounds 41-42 have DM1 as payload, while compounds 43-
44 show MMAE (29) as payload. Disulfide linkers are represented in compounds 41-42 and lysosomally-cleavable 
linkers for 43-44. 
In the same frame, a bivalent AAZ-(DM-1) SMDC 42 (Fig. 13) illustrated how the increased 
ligand avidity can lead to substantial modification of the SMDC performances [displayed better 
results when compared with SMDC 41]: In particular, the dimeric ligand showed 1) high affinity 
with no apparent dissociation from CAIX coated surface (binding affinity measured with 
Surface Plasmon Resonance – SPR); 2) approximately 3-fold higher tumor accumulation than 
SMDC 41; and 3) longer tumor residence (24 hours after administration, bivalent 42 showed 
40% total fluorescence signal when compared with 14% of monovalent 41). Moreover, SMDC 
42 showed better antitumor activity in vivo than monomeric 41, which is the result of the 
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improved and extended tumor accumulation.[70] More recently, the same group, showed that 
variations of the linker moiety (i.e. introduction of cathepsin-B cleavable linker Valine-Citruline 
compound 43, Fig. 13) and of the cytotoxic agents (i.e. MMAE and PNU-159682) can improve 
the antitumor activity, leading in some situations to complete cancer eradication in the case of 
conjugate bearing MMAE as payload.[71] Remarkably, with the use of a non-internalizing ligand 
and intracellularly cleavable linker, the authors observed in vivo therapeutic efficacy.[71] Neri 
and co-workers claim that cathepsin B, which is originally an intracellular enzyme, might be 
secreted to the extracellular environment by dying cells but also by tumor cells, initiating 
extracellularly proteolytic cascades to help tumor growth.[71,72] Against the widely-accepted 
assumption that internalization is a strict requirement for the conjugate efficiency, these data 
indicate that the delivery of cytotoxic agents to the tumor extracellular environment is also a 
promising strategy to achieve anticancer efficacy.[71] The ligand fragment of these compounds 
has been recently improved through an innovative affinity-maturation experiment, performed 
through development and screening of DNA-encoded chemical library technologies (DNA-
ECL).[73,74] A new CAIX ligand was achieved from DNA-ECL allowing the development of a 
new SMDC 44, displaying a Kd = 10 nM by SPR.[75] In terms of therapeutic efficacy, SMDC 44 
showed no substantial improvement of the anticancer activity exhibited by compound 43, with 
the authors claiming that the release of the drug might be too slow (i.e. a more labile linker 
could rise the rate of tumor cell killing to show more therapeutic efficacy).[75] 
1.5. Integrin αvβ3 as Tumor Target Receptor 
Another group of receptors that have been largely 
studied in cancer therapy are integrins. These proteins 
are a family of heterodimeric membrane glycoproteins 
formed by non-covalently associated α- and β- subunits 
(Fig. 14).[76] This large group is composed by 18 α and 
10 β subunits that can assemble leading to 24 identified 
heterodimers (Fig. 14), giving the possibility to act in 
crucial biochemical processes of the cell biology (i.e. 
cell replication, survival, migration, and intracellular 
signal transduction).[76,77] For example, it has been 
described that immunoglobulins and cytokines interact 
with integrin receptors and trigger signaling pathways 
by activating receptor tyrosine kinases (i.e. well-known 
receptor overexpressed in different types of cancer).[78] 
Particularly, each subunit is featured by: 1) an 
Figure 14. up) The integrin family; down) 
Schematic representation of the two integrin 
subunits. Adapted from[76] 
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extracellular domain; 2) a single transmembrane domain; and 3) a cytoplasmic region (Figure 
14).[77] As main function, integrins mediate cell-cell and cell-extracellular matrix (ECM) 
adhesion, playing key roles in the cytoskeleton organization during cell adhesion and 
migration.[79] Indeed, the name “integrin” was given to designate the role of such protein as an 
integral membrane complex involved in the transmembrane association between the 
extracellular matrix and the inner part of the cell.[79] This kind of proteins are also responsible 
for the regulation of many biochemical processes at the cellular level which happen during the 
formation and in the progression of several diseases (e.g. prostate carcinoma, breast cancer, 
pancreatic tumor and glioblastoma).[78] It has been reported that tumor cells enhance the 
expression of specific integrins, stimulating their proliferation, invasion and survival.[78]  
Among these integrins, αvβ3 is strongly involved in the regulation of angiogenesis. Particularly, 
the quantity of integrin αvβ3 in tumor neovasculature is often higher with respect to healthy 
tissues, resulting in a continuous stimulation of angiogenesis.[80] The role of integrin αvβ3 is not 
only important in natural biochemical processes (e.g. wound healing, tissues remodeling, 
embryogenesis, and female reproductive cycle), but also for growth and survival of tumors. As 
a matter of fact, αvβ3 integrin is not only overexpressed in angiogenic endothelial cells, but it is 
also upregulated in several tumors (e.g. glioblastoma, pancreatic, breast, prostate and cervical 
carcinoma, and melanoma).[80] Besides, αvβ3 is involved in ECM remodeling and degradation, 
which are crucial processes for tumor invasion and metastasis. For example, αvβ3 integrin is 
able to recruit and activate specific extracellular proteases [i.e. metalloproteinase-2 (MMP-2) 
and plasmin] which degrade different components of the extracellular and interstitial matrixes 
(i.e. angiogenesis event arises from interaction between αvβ3 and MMP-2, which destroys the 
collagen matrix) thus promoting the migration of cancer cells.[80] 
1.5.1 RGD Integrin Ligands 
Endogenous proteins (e.g. fibrinogen, vitronectin, plasminogen) presenting the tripeptide 
sequence arginine-glycine-aspartic acid (Arg-Gly-Asp, or RGD) can interact with different 
integrin receptors (e.g. αvβ3, αvβ5, α5β1), which have been associated to cancer development, 
metastasis and tumor angiogenesis.[81] For instance, Rouslahti and co-workers described that 
the cell-adhesion ability of fibronectin is mediated by the RGD peptide sequence (Fig. 15), 
included in one of the protein domains.[82,83] 
For this reason, different research groups designed and synthesized a variety of peptides and 
peptidomimetics displaying the RGD recognition motif (see Figure 15) to target and bind these 
specific integrins and, among all, some were found to bind integrin αvβ3 with high affinity.[81] 
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Figure 15. The RGD recognition motif. 
So far, several strategies were implemented to exhibit the RGD recognition motif in a stable 
conformation. Indeed, it was reported that the constrain of the RGD sequence in small cyclic 
structures leads to high-affinity ligands, showing low conformational flexibility (i.e. flexibility of 
flanking residues is limited).[84] Numerous RGD-based binders are described in literature. 
Among them, Kessler’s research group was pioneer in developing the potent integrin ligand 
Cilengitide (45, Fig. 16).[85,86] The structural rationale for the observed high ligand-receptor 
affinity was provided by Xiong and co-workers, which reported X-ray analysis of the structure 
of integrin αvβ3 co-crystalized with Cilengitide.[87] The latter study was able to describe an 
extended conformation of the RGD sequence in the binding pocket, characterized by a crucial 
9-Å distance between C-β atoms of the Arg and Asp residues: this essential interaction relies 
on the establishment of two bridge salts, where the first is located between the arginine side 
chain and negatively charged residues in the α subunit, and the other involving the β-
carboxylate moiety of aspartic and the Mn2+ divalent metal cation of the metal ion-dependent 
adhesion site (MIDAS) region in the β subunit (Figure 16).[88] 
 
Figure 16. The potent integrin ligand Cilengitide showing selectivity for αvβ3 over αvβ5 integrin receptors and 
Cilengitide bound to αvβ3. IC50 values from[89] and figure adapted from[88]  
Due to its high binding affinity to αvβ3 integrin receptor, Cilengitide was first developed as 
antiangiogenic molecule, thus being directly used as anticancer drug. Cilengitide reached 
clinical trials and, although it was found to be well tolerated in patients, its anti-angiogenic 
activity has been debated. By contrast, after the initially reported results, in specific 
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experimental conditions, Cilengitide was shown to act as an angiogenesis agonist, which 
caused the interruption of the clinical evaluation.[76,81,88] 
However, the significant work on the structural information and interaction between Cilengitide 
and αvβ3 integrin led to the development of cyclic RGD peptidomimetic and semi-peptidic 
ligands towards αvβ3 integrin. Some examples are shown in Figure 17, where the common 
feature of ligands 46-51 is the presence of the RGD tripeptide sequence within a cyclic 
structure, to limit the flexibility of the structure backbone.  
 
Figure 17. Selected examples of integrin ligands (46-51) and relative integrin affinity, expressed as IC50 value. The 
IC50 values were taken from literature: for compound 46,[90] 47,[91] 48,[92] 49,[89] 50,[81] and 51[81].  
Even after the clinical failure of Cilengitide, several αvβ3- and αvβ5-targeting ligands were able 
to enter clinical trials as well, due to their potent activity against tumor angiogenesis (i.e. this 
approach in cancer therapy was not successful).[93] Besides the use of αvβ3 integrin ligands as 
anti-angiogenic agents a different strategy arose, consisting in their use as tumor targeting 
agents. Due to the ability of these compounds to recognize overexpressed αvβ3 integrins on the 
membrane of tumor cells, different RGD-based small molecules have been used as carriers to 
deliver selectively: nanoparticles,[94] liposomes,[95] imaging agents,[96,97,98] and 
chemotherapeutics.[50,56,99,100] 
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1.5.2. RGD Integrin Ligands for the Delivery of Cytotoxic Drugs in Tumor Therapy 
Many different radiolabeled constructs containing RGD-based ligands were developed and 
validated in cancer imaging at the clinical level.[97,101,102] Alternatively, RGD-containing SMDCs 
are still under investigation and far from clinic. As previously mentioned, the overexpression of 
integrin αvβ3 by cancer cells can be exploited for the selective delivery of cytotoxic drugs by 
RGD-based SMDCs. Different dynamics of internalization-recycling of integrin receptors have 
been described. Upon interaction with their ligands, these processes are mediated by specific 
proteins (i.e. caveolin and clathrin), capable of activating the receptor insertion into 
characteristic vesicles that are delivered to endosomes.[103] In the case of integrin αvβ3, two 
pathways are available: 1) protein degradation by specific enzymes in endosomes or 
lysosomes and, 2) restoration to the cell membrane (i.e. recycling). Consequences of these 
processes involve cell migration and activation of other receptor families by cross-talk 
mechanisms (e.g. VEGFR-2, involved in angiogenesis).[104] 
Among the cytotoxic drugs used in traditional chemotherapy, doxorubicin (14, Fig. 2) was the 
first chemotherapeutic coupled to an RGD-bearing peptide (RGD4C, Fig. 18) in order to target 
integrin αvβ3. The RGD4C-doxorubicin SMDC developed by Ruoslahti and co-workers, triggered 
tumor growth inhibition of human breast cancer xenografts (i.e. MDA-MB-435 breast cancer cell 
line which features a high level of expression of αv integrins) in nude mice compared to the free 
cytotoxic drug. Furthermore, the RGD4C-doxorubicin SMDC showed decreased cardio- and 
hepatotoxicity than free cytotoxic drug as revealed by histopathological studies.[105] By contrast, the 
presence of stable amide linker showed some unspecific cleavage. For this reason, enzymatically 
cleavable linkers have been investigated to avoid non-specific cleavage. In 2002, De Groot and 
co-workers connected the bicyclic RGD4C ligand (Fig. 18) to doxorubicin, through a peptide 
substrate of protease plasmin (i.e. a tumor-associated enzyme, and involved in tumor invasion and 
metastasis) as cleavable linker, the D-Ala-Phe-Lys tripeptide sequence (52, Figure 18).[106] SMDC 
52 showed inhibition of vitronectin binding to HUVEC (human umbilical vein endothelial cells) 
cells at nanomolar concentration and the efficient linker cleavage by plasmin protease was 
confirmed.[107] However, only 30% of SMDC 52 was found to be converted into free doxorubicin. 
In the presence of protease, SMDC 52 was nearly as potent as the free drug against HT1080 and 
HUVEC cell lines (IC50 = 0.28 µM and IC50 = 0.75 µM).[106] Later on, Ryppa and co-workers 
developed two dimeric integrin-targeted doxorubicin SMDCs conjugated through an amide bond 
(53, Fig 18) and a peptide linker (54, Fig. 18).[108] The conjugates were designed to improve the 
affinity towards the target receptor by exploiting the multi-presentation of the recognition sequence. 
Such constructs were obtained after reaction of the thiolated divalent E-[c(RGDfK)2] linker with: 1) 
a maleimido functionalized doxorubicin, or 2) doxorubicin functionalized with a MMP2/9 cleavable 
octapeptide (53-54, Fig. 18). The MMP2/9 cleavable conjugate was efficiently cleaved in OVCAR-
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3 cancer cells (i.e. human ovarian carcinoma), releasing the free doxorubicin. On the other hand, 
the release of free doxorubicin from the amide-bearing conjugate was not observed, showing the 
specificity of the MMP cleavable octapeptide. Unfortunately both SMDCs did not display 
considerable effect in mice xenograft model bearing the OVCAR-3 cancer cell line.[108] 
 
Figure 18. Integrin-targeted DOXO SMDCs. Molecular structures of SMDCs bearing RGD-based integrin-targeting 
ligand and DOXO through enzymatically cleavable linkers 52 and 54 and amide bond 53. 
Camptothecin (CPT 11, Fig. 2) and hydrophilic derivatives such as Topetocan (12) and SN38 
(13) are another group of cytotoxic drug used for the development of SMDCs targeting integrin 
αvβ3.[107] Dal Pozzo and co-workers reported in 2010 the synthesis and biological evaluation of 
integrin-targeted SMDCs (compounds 55-56, Figure 19), in which a CPT analog was conjugated 
to an RGD cyclopentapeptide through a hydrazone linker. The SMDCs showed good binding 
affinity to αvβ3 (αvβ3 IC50 = 6-11 nM) and the cytotoxic activity of 55-56 was measured against 
PC3, A498 and A2780 cancer cell lines: despite the high cytotoxicity of this compound, the 
linker was reported to be poorly stable in vitro, resulting in a premature hydrazone cleavage 
and an non-specific drug release in vivo.[109] 
SMDC analogs of Cilengitide, conveniently modified with specific groups for conjugation, as 
well as derivatives of CPT at position 7, were described in a patent by Sigma-Tau.[110,111,112] 
The RGD targeting ligand was conjugated to CPT through stable linkers at physiological 
conditions, but promptly cleaved when the conjugate is internalized. Such conjugates present 
an enzymatically peptide cleavable linker, and short PEG spacer to increase the solubility, 
without affecting the RGD ligand binding affinity towards αvβ3/αvβ5 integrins.[107] Indeed, the 
binding affinity to αvβ3/αvβ5 isolated receptors (αvβ3 IC50 = 30-40 nM) and cytotoxicity against 
ovarian and prostate carcinoma cancer, were remarkable for all the SMDCs.[107] Interestingly, 
in vivo ability of SMDC 57 (Fig. 19) showed good antitumor efficacy with full tumor regression 
being observed at 25 mg/kg dose (i.e. in a mouse xenograft model of A2780 ovarian cancer 
cells). Good tolerability and effect persistence were observed after the treatment.[107, 111,112] 
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Figure 19. Integrin-targeted CPT SMDCs. Molecular structures of SMDCs bearing RGD-based integrin-targeting 
ligand and CPT through hydrolytically labile linker 55-56 and enzymatically cleavable linker 57. 
Another class of cytotoxic drugs that has been investigated as payloads in RGD-based SMDCs 
is Crytophycin-52 (27, Cry-52, Fig. 3). The latter was the first derivative of this drug family to 
reach clinical trials (developed by Eli Lilly).[113,114] While the use of free Cryptophycin resulted 
to severe neurotoxicity in patients,[18,115] the synthesis of targeted cryptophycin derivatives, 
aimed at improving the drug’s safety profile, has been an attractive research area, particularly 
pursued by the group of Prof. Sewald. Several cryptophycin derivatives were developed, as 
well as an RGD-(Cry-52) SMDC (58, Fig. 20A), bearing a triazole linkage.[116] Cell viability 
assays were performed in human cervix cancer cell lines KB-V1 and KB-3-1, through cell-
based resazurin assay. SMDC 58 displayed low cytotoxicity when compared with free drug 27 
(58 IC50 = 55.8 nM in KB-3-1 cells and 58 IC50 = 1.8 nM in KB-V1 cells vs. free drug IC50 = 15.5 
pM in KB-3-1 cells and free drug IC50 = 0.26 nM in KB-V1), probably due to the stable triazole 
connection. The RGD-(Cry-52) compound was derivatized with fluorescein, leading to a 
cRGDfK-fluorescein-(Cry-52) conjugate (59), which was used for imaging studies in terms of 
internalization and cell localization. It was proved that in 15 min, 59 was internalized through 
integrin-mediated endocytosis and it was localized in the lysosomes of WM-115 tumor cells 
(see Figure 20A).[116] 
Besides the contribution of Sewald and coworkers, the development of “theranostic” devices 
is now facilitating the overall understanding of the mechanism of αvβ3-targeted drug delivery. 
MMAE (29, Fig. 3) has also been conjugated to RGD peptides for theranostic applications (e.g. 
RGD-PLGC(Me)AG-MMAE-ACPP) by Tsien and co-workers).[117] The RGD ligand was 
conjugated to MMAE via a PEG spacer, an activable cell penetrating peptide (ACPP), a far-
red fluorophore (Cy5), and an intracellularly cleavable linker Val-Cit (SMDC 60, Fig. 20B). 
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ACPPs can help the cell uptake and they are generally structured with a polyanion, a 
polycationic peptide, and a metalloproteinase (MMP2/9) extracellularly cleavable linker 
(PLGC(Me)AG) - Fig. 20B. SMDC 60 displayed increased cellular uptake in U87MG 
glioblastoma cancer cells when compared with the RAD-bearing negative control (i.e. RAD- 
ACPP-PLGC(Me)AG-MMAE), proving the targeting ability of RGD sequence. As for the in vivo 
studies, SMDC 60 displayed better tumor volume regression in MDA-MB-231 breast cancer 
when compared with cyclic-RAD-PEG-6-MMAE and MMAE negative controls (i.e. MMAE 
therapeutic dose of 0.2 mg/kg).[117] 
 
Figure 20. A) Integrin-targeted Cry-52 SMDCs 58-59. On the right: Confocal microscopy. Incubation of WM-115 
melanoma cells with conjugate 59 for (I) 15 min, (II) 40 min, (III) 4 h. (Green) The fluorescent conjugate 59 (λex = 
458 nm) is localized intracellularly. (Red) Lysosomes are stained with LysoTrackerRed (λex = 561 nm). (Yellow) The 
overlay clearly proves colocalization.[116] B) Molecular structure of the “theranostic” (cRGD)-ACPP-PLGC(Me)AG-
MMAE SMDC 60. 
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As already mentioned, an important feature to increase the therapeutic efficacy is the affinity 
and selectivity of the conjugate. This can be achieved by the concept of multivalency (i.e. 
multivalent conjugates can carry two or more targeting units). The development of RAFT (i.e. 
regioselectively-addressable functionalized template) cyclodecapeptide scaffold by Boturyn 
and co-workers helped the synthesis of multi-presented constructs.[118] Moreover, reducible 
Pt(IV) complexes have been proved to be particularly useful as linkers in tumor-targeting. After 
internalization into αvβ3/αvβ5-expressing cells, the Pt(IV) reduction triggers the release of the 
Pt(II) complex (i.e. picoplatin active form). For example, Marchán and co-workers developed a 
mono (62, Fig. 21) and a tetrameric (63, Fig. 21) RGD-containing SMDCs by conjugation of 
the picoplatin Pt(IV) prodrug 61 bearing a succinic axial group.[119] Cytotoxicity assays were 
performed in αvβ3/αvβ5 integrin expressing SK-MEL-28 melanoma cancer cells, and in 1BR3G 
and CAPAN-1 cell lines (both showing low integrin expression). The tetrameric SMDC 63 was 
tested in all three cell lines and IC50 values were compared with IC50 values of monomeric 
conjugate and free drug. Tetrameric conjugate displayed 20-fold and 2.6-fold higher 
cytotoxicity in SK-MEL-28 integrin-expressing cell line when compared to free drug 5 and 
monomeric 62, respectively. No antiproliferative activity was shown in αvβ3-negative cells 
(1BR3G and CAPAN-1). ICP-MS technique was used to measure intracellular accumulation 
of platinum, proving that the increase of cytotoxicity is associated to the level of integrin 
expression of the cell line and, consequently to the number of targeting units of the SMDC.[119] 
 
Figure 21. Molecular structures of integrin-targeted platinum SMDCs 62 (monomeric) and 63 (tetrameric) bearing 
Pt(IV) complexes. 
Finally, paclitaxel (PTX, 20, Fig. 2) is one of the most widely employed in the construction of 
RGD-containing SMDCs. PTX is usually derivatized at the 2’-OH functional group, which is 
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crucial for the biological activity of the drug. This position has been often functionalized with 
targeting agents through ester linkers: this strategy increased the selectivity of paclitaxel in in 
vivo tests.[120] However, such PTX esters showed poor stability even in aqueous buffers and 
the premature release of the drug was observed, limiting the overall applicability of this kind of 
SMDCs. As a representative example of such PTX SMDCs, in 2009 Ryppa and co-workers 
synthesized conjugate 64 (Fig. 22), a divalent RGD compound designed to improve the affinity 
towards the target receptor, and its anti-proliferative activity was studied on HUVEC cell line. 
The short half-life of 64 (ca. 2 hours in phosphate buffer solution at 37 °C) compromised the 
targeting ability of the integrin binding portions.[121] 
 
Figure 22. Molecular structures of integrin-targeted PTX SMDCs 64-66 bearing an RGD-based structure as 
targeting ligand and PTX as cytotoxic drug. The graphic corresponds to the in vivo effect of 66 on ovarian carcinoma 
IGROV-1/Pt1. SMDC 66 was administered every fourth day four times.[122] 
In 2012, Zanardi, Manzoni and co-workers used cyclic RGD ligands based on modified 
aminoproline (Ampro) and azabicycloalkanes (Aba) moieties (Fig. 22).[122] These AmproRGD 
and AbaRGD ligands (i.e. displaying αvβ3 affinity) were used to the targeted delivery of PTX 
(65-66, Fig. 22). The SMDCs were obtained connecting the 2’-O position of PTX with 
AmproRGD and AbaRGD via succinic or diglycolic esters and different spacers (i.e. varying 
the hydrophilicity and length of the spacer). All synthesized conjugates showed good binding 
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affinity to αvβ3 integrin isolated receptor. At the same time, in vitro cytotoxicity assays on a 
panel of αvβ3/αvβ5-expressing cancer cell lines was evaluated. Also in this case, all conjugates 
displayed remarkable cytotoxic activity. Furthermore, in vivo efficacy was evaluated for one of 
the SMDCs (66), in a Pt-resistant (IGROV-1/Pt1) ovarian cancer xenograft model (Fig. 22). 
SMDC 66 displayed improved activity at a molar dose 50% lower than the one of free PTX.[122] 
In an additional study, the same group exploited the potential of multivalency, with the goal of 
increase binding affinity of the SMDCs to αvβ3/αvβ5 integrins. This work will be described in 
Chapter II. 
Other examples of αvβ3-targeted SMDCs are described in literature.[50,56,107,110] In conclusion, 
despite the notable efforts made in this research field, such type of SMDCs are still far from 
being evaluated in the clinic. Preclinical data supporting the potential of this pharmacologic 
approach are still missing and optimizations of each single fragments of integrin-targeted 
SMDCs may lead to deeper understanding of this drug delivery constructs. 
1.6. Work of Our Research Group in the Field – State of the Art 
Between 2009 and 2012, our research group developed a new library of cyclic integrin ligands 
where the 2,5-diketopiperazine (DK1-DK8, Fig. 23A) scaffold had the function of constrain the 
RGD tripeptide sequence. In addition to the decrease of flexibility of the peptide backbone, the 
cyclic peptidomimetic structure prevents metabolic cleavage of amide bonds in α-amino 
peptides. Furthermore, the DKP ring itself is able to participate to ligand-receptor interactions, 
owing to the presence of hydrogen bond donors and acceptors, such as amide protons and 
carbonyl groups, respectively. Thus, a better interaction with the biological target can be 
achieved by introducing diversity in the DKP ring at four positions. In this frame, our research 
group synthesized a small library of DKP scaffolds, varying the configuration at C3 and C6 and 
the substitution at N1 and N4 (DKP1-DKP8, Fig. 23A). Later on, with these DKPs in hands, a 
group cyclo[DKP-RGD] peptidomimetics bearing the RGD recognition motif was prepared (67-
74, Fig. 23B).[123,124] 
Figure 23. A) DKP1-DKP8 scaffold library and the B) corresponding cyclo[DKP-RGD] peptidomimetics (67-74).[124] 
In vitro binding assays on the isolated αvβ3 and αvβ5 integrin receptors (i.e. ability to compete 
with the endogenous ligand fibronectin for binding to integrins) qualified the previously 
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prepared ligands 67-74 as low nanomolar binders for αvβ3 and demonstrated that the DKP ring 
strongly influences the ligand affinity for the receptor.[124] In contrast to reference compound 
Cilengitide (45, Fig. 16), these peptidomimetics displayed a higher αvβ3/αvβ5 selectivity ration 
for αvβ3 integrin receptor.[124] Compounds 67-74 were studied by NMR technique and MC/SD 
simulations, to elucidate their conformational preferences: the highest affinity for the αvβ3 
receptor was associated to a defined and extended arrangement of the RGD tripeptide, due to 
the presence of intramolecular hydrogen bond patterns locking the backbone flexibility. Due to 
its low-nanomolar affinity for the αvβ3 receptor and to its relatively easy synthetic preparation, 
supplementary in vitro biological studies were performed on cyclo[DKP3-RGD] (69): the tested 
compound efficiently inhibited angiogenesis in HUVECs.[125] Additionally, ligand 69 has been 
recently classified as a αvβ3 antagonist, due to its inhibitory effect on integrin-mediated FAK/Akt 
transduction pathways and cell infiltration processes. For this reason, it is important to highlight 
the difference between cyclo[DKP-RGD] ligand (αvβ3 antagonist) and the well-known 
Cilengitide (45, αvβ3 agonist). Besides, ligand 69 did not affect other cellular aspects (e.g. cell 
viability and proliferation).[126] 
 
Figure 24. Molecular structures of cyclo[DKP-RGD] (75) integrin ligand and of cyclo[DKP-RGD]-PTX conjugate 
(76).[127] 
As the cyclo[DKP3-RGD] (69) was selected as hit compound, our research group 
functionalized the DKP scaffold of peptidomimetic 69 with a benzylamino moiety. This 
nucleophilic group on the new cyclo[DKP-RGD] ligand (compound 75, Fig. 24)[127] has been 
used as attaching point for the conjugation of different compounds, such as PTX,[127] a pro-
apoptotic SMAC mimetic compound[128] and an anti-angiogenic peptide.[129] Particularly, PTX 
was connected to the cyclo[DKP-RGD] targeting ligand (cyclo[DKP-RGD]-PTX 76, Fig. 24) 
through a succinate moiety and, despite the increased steric hindrance on the cyclo[DKP-
RGD] part, conjugate 76 retained a low nanomolar affinity and a high selectivity towards αvβ3 
integrin [IC50 (αvβ3) = (5.2 ± 2.3) nM and IC50 (αvβ5) = (219 ± 124) nM]. Antitumor assays of 
conjugate 76 in nude mice xenografted with IGROV-1/Pt1 cancer cells (i.e. an αvβ3-
overexpressing cell line) showed a better efficacy of the conjugate with respect to the free PTX. 
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Indeed, due to the active integrin targeting, the antitumor activity of 76 was superior than the 
free drug despite the lower molar dose administered to the animal (Fig. 25C), thus revealing 
that the conjugation with the cyclo[DKP-RGD] ligand improves the antitumor effect of PTX. 
However, while conjugate 76 showed stability for at least 7 days in physiological solution (Fig. 
25A), the ester linker proved to be less stable in plasma, and the release of free PTX occurred 
with half-lives of 143 min and 165 min in human and murine plasma respectively (Fig. 25B).[127] 
 
Figure 25. A) Stability of conjugate 76 (1.28 mM) in physiological solution; B) Stability of 76 in murine plasma; C) 
biological evaluation of 76 in vivo compared to paclitaxel (PTX) on IGROV-1/Pt1 ovarian carcinoma. Adapted 
from.[127] 
Such in vivo studies with conjugate 76 pointed out the advantage of using cyclo[DKP-RGD] 
integrin ligands as targeting compound for the selective tumor-targeted delivery of cytotoxic 
agents. At the same time, the plasma stability of this ester linker showed to be too low to 
exclude a premature drug release in circulation, confirming that the linker system is a critical 
point for the efficacy of the conjugate and its essential role in the selective release of the 
cytotoxic drug within the tumor site. These findings prompted the development of different 
systems to link the portions of the conjugate. 
In 2015, our research group synthesized the conjugate cyclo[DKP-RGD]-Val-Ala-PTX (77, Fig. 
26).[130] Conjugate 77 was composed by the integrin ligand cyclo[DKP-RGD], the cytotoxic 
agent (PTX), the dipeptide linker (valine-alanine, Val-Ala) and two different spacers (i.e. the 
spacer between the dipeptide linker and PTX allowed the conjugation through a carbamate 
bond, which is known to be more stable in plasma than esters or carbonates). The mechanism 
of drug release of this construct is similar to the one described for enzyme-cleavable linkers 
(Paragraph 1.4.2., Scheme 3A). Conjugate 77, showed a high affinity to the purified αvβ3 
receptor [IC50 (αvβ3) = (13.3 ± 3.6) nM and IC50 (αvβ5) = (924 ± 290) nM]. At the same time, 
noticeable selectivity was displayed for the integrin over-expressing cell line CCRF-CEM αvβ3 
with respect to the isogenic cell line CCRF-CEM devoid of the target receptor [i.e. the ratio 
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between the cytotoxicity in αvβ3(-) and αvβ3(+) cell lines (i.e. IC50 values) highlighted the 
selectivity (S) of such conjugate (S = 66.9)].[130] 
 
Figure 26. Molecular structures of the conjugates cyclo[DKP-RGD]-Val-Ala-PTX (77) and cyclo[DKP-RGD]-
uncleavable-PTX (78). 
The analog conjugate cyclo[DKP-RGD]-uncleavable-PTX 78 was designed to be unable to 
release of PTX, and thus used as negative control in anti-proliferative assays: the conjugate 
showed no cytotoxic activity against the tumor cell lines. Curiously, free PTX itself showed a 
marked selectivity against CCRF-CEM αvβ3(+) cells (S = 7.4), allowing the correction of the 
selectivity value of conjugate 77, by taking into account the different biological activity of PTX 
in the two cell lines (Targeting Index, TI). TI was calculated as follows: 
T. I. =  
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦SMDC 𝟕𝟕
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦Free Drug
 
Interestingly, conjugate 77 displayed a TI = 9.0, showing a remarkable value for the direct 
evaluation of the tumor-targeting ability of 77 in vitro.[130] Moreover, conjugate 77 has been 
evaluated in vitro with different cellular models.[131] 
Additionally, our research group has also been developing different SMDCs targeting αvβ3 
integrin receptor. In particular, the use of reductively cleavable disulfide linkers was explored 
with the synthesis of a cyclo[DKP-RGD]-SS-CPT conjugate. The compound showed TI = 0 
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due to the low stability of the α,α-unsubstituted disulfide bond in the cell medium.[132] Moreover, 
new payloads were employed, such as the natural product α-amanitin. Conjugates cyclo[DKP-
RGD]-Val-Ala-α-amanitin from our group displayed reduced potency in αvβ3(+) and αvβ3(-) cell 
lines when compared with free drug (i.e. α-amanitin). Moreover, no targeting was observed 
against αvβ3(+) cell line.[133] 
In order to improve the TI value of our conjugates, an intense analysis on the increase of the 
conjugates valency (i.e. exploitation of multivalency concept), the exploration of different linker 
structures and the implementation of more potent cytotoxic payloads have been proposed as 
strategies to achieve and develop more efficient integrin-targeted prodrugs. The mentioned 
topics will be discussed in the following Chapters. 
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Multimeric cyclo[DKP-RGD]-PTX Conjugates 
Part of the work described in this Chapter was published in the following articles: 
• A. Raposo Moreira Dias, A. Pina, A. Dal Corso, D. Arosio, L. Belvisi, L. Pignataro, M. Caruso, 
C. Gennari, Chem. Eur. J. 2017, 23, 14410-14415. 
• P. L. Rivas, I. Ranđelović, A. Raposo Moreira Dias, A. Pina, D. Arosio, J. Tóvári, G. Mező, A 
Dal Corso, L. Pignataro, C. Gennari, Eur. J. Org. Chem. 2018, 2902-2909. 
2.1 Introduction 
The choice of the linker is fundamental for the SMDC efficacy, being the key of the correct 
equilibrium between the linker stability in circulation and its fast cleavage at the tumor site. 
Besides, previous data reported by our research group (Chapter I, Paragraph 1.6) established 
that precise modifications of the linker structure are crucial for the achievement of good 
selectivity. It is important to note that most of the publications in the field of αvβ3-targeted 
chemotherapeutics do not report the required data for the calculation of the Targeting Index 
(TI), such as the in vitro cell antiproliferative activity of conjugate and free drug against two 
cancer cell lines, with different αvβ3 integrin expression. Considering all available literature 
reporting sufficient data for the calculation of this parameter, the TI of 9.0 achieved by 
cyclo[DKP-RGD]-Val-Ala-PTX 77 is still the highest ever reported.[50] Moreover, the TI of 9.0 
demonstrates that the use of the Val-Ala linker may be a promising starting point for the 
development of new-generation SMDCs, based on RGD ligands and the Paclitaxel payload. 
On the other hand, this TI value is still far from the data relative to a large number of ADC 
products. For instance, TI values in the order of 1000-2000 have been frequently reported for 
some ADCs, which indicates these biotherapeutics as the best-in-class in the active drug 
delivery field (Table 1).[50] However, some remarkable TI values can be calculated with 
literature data available for some SMDC products, specific to non-integrin targets. 
Nevertheless, TI values reported for SMDC constructs are often one order of magnitude lower 
than for ADCs. Generally, small molecules as tumor-homing devices are frequently described 
as weaker binders than mAbs. This is due to the different structural basis of antigen 
recognition: while most of small ligands bind to a small and specific binding pocket (e.g. the 
active site of an enzyme), high-affinity antibodies normally interact with a larger antigen surface 
(epitope), whose shape is complementary to the mAb’s variable region. As a result, it is 
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conceivable to correlate such lower binding affinity to the in vitro and in vivo selectivity 
displayed by the corresponding SMDCs, and consequently, the TI values. 
As an example, for ADCs, Table 1A and Fig. 27 demonstrate the highly selective 
antiproliferative activity of the PSMA-targeted ADC 79 against the PSMA expressing cancer 
cell line MDA PCa2b, achieving a TI of 1716.[134] 
Table 1. Antiproliferative activity of the PSMA-targeted ADC 79 (A)[134], Her2-targeted ADC 80 (B)[135], folate 
receptor-targeted SMDC 81 (C)[21], and SMDC 77 from our group (D)[130] against cancer cell lines with different 
expressions of PSMA, Her2, FR and αvβ3, respectively. [a] Selectivity (S): IC50(receptor −)/IC50(receptor +); [b] 
Targeting index (TI): selectivity/selectivity observed with free drug. 
 
Figure 27. Molecular structures of the examples described in Table 1. 
Structure 
IC50 (nM) 
S[a] T.I.[b] 
Negative Antigen  Positive Antigen  
A PC3 (PSMA −) MDA PCa2b (PSMA +)   
Monomethyl auristatin E (MMAE, 29) 0.970 0.363 2.7 1 
mAb(PSMA)-Val-Cit-MMAE (79) 83.4 0.018 4633.3 1716 
B MDA-MB-231 (Her2 −) SK-BR-3 (Her2 +)   
Monomethyl auristatin E (MMAE, 29) 0.038 0.004 9.5 1 
mAb(Her2)-Gal-MMAE (80) No cytotoxicity 0.009 >1000 >1000 
C A549 (FR −) KB (FR +)   
Monomethyl auristatin E (MMAE, 29) 0.872 0.240 3.6 1 
Folate-MMAE (81) 195.2 0.240 813.5 226 
D CCRF-CEM (αvβ3 −) CCRF-CEM (αvβ3 +)   
Paclitaxel (PTX, 20) 155 21 7.4 1 
cyclo[DKP-RGD]-VA-PTX (77) 5153 77 66.9 9.0 
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Another successful example of selective ADC development is the recent effort of Papot and 
co-workers (Table 1B), where a highly selective ADC construct was designed for the treatment 
of breast cancer.[135] Indeed, this construct displayed better therapeutic efficacy than 
commercial trastuzumab emtansine (Kadcyla 31, Fig. 8). Table 1B shows the noticeable 
antiproliferative activity of the Her2-targeted ADC 80 against the Her2-expressing cancer cell 
line SK-Br-3 (values obtained were in the picomolar range).[135] By contrast, ADC 80 did not 
show activity against Her2-non-expressing MDA-MB-231 cancer cells, leading to a remarkable 
TI. Regarding literature data about SMDCs, the TI value of one of the best conjugates targeting 
folate (compound 81, Fig. 27) was around 226 (Table 1C), indicating that it is actually possible 
to calculate TI values higher than 9.0 using SMDC products.[21]  
A well-known strategy to increase the binding affinity and selectivity of a SMDC towards the 
cells overexpressing integrin αVβ3 is the formation of multivalent interactions between the 
ligand and the target antigen. This strategy is the most common approach to increase this 
binding strength, according to a biomolecular principle often referred to as “avidity”.[136]  
Accordingly, this Chapter aimed at synthesizing new multimeric αvβ3-targeted SMDCs, in order 
to increase their binding avidity, potentially resulting in higher T.I. values. 
2.1.1. Multivalency 
Multivalent interactions are used by nature to generate stronger binding between two units 
(e.g. ligand/receptor). For instance, viruses, antibodies, protein complexes are multivalent 
entities possessing a high number of recognition units or binding moieties (e.g. targeting 
ligands) able to interact with another multivalent entity (Fig. 28).[137] Essentially, the interesting 
feature of multivalent interactions is the ability of enhancing the avidity  of multivalent species, 
resulting in an apparent enhancement of the binding affinity of each individual binding 
unit.[138,139,140] Indeed, the increased ligand binding strength in multivalent constructs can derive 
from several different mechanisms: 1) receptor/protein aggregation or clustering, 2) chelation, 
and 3) statistical rebinding (Fig. 28).[141] 
 
Figure 28. Up) Example of multivalent interactions between two entities to increase the binding strength.[136] Down) 
A) binding to a cluster of receptors; B) chelation to a divalent protein; C) statistical rebinding with the increase of 
ligand concentration, enhancing the rebinding rate and, consequently, the binding strength.[141] 
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Translating this for tumor-targeted therapy or diagnosis, a variety of radiotracers for tumor 
imaging have been conjugated to multimeric RGD peptides, showing increased tumor uptake 
and reduced site accumulation to other organs.[142,143,144,145] Besides the applications for tumor 
imaging in vivo, which have reached the clinic, the advantages of using multimeric ligands 
have been also studied in vitro.[102,120,146,147] In particular, a large contribution in this field has 
been given by Boturyn and co-workers,[148] who developed a RAFT scaffold for the use of 
multipresentation in RGD constructs, as previously mentioned in Paragraph 1.5.2.[149,150,151] 
Notably, it was demonstrated that a tetrameric probe 82 (RAFT-c[RGDfK]4-Cy5) displayed 
higher binding affinity for the isolated integrin αvβ3 receptor when compared to monomeric 
analog (Kd = 3.87 nM for tetrameric construct VS Kd = 41.70 nM for the monomeric analog). 
Interestingly, when the RGD ligand was replaced by a non-targeting RAD ligand (RAFT-
c[RADfK]4-Cy5), the construct lost the affinity for the receptor (Kd > 10000 nM). Later on, the 
same research group proved that the tetrameric construct 82 increased the endocytosis of a 
fluorescent probe in HEK293 cells (i.e. β3-transfected human kidney cell line) by 12%, 
compared to the monomeric analog, after incubation for 10 minutes.[152]  
This study proved that multimeric αvβ3-targeting systems can exhibit higher binding affinity to 
the receptor when compared to monomeric analogs, which reflects in a higher cell adhesion 
and in a more efficient receptor-mediated endocytosis.[153,154]  
 
Figure 29. Molecular structure of RAFT-c(RGDfK)4-Cy5 (82) and confocal analysis on HEK293(β3) cells (A – 
incubation with 1 µM of tetrameric 82 and B - 1 µM of monomeric c(RGDfK)-Cy5 compound) after 10 minutes. Cells 
were analyzed at 633 nm.[152] 
The use of multimeric αvβ3-targeted compounds for delivery of cytotoxic payloads has been 
investigated by Zanardi,[122] Manzoni and co-workers.[155] In 2012, a monomeric and dimeric 
conjugates [i.e. [AmproRGD]-PTX (65) and [AmproRGD]2-PTX (83)] carrying AmproRGD as 
targeting ligand (Fig. 30) were developed. Later on, the same group evaluated the use of 
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AbaRGD (Fig. 30) as targeting ligand, preparing monomeric (66), dimeric (84) and tetrameric 
(85) [AbaRGD]n-PTX SMDCs (n = 1, 2 or 4). 
 
Figure 30. Molecular structures of mono and multimeric conjugates synthesized bearing AmproRGD and AbaRGD 
as targeting ligands. Molecular structures of 65 and 83 taken from ref.[122] and 66, 84 and 85 from ref.[155] 
Table 2. Cytotoxicity assays of conjugates bearing AmproRGD and AbaRGD as targeting ligands and free PTX in 
IGROV-1 and IGROV-1/Pt1 cell lines. Table adapted from[122,155]. 
 
 
 
 
These works represented the proof of concept that the apparent integrin affinity can be 
increased by multipresentation of RGD units.[122,155] However, the increased avidity was not 
found to correlate with the selective anticancer activity of the conjugates for αvβ3-expressing 
cells. In fact, cell antiproliferative tests were run against two cell lines expressing different 
Cpd Structure IC50 (nM) 
  
IGROV-1 
(v3 −) 
IGROV-1/Pt1 
(v3 +) 
  65 [AmproRGD]-PTX 43.1 ± 6.8 3.4 ± 2.4 
83 [AmproRGD]2-PTX 28.0 ± 2.2 1.6 ± 0.5 
20 PTX 23.4 ± 8.2 2.2 ± 0.8 
  
IGROV1 
(αvβ3 −) 
IGROV-1/Pt1 
(αvβ3 +) 
66 [AbaRGD]-PTX 1.6 ± 0.9 1.6 ± 1.1 
84 [AbaRGD]2-PTX 32.67 ± 7.5 6.65 ± 3.76 
85 [AbaRGD]4-PTX 12.18 ± 1.00 8.81 ± 2.14 
20 PTX 58.55 ± 11.71 4.3 ± 1.17 
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integrin levels: in particular, the IC50 values reported for all tested conjugates highlighted a 
remarkable potency of the SMDCs against the αvβ3 integrin-expressing cell line. However, 
such intrinsic selectivity is also displayed by the free PTX. This lack of selectivity is probably 
due to the fast hydrolysis of the ester linker, as already reported in the literature.[127] 
Inspired by these literature data, we set to design new multimeric (cyclo[DKP-RGD]-PEG-4)n-
VA-PTX conjugates (n = 1-4) for tumor targeting (Fig. 31), aiming at improving the binding 
affinity and TI towards αvβ3-expressing cells shown by the monomeric cyclo[DKP-RGD]-VA-
PTX (77). 
 
Figure 31. General structure of multimeric (cyclo[DKP-RGD]-PEG-4)n-VA-PTX conjugates (n = 1-4) and 
retrosynthetic analysis of multimeric conjugates (disconnection into azide 86 and different alkyne intermediates 
bearing multimeric scaffolds 87-90). 
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In order to allow an easy and general synthetic preparation, a mono- (86) and polyalkyne 
scaffolds (87-90) were connected to the N-terminus of the Val-Ala linker. The monomeric 
scaffold (commercial 4-pentynoic acid 87) was included for the synthesis of a monomeric 
conjugate, to be used as control for the biological evaluations of the multimeric analogs. The 
scaffolds were chosen taking into account the central connection of such molecules, which 
need to be balanced in terms of rigidity and flexibility, so that the loss of conformational entropy 
can be minimized.[156] Therefore, the terminal alkyne moieties of the paclitaxel prodrug (Fig. 
31) were used as anchoring point for the installation of one, two, three or four cyclo[DKP-RGD] 
integrin ligands, through Cu-catalyzed azide-alkyne cycloaddition (CuAAC).[157] A derivative of 
the RGD peptidomimetic bearing an azido-tetraethylene glycol spacer (compound 86) was 
designed and synthesized to be coupled to the alkyne moieties, in the final conjugation 
reaction. This particular molecular structure was chosen as it is known that polyethylene glycol 
(PEG) spacers are ”inert” to nonspecific adsorption to proteins, promoting the specific binding 
of each individual unit to the receptor.[158] Moreover, this flexible layout could help the SMDC 
to adapt to the target αvβ3 integrin.[141] Finally, besides improving the SMDC solubility in 
aqueous media, short PEG spacers are known to minimize the generation of bulky loops, that 
can limit the ligand avidity to the antigen.[111] 
2.2. Synthesis and Biological Evaluation of a New Monomeric 
cyclo[DKP-RGD]-PEG-4-VA-PTX Conjugate 
2.2.1. Synthesis of a New Monomeric cyclo[DKP-RGD]-PEG-4-VA-PTX Conjugate 
Following the retrosynthetic scheme represented in Figure 31, the synthesis of fragments 86 
and paclitaxel derivative containing commercial alkyne 87 converged to the final isolation of 
the new PEG-containing monomeric cyclo[DKP-RGD]-PEG-4-VA-PTX conjugate. 
As for the synthesis of the functionalized integrin ligand with the azido-tetraethylene glycol 
spacer 86 is shown in Scheme 4. 
 
Scheme 4. Synthesis of cyclo[DKP-RGD]-PEG-4-Azide (86). Reagents and conditions: a) EDC∙HCl, N-
Hydroxysuccinimide, CH2Cl2, overnight; b) cyclo[DKP-RGD] (75), MeCN/PBS pH 7.5 (1:1), overnight. 
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Azido-acid 91 was synthesized according to a previously reported methodology, starting from 
commercially available tetraethylene glycol.[159] Azido-acid 91 was transformed into the 
corresponding N-hydroxysuccinimidyl ester, which was purified by flash chromatography, 
affording the activated ester 92 with 64% yield. The purified electrophile 92 was then reacted 
with the cyclo[DKP-RGD] ligand (75),[127] affording the final azide 86 in 77% yield, after 
purification by semi-preparative HPLC and freeze-drying. As a well-established procedure from 
our group, this conjugation step was run at controlled pH, since at pH < 7.0 the reaction does 
not proceed, whereas at pH > 7.6 the hydrolysis of the NHS ester competes significantly with 
the desired coupling. The pH was maintained in the 7.3-7.6 range by adding aliquots of 0.2 M 
aq. NaOH to the reaction mixture.[130]  
 
Scheme 5. Synthesis of monomeric cyclo[DKP-RGD]-PEG-4-VA-PTX conjugate 97. Reagents and conditions: a) 
1) piperidine, DMF, r.t., 2 h; 2) 4-pentynoic acid 87, HATU, HOAt, iPr2NEt, DMF, r.t., overnight; b) 1) 1:2 TFA/CH2Cl2, 
45 min; 2) 95, iPr2NEt, DMF, r.t., overnight; c) 86, CuSO4∙5H2O, NaAsc, 1:1 DMF/H2O, 35 ºC, overnight. 
After the synthesis of the necessary azide fragment 86 for the construction of the final 
conjugate, the monomeric cyclo[DKP-RGD]-PEG-4-VA-PTX, featuring the alkyl scaffold (97), 
was synthesized by coupling of the free alkyne present in Val-Ala-PTX (96, Scheme 5) moiety 
with the azide 86 – Scheme 5. The alkyne derivative of PTX (96) was synthesized starting from 
the protected Val-Ala linker 93 (previously synthesized and described by our laboratory)[130] 
that was treated with piperidine for the Fmoc removal and then coupled with commercial 4-
pentynoic acid to give the alkyne 94 (88% yield). Later on, the Boc group in amide 94 was 
removed and the corresponding free amine was reacted with 2’-(4-
nitrophenoxycarbonyl)paclitaxel (95, previously synthesized and described by our 
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laboratory)[130] affording carbamate 96 with 66 % yield over two steps. A Cu-Catalyzed Azide-
Alkyne Cycloaddition (CuAAC)[160] was performed between alkyne 96 and azide 86, affording 
the monomeric conjugate cyclo[DKP-RGD]-PEG-4-VA-PTX (97) in 81% yield after HPLC 
purification and freeze-drying. 
2.2.2. Cell Proliferation Analysis 
In order to first assess the ability of the synthesized monomeric conjugate (97) to selectively 
target αvβ3 integrin in human cancer cells, the antiproliferative activity of cyclo[DKP-RGD]-
PEG-4-VA-PTX (97) was tested in parallel with other monomeric RGD-PTX conjugates 
developed by our research group (Figure 32).[161] In particular, the tested compounds differed 
from the targeting ligand (RGDfK or cyclo[DKP-RGD]), the spacer between the linker and the 
homing-device (glutarate or PEG spacer) and the lysosomally-cleavable peptide linker (Gly-
Phe-Leu-Gly or Val-Ala) (77, 98-101, Fig. 32). 
 
Figure 32. Molecular structures of cyclo[DKP-RGD]-VA-PTX (77), cyclo[DKP-RGD]-GFLG-PTX (98), 
cyclo[RGDfK]-GFLG-PTX (99), cyclo[DKP-RGD]-PEG-4-GFLG-PTX (100) and cyclo[RGDfK]-PEG-4-GFLG-PTX 
(101). 
In collaboration with the National Institute of Oncology in Budapest, Hungary (Prof. József 
Tóvári) all six compounds (77 and 97-101) were tested in two different cell lines expressing 
the integrin receptor at different levels: 1) the human colorectal adenocarcinoma cell line HT29 
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(αvβ3 −) and, 2) the human glioblastoma cell line U87 (αvβ3 +). The different αvβ3 expression 
on the cell membrane of the two cell lines was confirmed by treatment the cells with a 
fluorescein-labeled αvβ3-selective mAb, followed by cell immunofluorescence analysis and flow 
cytometry (Fluorescence Activated Cell Sorter - FACS). The graphics of αvβ3 expressions for 
each cell line are shown in the Experimental Section (Figures 45-46). 
The two cell lines were incubated with increasing doses of free PTX and conjugates (77 and 
97-101). After 96 hours, the cell viability was analyzed by MTT assay (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide). 
The measured IC50 values are shown in Table 3. 
Table 3. Cytotoxicity assays of conjugates 77 and 97-101 and free PTX in U87 and HT29 cell lines. 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability. Both 
cell lines were treated with different concentrations of PTX and compounds 77, 97-101 for 96 hours. The samples 
were measured in triplicate; [b] Relative Potency in U87 cell line (RPU87): IC50 PTX in U87/ IC50 Conjugate in U87; 
[c] Relative Potency in HT29 cell line (RPHT29): IC50 PTX in HT29/ IC50 Conjugate in HT29; [d] Targeting Index (TI): 
RPU87/RPHT29. 
From the in vitro assays emerged that all conjugates displayed a significant loss of potency 
(higher IC50 values) when compared to the free drug PTX 20 (i.e. for U87 and HT29 cell lines). 
In general, all conjugates featuring a PEG spacer (97 and 100-101) proved 2.4-6.2 times more 
potent (compared to the analogs having a glutarate spacer – 77 and 98-99) against the αvβ3-
expressing cell line (U87). This is in line with the benefits of PEG spacers in terms of 
hydrophilicity and flexibility, possibly facilitating the binding to the antigen.[141] Moreover, the 
replacement of the cyclo[DKP-RGD] ligand moiety with the well-known cyclo[RGDfK] did not 
influence significantly the targeting properties. Relative Potencies (RP) were calculated (i.e. 
RP = IC50PTX / IC50SMDC) for the conjugates in both cell lines. This parameter was introduced 
as a normalization of conjugates’ potency considering the sensitivity of each cell line for free 
PTX. Accordingly, it can be observed that for all conjugates, the RP in HT29 cell line (αvβ3-) 
was 1-2 orders of magnitude lower than in αvβ3-expressing cell line (U87). This suggests that 
the loss of potency of the conjugates with respect to PTX is more evident when αvβ3 receptor 
is not presented on the surface of tumor cells. Moreover, good TI’s were detected for all 
conjugates (Table 3), with values between 30-45. To our delight, the new monomeric conjugate 
Cpd Structure 
IC50 (nM)[a] 
RPU87[b] RPHT29[c] TI[d] 
U87 (v3 +) HT29 (v3 −) 
20 PTX 1.8 ± 1.9 32.7 ± 21.8 1 1 1 
77 cyclo[DKP-RGD]-VA-PTX 2686 ± 589 6452 ± 1723 0.01216 0.0002821 43 
97 cyclo[DKP-RGD]-PEG-4-VA-PTX 432.6 ± 129.3 12840 ± 2730 0.07550 0.0001417 533 
98 cyclo[DKP-RGD]-GFLG-PTX 2031 ± 454 3413 ± 983 0.01608 0.00053 30 
99 cyclo[RGDfK]-GFLG-PTX 1250 ± 293.6 2692 ± 676 0.02613 0.000692 38 
100 cyclo[DKP-RGD]-PEG-4-GFLG-PTX 854.7 ± 165.1 1979 ± 252 0.03821 0.0009196 42 
101 cyclo[RGDfK]-PEG-4-GFLG-PTX 
506.20 ± 
113.60 
1272 ± 156 0.06452 0.001431 45 
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cyclo[DKP-RGD]-PEG-4-VA-PTX (97) displayed a TI = 533, becoming the best throughout the 
series. Additionally, competition experiments demonstrated that the potency of 97 against 
αVβ3-positive cells (U87) was decreased by the presence of a large excess of free ligand 
cyclo[DKP-RGD] in the cell medium, in keeping of the hypothesis of conjugate internalization 
by αVβ3-mediated endocytosis.[161] 
Finally, conjugate cyclo[DKP-RGD]-PEG-4-VA-PTX (97) led to the best targeting 
performances, which prompted its use as starting point for the development of the multimeric 
library (Figure 31) previously mentioned. 
2.3. Synthesis and Biological Evaluation of Multimeric (cyclo[DKP-
RGD]-PEG-4)n-VA-PTX Conjugates (n = 1-4) 
2.3.1. Synthesis of Multimeric (cyclo[DKP-RGD]-PEG-4)n-VA-PTX (n = 1-4) Conjugates 
Following the retrosynthetic analysis shown in Figure 31, four different (cyclo[DKP-RGD]-PEG-
4)n-VA-PTX (n = 1-4) conjugates have been synthesized, and their molecular structures are 
reported in Fig. 33. In addition to the three multimeric (cyclo[DKP-RGD]-PEG-4)n-VA-PTX (n = 
2-4) conjugates (103-105), a new monomeric construct (102) was prepared, in which the 
aliphatic scaffold of monomeric conjugate 97 is replaced by an aromatic scaffold. This 
derivative was designed to investigate the biological contribution of the aromatic scaffolds 
present in the multimeric conjugates (103-105). 
 
Figure 33. Molecular structures of monomeric (102) and multimeric (103-105) (cyclo[DKP-RGD]-PEG-4)n-VA-PTX (n 
= 1-4). 
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As a further step, the mono-alkyne (109, Scheme 6) and polyalkyne scaffolds 87-90 (Schemes 
7-9) were synthesized to be connected to the Val-Ala-PTX module, at the N-terminus of the 
peptide linker. (Fig. 31). The mono-alkyne scaffold 109 was synthesized starting from 4-
hydroxybenzoic acid 106, which was firstly converted in the corresponding ester 107. 
Compound 107 was mixed with propargyl bromide affording 108 and then saponified giving 
109 with high overall yield – Scheme 6. 
 
Scheme 6. Synthesis of monomeric aromatic scaffold (109). Reagents and conditions: a) H2SO4, MeOH, reflux, 4 
h; b) propargyl bromide, K2CO3, acetone, r.t., 24 h; c) NaOH, MeOH/H2O (3:1), r.t., 5 h. 
The dimeric scaffold was synthesized starting from commercially available methyl 3,5-
dihydroxyphenyl acetate (110), which was reacted with propargyl bromide allowing the 
isolation of 111 and then saponified, affording carboxylic acid 88, with quantitative yields – 
Scheme 7. 
 
Scheme 7. Synthesis of dimeric scaffold (88). Reagents and conditions: a) propargyl bromide, K2CO3, acetone, r.t., 
24 h; b) LiOH∙H2O, THF/H2O (2:1), 0 °C, 1.5 h. 
As for the trimeric scaffold 89 (Scheme 8), the commercially available methyl 3,5-
dihydroxyphenylacetate 110 was firstly refluxed in acetone in presence of commercially 
available 2-(Boc-amino)ethyl bromide and base, affording the fully protected diamine 112 in 
87% yield. Later on, two reactions were carried out in parallel: 1) first, the Boc protecting groups 
were removed by reaction with TFA, yielding the salt 113, and 2) dimeric scaffold 88 was 
activated in presence of thionyl chloride for one hour in CH2Cl2 affording the acyl chloride 114. 
The coupling between 113 and 114 was then performed in a 5:1 molar ratio, respectively, at 0 
ºC, leading to the mono amine 115. The latter, without being isolated, was coupled to 
monomeric scaffold 109, affording the trimeric alkyne ester 116 in 30% yield after three steps 
(Scheme 8). Finally, trimeric scaffold 89 was obtained after saponification reaction of 116 in 
presence of LiOH and flash chromatography purification (99% yield). 
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Scheme 8. Synthesis of trimeric scaffold (89). Reagents and conditions: a) 2-(Boc-amino)ethyl bromide, K2CO3, 
acetone, reflux, overnight; b) TFA/CH2Cl2 (1:2), r.t., 45min; c) 114, Et3N, DMF, r.t., overnight; d) 109, HATU, HOAt, 
iPr2NEt, DMF, overnight; e) LiOH∙H2O, THF/H2O (2:1), 0 °C, 1.5 h. 
In the synthesis of the tetrameric aromatic scaffold 90, the commercially available methyl 3,5-
dihydroxyphenylacetate 110 was again refluxed in acetone in the presence of commercially 
available 2-(Boc-amino)ethyl bromide and potassium carbonate, affording the fully protected 
diamine 112 in 87% yield. The Boc protecting groups were removed in the presence of TFA, 
and the resulting diamine-TFA salt 113 was coupled with bis-alkyne 85, which in turn had been 
prepared from methyl 3,5-dihydroxyphenylacetate 110 (by treatment with propargyl bromide 
and ester hydrolysis) – Scheme 7. The coupling of 113 with 88 was carried out in the presence 
of HATU, HOAt and base in DMF, affording amide 117 in 77% yield. The latter compound 117 
was deprotected, affording the desired tetrameric aromatic scaffold 90 in 85% yield (Scheme 
9). 
 
Scheme 9. Synthesis of tetrameric scaffold (90). Reagents and conditions: a) 2-(Boc-amino)ethyl bromide, K2CO3, 
acetone, reflux, overnight; b) TFA/CH2Cl2 (1:2), r.t., 45 min; c) 88, HATU, HOAt, iPr2NEt, DMF, overnight; d) 
LiOH∙H2O, THF/H2O (2:1), 0 °C, 1.5 h. 
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Scheme 10. Synthesis of (cyclo[DKP-RGD]-PEG-4)n-VA-PTX (n = 1-4) conjugates 102-105. Reagents and 
conditions: a) 1) piperidine, DMF, r.t., 2 h; 2) acids 109, 88-90, HATU, HOAt, iPr2NEt, DMF, r.t., overnight (118a-
118d); b) 1) 1:2 TFA/CH2Cl2, 45 min; 2) 95, iPr2NEt, DMF, r.t., overnight; c) 86, 119a (1.5 equiv), CuSO4∙5H2O, 
NaAsc, 1:1 DMF/H2O, 35 ºC, overnight; d) 119b (1 equiv), 86 (3 equiv) CuSO4∙5H2O, NaAsc, 1:1 DMF/H2O, 35 ºC, 
overnight; e) 119c (1 equiv), 86 (3.6 equiv), CuSO4∙5H2O, NaAsc, 1:1 DMF/H2O, 35 ºC, overnight; f) 119d (1 equiv), 
86 (4.8 equiv) CuSO4∙5H2O, NaAsc, 1:1 DMF/H2O, 35 ºC, overnight. 
The monomeric cyclo[DKP-RGD]-PEG-4-VA-PTX, featuring an aromatic scaffold (102, Figure 
33), was synthesized using the same synthetic strategy described above for the monomeric 
conjugate bearing an alkyl scaffold (97, Scheme 5). Thus, conjugate 102 (Figure 33) was 
prepared through the convergent synthesis shown in Scheme 10. Also in this case, the Boc 
group of amide 118a was removed, and the corresponding free amine was reacted with 2’-(4-
nitrophenoxycarbonyl)paclitaxel (95), leading to carbamate 119a in 93% yield. The final 
CuAAC was performed using alkyne 119a and azide 86, affording the cyclo[DKP-RGD]-PEG-
4-VA-PTX (102, Fig. 33) possessing an aromatic scaffold, in 70% yield (after HPLC purification 
and freeze-drying). 
Later on, with the dimeric (88), trimeric (89), and tetrameric (90) scaffolds in hands, the 
synthesis of the multimeric (cyclo[DKP-RGD]-PEG-4)n-VA-PTX (n = 2-4) conjugates (103-105, 
Fig. 33) was performed following the same synthetic pathway (Scheme 10). Protected Val-Ala 
fragment 93 was treated with piperidine for Fmoc removal, and subsequent coupling with the 
acids 88-90 led to compounds 118b-118d with good yields (71-92%, Scheme 10). The Boc 
group of amides 118b-118d was then removed, and the corresponding free amines were 
reacted with 2’-(4-nitrophenoxycarbonyl)paclitaxel (95) to afford carbamates 119b-119d with 
moderately good yields (69-75%, Scheme 10).  
Copper(I)-catalyzed azide-alkyne cycloadditions were performed by varying the relative 
stoichiometric amounts of azide 86 (Scheme 10): while alkyne derivatives of PTX (119b-119d) 
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were used as limiting agent, the amount of azide 86 varied considering the valency of the 
conjugate. As for the dimeric conjugate (103), the excess of azide was 1.5 equivalents for each 
alkyne, affording (cyclo[DKP-RGD]-PEG-4)2-VA-PTX 103 (Fig. 33) in quantitative yield after 
HPLC purification and freeze-drying – Scheme 10. The final “click” reaction for trimeric and 
tetrameric conjugates (104-105, Fig. 33) was performed with a 20% excess of azide 86, with 
respect to the alkyne (3.6 and 4.8 equivalents, respectively). The final (cyclo[DKP-RGD]-PEG-
4)3-VA-PTX 104 and (cyclo[DKP-RGD]-PEG-4)4-VA-PTX conjugates 105 were isolated with 
good yields (62 and 73%, respectively) after HPLC purification and freeze-drying. 
2.3.2. Integrin Receptor Competitive Binding Assays 
As reported for previous conjugates developed in our research group (e.g. 76-77), the newly 
synthesized monomeric cyclo[DKP-RGD]-PEG-4-VA-PTX (97 and 102) and multimeric 
(cyclo[DKP-RGD]-PEG-4)n-VA-PTX (n = 2-4) 103-105 conjugates were evaluated in vitro for 
their ability to compete with vitronectin for the binding to the purified αvβ3 integrin. Screening 
assays were carried out through incubation of the immobilized integrin receptors with serial 
dilutions of the tested compounds (concentration values in the 10−12-10−5 M range) in the 
presence of a constant concentration of biotinylated vitronectin (1 μg/mL), and measuring the 
concentration of bound upon equilibration. The IC50 values obtained are listed in Table 4. 
 
Table 4. Inhibition of biotinylated vitronectin binding to 
purified integrin αvβ3. 
Cpd Structure 
v3 
IC50 [nM][a] 
97 
cyclo[DKP-RGD]-PEG-4-VA-PTX 
(aliphatic scaffold) 
14.8 ± 3.9 
102 
cyclo[DKP-RGD]-PEG-4-VA-PTX 
 (aromatic scaffold) 
27.3 ± 9.8 
103 (cyclo[DKP-RGD]-PEG-4)2-VA-PTX 4.0 ± 0.1 
104 (cyclo[DKP-RGD]-PEG-4)3-VA-PTX 1.2 ± 0.5 
105 (cyclo[DKP-RGD]-PEG-4)4-VA-PTX 1.3 ± 0.3 
69 cyclo[DKP3-RGD] 4.5 ± 0.1 
[a] IC50 values were calculated as the concentration of compound required 
for 50% inhibition of biotinylated vitronectin binding as estimated by 
GraphPad Prism software. All values are the arithmetic mean ± the 
standard deviation (SD) of triplicate determinations. 
 
Figure 34. Inhibition of biotinylated vitronectin binding to 
purified integrin αvβ3. X-axis shows the [tested 
compounds] in log scale; Y-axis shows the % of inhibition 
of the binding of biotinylated vitronectin in the presence 
of conjugates. 
As expected, all conjugates displayed binding affinity in the nanomolar range. As highlighted 
in Table 4, the two monomeric conjugates (97 and 102), bearing a single cyclo[DKP-RGD] 
targeting ligand moiety, showed little reduction of binding avidity when compared to the free 
ligand cyclo[DKP3-RGD] (69). In particular, while the free ligand showed a IC50 value of 4.5 
nM, conjugate 97 (aliphatic scaffold) and conjugate 102 (aromatic scaffold) showed IC50 values 
of 14.8 and 27.3 nM, respectively. As expected, when the number of targeting moieties in the 
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constructs raised from one to three (102-104), a clear tendency of binding affinity increments 
as well as the decrease of IC50 values was detected (IC50 conjugate 97 and 102 > 103 > 104), 
reaching lower IC50 values than the one of free cyclo[DKP3-RGD] ligand (69) – Table 4.[162] 
In particular, a plateau is reached with the trimeric conjugate 104 (IC50 = 1.2 ± 0.5 nM), 
evidencing no further improvement with the tetrameric conjugate 105 (Fig. 34). Although the 
increment of steric bulk seems to affect the binding affinity (plateau reached with 104), the 
binding potency of the trimeric conjugate was slightly higher than the one of free cyclo[DKP3-
RGD] ligand (i.e. 1.2 and 4.5 nM, respectively). 
2.3.3. Cell Proliferation Analysis 
Multimeric conjugates were tested for their ability to selectively target αvβ3 integrin in human 
cancer cells, in comparison with previously tested monomeric conjugate 97. Among the 
synthesized two monomeric conjugates, the latter was included in this test as a consequence 
of its higher binding affinity, compared to conjugate 102, endowed with the aromatic scaffold. 
Following the same approach of previous in vitro assays, (Paragraph 2.2.2.), two different cell 
lines were chosen expressing the integrin receptor at different levels: 1) the human colorectal 
adenocarcinoma cell line HT29 (αvβ3 −) and, 2) the human glioblastoma cell line U87 (αvβ3 +). 
The two cell lines were incubated with increasing doses of free PTX and conjugates 97 and 
103-105. After 96 hours, the cell viability was analyzed by MTT assay. 
The calculated IC50 values are shown in Table 5. 
Table 5. Cytotoxicity assays of conjugates 97, 103-105 and free PTX in U87 and HT29 cell lines. 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability. Both 
cell lines were treated with different concentrations of PTX and compounds 97, 103-105 for 96 hours. The samples 
were measured in triplicate; [b] Relative Potency in U87 cell line (RPU87): IC50 PTX in U87/ IC50 Conjugate in U87; 
[c] Relative Potency in HT29 cell line (RPHT29): IC50 PTX in HT29/ IC50 Conjugate in HT29; [d] Targeting Index (TI): 
RPU87/RPHT29. 
As reported for similar compounds investigated previously, all conjugates showed reduced 
potency (IC50 values) when compared to PTX (i.e. for U87 and HT29 cell lines). Importantly, 
our data showed that the valency increase in the multimeric conjugates was associated to a 
decrease of cytotoxic activity against both cell lines. These data seemed to discredit the 
hypothesis that the increased binding affinity could promote the ligand internalization and the 
Cpd Structure 
IC50 (nM)[a] 
RPU87[b] RPHT29[c] TI[d] 
U87 (v3 +) HT29 (v3 −) 
 20 PTX 24.1 ± 13.3 2.5 ± 1.2 1 1 1 
97 
cyclo[DKP-RGD]-PEG-4-VA-PTX 
(aliphatic scaffold) 
682.6 ± 169.6 6591 ± 1236 0.035335 0.000375 94.3 
103 (cyclo[DKP-RGD]-PEG-4)2-VA-PTX 2360 ± 955 7349 ± 1192 0.01022 0.000336 30.4 
104 (cyclo[DKP-RGD]-PEG-4)3-VA-PTX 13580 ± 8297 12910 ± 1700 0.001776 0.000191 9.3 
105 (cyclo[DKP-RGD]-PEG-4)4-VA-PTX 11140 ± 5908 9006 ± 1669 0.002165 0.000274 7.9 
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resulting SMDC efficiency, even though this concept has been extensively supported by 
literature data.[148,152,163] Although a loss of potency can be noticed, all conjugates resulted 
substantially more potent in U87 cells (αvβ3+) in comparison with HT29 cells (αvβ3−). The added 
value of these data is the 10-fold enhanced selectivity of PTX for the αvβ3-negative cells. The 
observation that the PTX conjugation resulted in the alteration (or in the inversion, in mono 
and dimeric conjugates) of the intrinsic selectivity of the payload, it can be ascribed to an αvβ3-
targeting effect.  
Considering RP values, TI’s were calculated (TI = RPαvβ3+ / RPαvβ3 )̶ and the best targeting 
performances was shown by the monomeric conjugate 94 (TI = 94.3). 
2.4. Results and Discussion 
Overall, the reported experiments indicate that multipresentation of RGD ligands can efficiently 
lead to enhanced functional affinity for αvβ3 integrin receptor through different structural design. 
In our constructs, ligands were connected to easily accessible multimeric scaffolds through 
short PEG spacers, with final conjugation with efficient and chemoselective synthesis. On the 
other hand, complex biological mechanisms requiring more than a simple receptor binding 
(e.g. internalization and linker cleavage), may be highly dependent on the different design of 
the construct. In particular, our multimeric conjugates (103-105) showed relatively low RP and 
TI values, even though these compounds proved more selective than other multimeric RGD-
PTX devices developed in the past (see Table 2 in this Chapter). The observed loss of 
selectivity could be explained by the increased steric bulk around the peptide linker, which is 
likely to affect significantly the intracellular proteolytic action, thus affecting progressively the 
drug release. Cleavage experiments on multimeric conjugates in the presence of lysosomal 
extract are currently in progress, with the aim to provide a rationale for the in vitro assays. 
Moreover, it is important to note that monomeric conjugate 97 has been tested twice under the 
same experimental conditions: the observed TI values were found to be 533 (Table 3) and 94 
(Table 5). These data reflect the limit of the TI value measurement, which takes into account 
the IC50 values relative to four different experiments (i.e. cell antiproliferative activity of both 
free PTX and SMDC against two different cell lines) and it is therefore subjected to high 
variability. On the other hand, both TI values indicate the high targeting potency of conjugate 
97, which can be considered as a new hit compound in the field of αvβ3-integrin-targeting 
SMDCs.  
While showing remarkable selectivity, the best-performing conjugate 97 was found to be much 
less potent than the free toxin, even against the αvβ3-positive cells. In general, this observation 
is common for most therapeutic prodrugs reported in the literature, consisting in a stable, 
chemical functionalization of the parent drug. However, our data may indicate that the 
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conjugate is poorly internalized by the targeted cell. A different approach can be also used in 
presence of different type of “smart linkers” (e.g. extracellularly-cleavable linkers) or more 
effective drugs (e.g. auristatins), improving the potency of such anticancer prodrugs for 
therapeutic use. 
 
  
 
Chapter III 
cyclo[DKP-RGD]-PTX Conjugates bearing an 
Extracellularly-Cleavable Linker 
 
  
 
cyclo[DKP-RGD]-PTX Conjugates bearing 
an Extracellularly-Cleavable Linker 
3.1 Introduction 
As discussed in Paragraph 2.4, a quantification of the targeting ability of RGD-containing 
conjugates to αvβ3-expressing cells has been rarely described in the literature. Despite the 
remarkable selectivity displayed by the monomeric and multimeric conjugates (described in 
the previous Chapter), the drop of potency displayed by such constructs, as compared to the 
activity of the free PTX payload, limits their in vivo application. 
An alternative strategy is here reported, aimed at improving the drug delivery efficacy and to 
achieve a more potent therapeutic activity. This approach consists in the development of 
conjugates that can be cleaved in the vicinity, rather than inside, of targeted cancer cells. 
Generally, it is assumed that ADCs and SMDCs should be internalized through the tumor-
associated antigens and activated by intracellular agents, to exhibit their therapeutic effect and 
to avoid undesired cytotoxic activity against healthy tissues. However, this assumption has 
been recently challenged, as non-internalizing ADC and SMDC products have shown excellent 
therapeutic profiles in vivo.[45] This approach relies on the synthesis of nontoxic SMDCs that 
can recognize non- or poorly internalizing 
tumor antigens (either specific ECM 
proteins or transmembrane receptors, 
Fig. 35, step 1): this selective binding is 
required to improve the accumulation of 
the cytotoxic agent at the site of disease. 
Later on, the linker cleavage is triggered 
in the extracellular environment, by a 
tumor-associated enzyme (Fig. 35, step 
2). While this approach focused originally 
on proteases expressed in the tumor 
stroma (e.g. Carboxylesterase 1C,[164] 
Matrix Metalloproteinases -2 and -9,[165] 
Figure 35. The principle of tumor targeting in presence of 
tumor-associated enzymes and extracellularly-cleavable 
conjugates. Targeting ligand (green ball), extracellularly-
cleavable linker (yellow), cytotoxic drug (blue) and enzyme 
(red). 
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Elastase[166]), it has been demonstrated that other types of proteases that are originally located 
in the intracellular compartments, can be released externally, for instance by dead cells in 
necrotic tumors (e.g. Cathepsin B).[71,167]  In this context, the active anticancer drug can be 
released extracellularly within the tumor microenvironment (Fig. 35, step 3),  and diffuse in the 
tumor tissue (Fig. 35, step 4).[45] Here, the cytotoxic agent would be free to kill a large variety 
of cells (e.g. endothelial cells, cancer cells devoid of the target antigen, etc.) and the resulting 
localized damage may have therapeutic benefits against certain indications. 
In this Chapter, we focused on an extracellularly-cleavable linker by elastase as tumor-
associated enzyme. Elastase is a serine protease secreted from activated neutrophils upon 
inflammation and, for this reason, it is known to be involved in the progress of certain 
inflammatory diseases (e.g. cystic fibrosis and arthritis) and of certain solid tumors  (e.g. breast, 
lung and skin cancers).[168] The pro-inflammatory nature of these tumors is characterized by a 
high number of tumor-invading leucocytes, such as neutrophils, resulting in a high expression 
of elastase in the tumor stroma.[169] Therefore, elastase can be used as extracellular trigger for  
αvβ3 integrin-targeted SMDC products, aimed at releasing the free drug in the vicinity of tumor 
cells, rather than in intracellular compartments. 
Among the few elastase tetrapeptide cleavable linkers that have been used to conjugate 
anticancer drugs (e.g. Ala-Ala-Pro-X, X = Val, NaI or Nva),[170] we focused on the Asn-Pro-Val 
(NPV) tripeptide sequence described by Lerchen and co-workers for the synthesis of αvβ3 
integrin ligands-CPT conjugates (120, Fig. 36).[171] This tripeptide linker is selectively cleaved 
by elastase at the Valine C-terminus.[171] The authors proved the efficiency of this approach by 
evaluating the stability of 120 in cellular medium supplemented with elastase, which resulted 
in the full release of the CPT payload within 24 hours.[171] 
 
Figure 36. Molecular structure of a conjugate 120 bearing extracellularly-cleavable linker NPV designed by Lerchen 
and co-workers[171] 
Thus, we designed an extracellularly-cleavable SMDC (121, Fig. 37) in which the αvβ3 integrin 
ligand cyclo[DKP-RGD] (75) is connected to PTX via a self-immolative spacer, an elastase-
cleavable tripeptide linker (Asn-Pro-Val), a triazole linkage and a PEG-4 spacer. In order to 
allow an easy and general synthetic preparation, an alkyne-bearing alkyl scaffold was 
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connected to the N-terminus of the Asn-Pro-Val linker. Similarly to the preparation of the 
monomeric conjugate 97 (described in Chapter II), the single terminal alkyne moiety of the 
PTX prodrug (compound 122, Fig. 37) was used as anchoring point for the connection of the 
cyclo[DKP-RGD] integrin ligand 86, through CuAAC “click” reaction. Moreover, the PEG-4 
spacer emerged from the screening of previous RGD-PTX conjugates (see Chapter II) was 
maintained in this structure.[161]  
 
Figure 37. Molecular structure of the conjugate 121 bearing extracellularly-cleavable linker designed by our group 
and described in this chapter. Retrosynthetic analysis of 121 is also present: disconnection into alkyne 122 and 
azide 86. 
3.2. Synthesis of cyclo[DKP-RGD]-PEG-4-NPV-PTX conjugate 
bearing an Extracellularly-Cleavable Linker 
Three different cyclo[DKP-RGD]-PTX conjugates have been synthesized, and their molecular 
structures are reported in Fig. 38. 
In addition to the peptide linker-bearing conjugate cyclo[DKP-RGD]-PEG-4-NPV-PTX (121), 
another cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX conjugate (123), featuring the non-natural 
amino acid [D]-Valine, was also prepared as negative control for cleavage experiments in the 
presence of elastase. Furthermore, a third conjugate (compound 124) was prepared, in which 
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the tripeptide moiety is replaced by a tertiary amide bond. This proteolytically-stable or 
“uncleavable” linker was designed as negative control for the evaluation of the biological 
performances of conjugate 121. 
 
Figure 38. Molecular structures of the SMDCs synthesized in this: cyclo[DKP-RGD]-PEG-4-NPV-PTX 121, 
cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX 123, and cyclo[DKP-RGD]-uncleavable-PTX 124. 
Similarly to the preparation of cyclo[DKP-RGD]-PEG-4-VA-PTX 97, the new conjugate 
cyclo[DKP-RGD]-PEG-4-NPV-PTX 121 was synthesized as described in Scheme 11, starting 
with the preparation of the new tripeptide linker. In particular, Fmoc-Asn(Trt)-OH 125 was 
activated with N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) and N-
hydroxysuccinimide (NHS) in CH2Cl2, affording the corresponding activated ester. The latter 
was reacted with L-proline in the presence of sodium hydrogen carbonate as base in a 
THF/H2O mixture, affording dipeptide 126 in moderate yield (52%). The same procedure was 
used to obtain the tripeptide 127, featuring L-valine. The next coupling was carried out with a 
pre-activation of the carboxylic acid 127 with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 
(EEDQ) in CH2Cl2/MeOH: the activated ester formed in situ was directly reacted with 4-
aminobenzyl alcohol affording the resulting benzyl alcohol, which was directly activated as 4-
nitrophenyl carbonate 128 with moderated yield (54% over two steps). The latter, was reacted 
with mono-Boc protected N,N’-dimethylethylenediamine (synthesized according to previously 
reported procedures),[130] affording carbamate 129 with 80% yield. The Fmoc protecting group 
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was efficiently removed in the presence of piperidine and the resulting free amine was treated 
with 4-pentynoic acid, which led to amide 130 in high yield (90% over two steps). Treatment of 
130 with trifluoroacetic acid (TFA) for the removal of Trityl and Boc protecting groups afforded 
the corresponding primary amide and secondary amine, respectively. The latter was reacted 
with 2’-(4-nitrophenoxycarbonyl)paclitaxel 95[130] affording carbamate 122 in good yield (71%, 
over two steps). Finally, alkyne 122 was linked to cyclo[DKP-RGD]-PEG-4-N3 (86), through a 
CuAAC reaction, as previously reported in Chapter II, affording SMDC 121 in high yield (94%). 
 
Scheme 11. Synthesis of cyclo[DKP-RGD]-PEG-4-NPV-PTX conjugate (121). Reagents and conditions: a) 1) NHS, 
EDC·HCl, CH2Cl2, r.t., overnight; 2) L-Proline, NaHCO3, THF/H2O (1:1), r.t., overnight; b) NHS, EDC·HCl, CH2Cl2, 
r.t, overnight; 2) L-Valine, NaHCO3, THF/H2O (1:1), r.t., overnight; c) 4-aminobenzyl alcohol, EEDQ, CH2Cl2/MeOH 
(2:1), r.t., overnight; d) 4-nitrophenyl chloroformate, pyridine, r.t., THF, 2 h; e) N-(Boc)-N,N′-
dimethylethylenediamine, iPr2NEt, r.t., THF, overnight: f) 1) piperidine, DMF, r.t., 2 h; 2) 4-pentynoic acid, HATU, 
HOAt, iPr2NEt, DMF, r.t., overnight; g) 1) TFA/CH2Cl2 (1:2), 15 min; 2) 95, iPr2NEt, DMF, r.t., overnight; h) 
cyclo[DKP-RGD]-PEG-4-N3 86, CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 30 ºC, overnight. 
The synthesis of cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX conjugate 123 is reported in Scheme 
12. In this case, the tripeptide sequence Asn-Pro-[D]-Val was produced starting from the C-
terminus (D-Valine) due to epimerization problems. As a matter of fact, it was observed that 
the coupling of the Asn-Pro-OH fragment with [D]-Val-NH2 resulted in a mixture of epimers, 
even at lower temperatures (0-5 ºC). Hence, Fmoc-[D]-Val-OH 131 was activated with EEDQ 
in situ, and then reacted with 4-aminobenzyl alcohol affording compound 132 in 84% yield 
(Scheme 12). The conversion of 132 into the corresponding amine after treatment with 
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piperidine was followed by the coupling with Fmoc-L-proline through traditional peptide 
coupling protocols (i.e. pre-activation of the acid with HATU, HOAt, DIPEA in DMF, followed 
by addition of the amine). The formation of 133 was observed but the large amount of DIPEA 
and complications during the work-up (i.e. presence of a free benzylic alcohol significantly 
enhances the partition easily allows the partition of the product into the aqueous layer) did not 
allow the isolation of 133. The same happened during the coupling with Fmoc-[L]-Asn(Trt) 134, 
but upon activation of the benzyl alcohol by conversion into the corresponding 4-nitrophenyl 
carbonate, the purification was possible to afford the intermediate 135, in 47% yield over five 
steps (Scheme 12, 132-135).  
 
Scheme 12. Synthesis of cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX conjugate (123). Reagents and conditions: a) 4-
aminobenzyl alcohol, EEDQ, CH2Cl2/MeOH (2:1), r.t., overnight; b) 1) piperidine, DMF, r.t., 2 h;  Fmoc-L-Proline, 
HATU, HOAt, iPr2NEt, DMF, r.t., overnight; c) 1) piperidine, DMF, r.t., 2 h; 2) Fmoc-L-Asn(Trt), HATU, HOAt, 
iPr2NEt, DMF, r.t., overnight; d) 4-nitrophenyl chloroformate, pyridine, r.t., THF, 2 h; e) N-(Boc)-N,N′-
dimethylethylenediamine, iPr2NEt, r.t., THF, overnight; f) 1) piperidine, DMF, r.t., 2 h; 2) 4-pentynoic acid, HATU, 
HOAt, iPr2NEt, DMF, r.t., overnight; g) 1) TFA/CH2Cl2 (1:2), 15 min; 2) 95, iPr2NEt, DMF, r.t., overnight; h) 
cyclo[DKP-RGD]-PEG-4-N3 86, CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 30 ºC, overnight. 
From this step, the final compound was assembled analogously to conjugate 121. The reaction 
of 135 with N-(Boc)-N,N’-dimethylethylenediamine led to carbamate 136 in high yields (87%) 
and a fast deprotection of the N-terminus of the asparagine residue followed by coupling with 
4-pentynoic acid afforded the terminal alkyne-functionalized compound 137. The deprotection 
of Boc and Trityl groups and the amine conjugation with the carbonate-derivative of PTX 95 
led to the carbamate 138 in moderate yield (54% over two steps). Finally, from the click 
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reaction between alkyne 138 and azide 86, the final cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX 
conjugate 123 was formed. 
The synthesis of the RGD-paclitaxel conjugate featuring the “uncleavable” linker (124) is 
reported in Scheme 13. Here, 4-pentynoic acid was reacted with the mono-protected diamine 
139 affording tertiary amide 140. The Boc group was removed at this stage, and the resulting 
secondary amine was reacted with paclitaxel derivative 95 to yield compound 141. Again, as 
described for previous conjugates, a final click reaction afforded cyclo[DKP-RGD]-
uncleavable-PTX (124) in quantitative yield. 
 
Scheme 13. Synthesis of cyclo[DKP-RGD]-uncleavable-PTX conjugate (124). Reagents and conditions: a) 4-
pentynoic acid, HATU, HOAt, iPr2NEt, DMF, r.t., overnight; b) 1) TFA/CH2Cl2 (1:2), 45 min; 2) 95, iPr2NEt, DMF, 
r.t., overnight; c) cyclo[DKP-RGD]-PEG-4-N3 86, CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 30 ºC, overnight. 
The final compounds 121, 123-124 were all purified by semi-preparative HPLC and freeze-
dried before being subjected to biological assays.  
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3.3. In vitro Biological Evaluation 
3.3.1. Integrin Receptor Competitive Binding Assays 
Analogously to all the SMDCs described so far, the newly synthesized cyclo[DKP-RGD]-PTX 
121, 123-124 conjugates were evaluated in competitive assays for the binding to the purified 
αvβ3 integrin, in the presence of biotinylated vitronectin. The IC50 values obtained are shown in 
Table 6. 
Table 6. Inhibition of biotinylated vitronectin binding to isolated αvβ3 receptor. 
Cpd Structure 
v3 
IC50 [nM][a] 
121 cyclo[DKP-RGD]-PEG-4-NPV-PTX 12.9 ± 1.4 
123 cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX 24.9 ± 2.1 
124 cyclo [DKP-RGD]-uncleavable-PTX 5.8 ± 1.2 
69 cyclo[DKP3-RGD] 4.5 ± 0.1 
Also in this case, the results showed that despite their remarkable steric bulk, the conjugates’ 
affinity for the purified αvβ3 receptor is comparable to that of the free ligand 69. Remarkably, 
the high affinity observed towards the αvβ3 receptor (IC50 = 5.8-24.9 nM), demonstrates that 
the use of a new tripeptide sequence as cleavable linker in the presence of this type of 
constructs does not impair the binding to the integrin receptor. 
3.3.2 Cleavage Experiments in Presence of Elastase and Stability Assays  
To evaluate the effective cleavage of the tripeptide linker and the subsequent paclitaxel release 
in the presence elastase, conjugate 121 was treated with human elastase, and metabolites 
were detected by HPLC-MS analysis (in collaboration with Nerviano Medical Sciences, Milan). 
The enzymatic cleavage of the tripeptide linker in compound 121 was observed over a 2 h 
period, at 37 ºC. First of all, elastase was inactivated in presence of trifluoroacetic acid (TFA), 
and the intact conjugate 121 was detected as major metabolite, indicating its stability under 
such conditions (Fig. 39A). In a second experiment, conjugate 121 was subjected to the same 
conditions, in the presence of activated elastase. In particular, the metabolite analysis of this 
compound revealed the presence of N,N’-dimethylethylenediamine spacer-bearing paclitaxel 
(i.e. compound 142, “Pro-PTX”, Fig 39B) as the main product. Moreover, this result confirms 
the cleavage of conjugate 121 at valine C-terminus and the release of the drug through the 
mechanism described in Paragraph 1.4.2 (Scheme 3). 
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Figure 39. HPLC-MS chromatograms from cleavage experiments of conjugate 121. A) Analysis of conjugate 121 
in presence of inactivated elastase; B) Analysis of conjugate 121 in presence of activated elastase. Signal detected 
for m/z 968.4 was attributed to compound 142. 
The detection of metabolite 142 is consistent with the drug release mechanism described by 
Scheeren and co-workers for prodrugs featuring both the dimethylethylenediamino chain and 
the p-aminobenzylcarbamate (PABC) structures: among the two mechanism of self-
elimination, the cyclization of the diamine spacer was claimed as the rate-limiting step of the 
drug release.[172,173] 
 
Figure 40. HPLC-MS chromatograms from cleavage experiments of conjugate 121. A) Analysis of conjugate 121 
in presence of inactivated lysosomal extract; B) Lysosomal extract digestion in the presence of cysteine proteases 
inhibitor (E-64) and; C) Lysosomal extract digestion. 
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In order to analyze more in detail the selectivity of the linker cleavage, SMDC 121 was treated 
with lysosomal extract and the cysteine proteases inhibitor E-64 was also included to gain 
insights into the effector enzymes involved in the cleavage. The effect of protease inhibition, 
evaluated by HPLC-MS, is shown in Fig. 40. Firstly, lysosomal enzymes were inactivated in 
presence of TFA (Fig. 40A). Noticeably, SMDC 121 was digested only partially by the 
lysosomal extract upon 2 hours (Fig. 40C), with conjugate 121 detected as the main species 
present. ‘Pro-PTX’ 142 was slightly detectable, which may indicate the presence of lysosomal 
elastase in the extract.[174] This hypothesis was supported by the observation of metabolite 142 
also in the presence of the E-64 inhibitor, (Fig. 40B) indicating that cysteine proteases are not 
responsible for the cleavage of this linker. 
To our delight, these results showed that the tripeptide Asn-Pro-[L]-Val linker is mainly cleaved 
by elastase and partially digested by other components of the lysosomal extract (e.g. 
lysosomal elastase or other lysosomal proteases). Conjugates 97 and 123 (i.e. Val-Ala linker 
and NP-[D]-V at the cleavage site as negative control, respectively) are now being subjected 
to the same cleavage tests in order to confirm the substrate selectivity of this NP-[L]-V 
tripeptide. 
While these stability tests confirmed the efficacy of the linker system, from these assays it was 
not possible to gain information on the actual release of the free PTX, as the Pro-PTX 142 was 
always detected as main metabolite. According to literature data, while in 2015, our research 
group reported the release of Pro-PTX after enzymatic cleavage,[130]  Scheeren and co-workers 
described the release of free PTX from a similar construct within 47 minutes after 
proteolysis.[173] To clarify this issue, we set up a model to investigate the kinetic of free PTX 
release, after cyclization of N,N’-dimethylethylenediamine spacer and formation of the cyclic 
urea imidazolidinone. 
 
Scheme 14. Synthesis of “Pro-PTX” intermediate (142). Reagents and conditions: a) N-(Boc)-N,N′-
dimethylethylenediamine, iPr2NEt, DMF (2:1), r.t., overnight; b) TFA/CH2Cl2 (1:2), 20 min, 0 ºC. 
The synthesis of Pro-PTX 142 is shown in Scheme 14. As mentioned, PTX derivative 95 was 
synthesized according to previously described protocol by our group.[130] Later on, the 
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secondary amine of N-(Boc)-N,N’-dimethylethylenediamine 139 was reacted with 95 to yield 
compound 143 (95% yield). The latter was treated with TFA leading to the TFA salt of 142 in 
68% yield, after purification by semi-preparative HPLC and lyophilization. 
In order to evaluate the half-life (t1/2) of Pro-PTX (142), we followed a similar stability assay 
described by Scheeren and co-workers.[173] In particular, the cyclization of the amine spacer at 
37 ºC was measured in a 250 µM DMSO:PBS (1:1) solution at pH 7.5. Aliquots were taken at 
different time points and analyzed by HPLC, revealing 50% of free PTX release after 
approximately 8 hours (t1/2(Pro-PTX) ~ 8 h, Fig. 41) - all chromatograms are shown in the 
Experimental Section.  
 
 
Figure 41. Graphic concerning the linear regression between cyclization of Pro-PTX 142 (Y-axis) over the time (X-
axis). The linear equation (y=-0.0917x+94.608) was used to calculate the t1/2 when 50% of Pro-PTX is already 
cyclized. 
This result proved that free PTX is released slowly, which may be the cause of the observed 
loss of cytotoxicity displayed by our RGD-PTX conjugates, as compared to the free drug. 
However, this analysis contrasts the data shown by Scheeren and co-workers, who observed 
the release of free PTX after 47 minutes. This discrepancy may be explained by the different 
concentration of starting Pro-PTX 142 in the experimental conditions, or by the differences in 
the buffer used to monitor the cyclization reaction.[173] 
Additionally, SMDC 121 was tested in 5 μM blank mouse plasma for 24 hours at 37 ºC. Notably, 
conjugate 121 showed a t1/2 in mouse plasma of 35.3 hours (for more details, see Experimental 
Section). This result indicates that, in case of good in vitro antiproliferative assays, SMDC 121 
is a promising candidate for in vivo studies. As for the chemical stability under different 
chemical conditions, our group reported that conjugate 77 (i.e. cyclo[DKP-RGD]-VA-PTX with 
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a similar system than 121) was fully stable after 4-hour incubation in neutral (pH 7.4) and acidic 
(pH 5.5) buffers.[130] 
3.3.3. Cell Proliferation Assays 
In a preliminary analysis, cyclo[DKP-RGD]-PEG-4-NPV-PTX conjugate 121 was tested in vitro 
for its ability to inhibit the proliferation of 786-O renal cancer cell line in the presence or absence 
of elastase from human leucocytes. These assays were designed as a model to test the 
extracellular cleavage of the NPV linker by elastase and to evaluate whether the PTX 
metabolite can undergo subsequent passive diffusion into the cancer cell and display its 
anticancer activity. In the absence of elastase, 786-O cell line was incubated with increasing 
doses of free PTX, Pro-PTX 142 and SMDCs 121, 123-124. In one experimental set, elastase 
was added after treatment with PTX, Pro-PTX 142 and SMDCs 121, 123-124. After 96 hours, 
the cell viability was analyzed by Envision microplate reader using the CellTiter-Glo luciferase-
based ATP detection assay (Table 7).  
Table 7. Cytotoxicity assays of conjugates 121, 123, 124, 142 and free PTX in 786-O renal cancer 
cell line (in presence or absence of elastase). 
 
 
 
 
 
[a] IC50 values were calculated as the concentration of compound required for 50% 
inhibition of cell viability in presence or absence of 50 nM of elastase. 786-O renal cancer 
cell line was treated with different concentrations of PTX and compounds 121, 123, 124, 
142 for 96 hours. The samples were measured in triplicate. 
Under these conditions, in the absence of elastase from the cellular media, no activity is shown 
by SMDC 121 (IC50 > 5000 nM) – Table 7. Remarkably, the same SMDC 121 displayed a 256-
fold increased activity (IC50 = 19.6 ± 4.1 nM), upon addition of elastase (Table 7), whereas the 
IC50 of free PTX was unaffected by the presence of the enzyme (IC50 = 29.5 ± 7.6 nM without 
elastase VS IC50 = 35.8 ± 16.7 nM with elastase). Notably, in the presence of elastase, the IC50 
value of SMDC 121 decreases to a final concentration, comparable to the one of free PTX 
(IC50 = 19.6 ± 4.1 nM VS IC50 = 35.8 ± 16.7 nM, respectively), demonstrating the importance of 
the linker cleavage efficiency for the SMDC potency. 
As for the control compounds, conjugates 123 (i.e. featuring a [D]-Val residue at the cleavage 
site) and 124 (the “uncleavable” version of 121), showed no antiproliferative activity (IC50 > 
5000 nM), regardless the presence or the absence of elastase. We were delighted to see that 
Cpd Structure IC50 (nM)[a] 
  
ADDED 
ELASTASE 
̶   
121 cyclo[DKP-RGD]-PEG-4-NPV-PTX 19.6 ± 4.1 > 5000 
123 cyclo[DKP-RGD]-PEG-4-NP-[D]-V-PTX > 5000 > 5000 
124 cyclo [DKP-RGD]-uncleavable-PTX > 5000 > 5000 
142 Pro-PTX 208.9 ± 133.9 186.4 ± 6.5 
20 PTX 35.8 ± 16.7 29.5 ± 7.6 
  
75 cyclo[DKP-RGD]-PTX Conjugates bearing an Extracellularly-Cleavable Linker 
the presence of [L]-Val at the cleavage site is crucial for the recognition of the tripeptide 
sequence by elastase and subsequent activity of the conjugate 121. Moreover, the lack of 
activity of conjugate 124 further confirmed that the PTX payload is not active when it is not 
released from the targeting vehicle. 
Finally, this experiment showed that Pro-PTX 142 was less active than the free toxin. This is 
in agreement with the slow cyclization process resulting in the PTX release, which may be 
even slower in the cell culture medium (this data is not available yet). 
Such preliminary in vitro data proved that the release of the payload within the tumor stroma 
can be a valuable tool to raise the potency of our constructs. For this reason, conjugate 121 
will be evaluated in in vivo anticancer therapy experiments, in order evaluate the payload 
accumulation at the tumor site mediated by the cyclo[DKP-RGD] ligand. 
 
3.4. Results and Discussion 
These preliminary results demonstrate that the approach used by SMDC 121, relying in the 
extracellular release of the payload, can be more effective than the design of internalizing 
RGD-drug conjugates. Also in this case, the linker turned out to play a fundamental role for 
drug activity. In particular, the peptide sequence should be a preferential substrate of an 
extracellular enzyme, whose expression in the targeted tissue has to be validated. 
The elastase-specific NPV linker was selected and evaluated in this Chapter. First of all, the 
binding ability to the purified αvβ3 integrin of the new RGD-PTX conjugates 121, 123 and 124 
was found to be comparable to the one of the free ligand 69 and of SMDCs developed in 
Chapter II (97 and 102-105). 
Moreover, we observed that in the presence of elastase, the SMDC 121 is fully converted to 
the intermediate Pro-PTX 142 within 2 hours (Fig. 39B), confirming the two-step mechanism 
of PTX release described by Scheeren and co-workers.[173] In particular, we demonstrated that 
the NPV linker is cleaved by human elastase at the C-terminus, releasing the intermediate 144 
(Fig. 42). The latter undergoes a fast 1,6-elimination of the aromatic p-aminobenzylcarbamate 
(PABC) spacer, leading to the formation of the metabolite Pro-PTX 142 (Fig. 42). Moreover, 
our cleavage experiments confirm that the cyclization of the diamine spacer is actually the rate-
limiting step of the drug release.  
While literature data indicate that the intermediate results in PTX release with a half-life of 47 
min,[173] we observed release of free PTX within ~8 hours in a DMSO:PBS (1:1) mixture at 
physiological pH and temperature (i.e. pH 7.4 and 37 ºC, respectively). 
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Figure 42. Enzymatic cleavage of conjugate 121 leading to the release of free paclitaxel. 
Cell antiproliferative studies were performed in the absence or presence of elastase, aimed at 
the evaluation of SMDC 121 activity triggered by the enzyme in the cell medium. In the absence 
of elastase, no potency is shown by SMDC 121 (IC50 > 5000 nM) – Table 7. Remarkably, the 
same SMDC 121 displayed a 256-fold increased activity of (IC50 = 19.6 ± 4.1 nM) upon addition 
of elastase (Table 7). Remarkably, negative controls 123 and 124 showed to be inactive in 
presence or absence of elastase (IC50 > 5000 nM), proving the importance of the NPV linker in 
this system. This in vitro model experiment was already described for similar SMDCs: 1) Papot 
and co-workers incubated a SMDC with the targeted effector enzyme (i.e. β-Glucuronidase), 
observing a dramatic decrease of the IC50 values;[175] 2) Oliff and co-workers prepared a MMP-
2 cleavable prodrug, which was treated with the protease and then added to the cell medium, 
unveiling the effect of the active metabolite.[176] 
However, Pro-PTX 142 proved generally less potent than the free PTX toxin. While this is 
ascribed to the slow cyclization of the spacer, it is conceivable that the presence of a secondary 
amine moiety influences also on the ability of Pro-PTX to penetrate the cell membrane, 
eventually affecting the biological activity.[177] Overall, these data possibly indicate that PTX 
payload is not the best candidate for extracellular delivery, while this approach may be more 
attractive when the toxin is linked to the SMDC through a fast-eliminating spacer. For instance, 
compounds bearing an amino moiety (e.g. doxorubicin, dolastatin analogs, 
pyrrolobenzodiazepines etc.) could be considered for this application. 
Finally, the selective release of payloads within the tumor microenvironment is gaining much 
interest in this field. Giving strength to this strategy, Neri and co-workers have been 
demonstrating that non-internalizing mAbs bearing an intracellularly-cleavable linker (e.g. Val-
Cit and Val-Ala), can release the payload within the tumor stroma, observing therapeutic 
effects in mice.[178] Furthermore, this strategy has also been exploited for SMDCs bearing 
linkers as substrates of different extracellular tumor-associated enzymes: 1) Matrix 
Metalloproteinases-2 and -9,[117,176,179] 2) β-Galactosidase[21], 3) β-Glucuronidase,[175] and 4) 
Elastase.[171]
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cyclo[DKP-RGD]-MMAE/MMAF conjugates 
bearing Lysosomally and Extracellularly-
Cleavable Linkers 
4.1 Introduction 
The research activity described so far has consisted in the development of cyclo[DKP-RGD]-
PTX conjugates, showing remarkable results in terms of synthetic accessibility, affinity for αvβ3 
integrin, stability and solubility properties. However, the biological evaluation of the cyclo[DKP-
RGD]-VA-PTX (77) and cyclo[DKP-RGD]-PEG-4-VA-PTX (97) highlighted some important 
weaknesses of these compounds. As discussed in Chapter II and III, although conjugates 77 
and 97 displayed promising targeting ability skills (TI = 39 - 533), the low potency showed by 
these conjugates in cell antiproliferative assays against αvβ3+/αvβ3− cells, represents a major 
drawback. These findings prompted the development of the extracellularly-cleavable SMDC 
cyclo[DKP-RGD]-PEG-4-NPV-PTX (121), which showed promising results in terms of PTX 
release in the proximity of tumor cells and subsequent passive drug uptake. In addition, the 
cell-antiproliferative properties of proper control compounds (i.e. uncleavable SMDCs 123 and 
124, see Chapter III) were evaluated, showing no activity in the presence of elastase. 
While therapy studies on conjugate 121 will give important information about the feasibility of 
extracellular-cleavable linkers in our technology, the use of highly potent payloads represents 
a “more traditional” approach to increase the potency of targeted prodrugs. Accordingly, this 
Chapter focuses on the design of new cyclo[DKP-RGD]-auristatin conjugates. In particular, 
whereas PTX (20, Fig. 2, Chapter I) is still sold as first-line treatment of different types of 
cancer, the use of more potent tubulin poisons, such as maytansinoids and auristatins, was 
found to be the key for the clinical success of antibody-drug conjugates.[180] In particular, 
auristatins are synthetic peptide-like cytotoxic agents belonging to the family of dolastatins. 
Dolastatin 10 (25, Fig. 3, Chapter I) was the most cytotoxic component of a mixture extracted 
from cyanobacteria Symploca hydnoides and Lyngbya majuscula.[181] This compound entered 
phase I clinical trials in the 1990s[182] and successfully progressed to phase II trials. However, 
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these clinical trials were later stopped, as the drug exhibited insufficient activity and severe 
side effects when used as single agent.[183] Auristatins are synthetic analogs of dolastatin 10, 
lacking a thiazole ring and containing a terminal benzylamine moiety (Fig. 3, Chapter I).[184] 
These compounds act as potent microtubule-destabilizing agents, leading to apoptosis in 
dividing cells. Monomethyl auristatin-E (MMAE 29, Fig. 3) and monomethyl auristatin-F (MMAF 
26, Fig. 3) are fully synthetic drugs, selected from SAR (structure-activity relationship) studies 
and then derivatized for their use as payloads in ADCs and SMDCs products. Designed to be 
exclusively used as payload for internalizing ADCs, MMAF differs from MMAE by the presence 
of a phenylalanine residue at the C-terminus. This structural modification substantially 
increases the hydrophilicity and thus reducing the membrane permeability, limiting off-target 
toxicities. Indeed, MMAE and MMAF were demonstrated to be similarly potent (IC50 in the 
subnanomolar range) when released intracellularly by ADCs.[185] On the other hand, such 
drugs display very different cytotoxicity properties when added, in the unconjugated form, to 
tumor cells. While MMAE still displays subnanomolar activity, MMAF shows submicromolar 
activity, as a result of its altered membrane permeability.[186,187] 
Attracted by the unique structural and biological features of the payload pair MMAE/MMAF, 
we designed cyclo[DKP-RGD]-MMAE/MMAF conjugates bearing the lysosomally-cleavable 
linker Val-Ala (SMDCs 145 and 146, Fig. 43) and their respective negative controls (147-149, 
Fig. 43). Compound 147 (with MMAE), devoid of the cyclo[DKP-RGD] ligand, was designed 
as negative control of 145 to evaluate the targeting ability of the RGD homing device. 
 
Figure 43. Molecular structures of designed lysosomally-cleavable cyclo[DKP-RGD]-PEG-4-VA-MMAE/MMAF 
conjugates (145-146) and their relative control compounds (147 and 148-149). 
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Given the poor internalization properties of the free payload MMAF, a RGD-lacking control 
compound relative to the cyclo[DKP-RGD]-MMAF conjugate 146, was considered 
unnecessary and it was not prepared. SMDCs 148 and 149 represent the uncleavable versions 
of 145 and 146 (Fig. 43), respectively, and they were designed as reference for the evaluation 
of the antiproliferative performance of the cleavable conjugates. 
Within this frame, another cyclo[DKP-RGD]-MMAE conjugate was prepared, endowed with the 
extracellularly-cleavable linker Asn-Pro-Val (SMDC 150, Fig. 44). This compound represents 
a structural optimization of PTX-containing SMDC 121 described in Chapter III. This new 
conjugate represents an excellent candidate for in vivo applications, since MMAE has shown 
excellent antitumor properties, also when released in the extracellular tumor 
environment.[178,187]  
 
Figure 44. Molecular structure of the designed cyclo[DKP-RGD]-PEG-4-NPV-MMAE 150 conjugate. Structures of 
cyclo[DKP-RGD] and MMAE can be seen in Figure 43. 
4.2. Synthesis of cyclo[DKP-RGD]-PEG-4-VA-MMAE Conjugate 
bearing a Lysosomally-Cleavable Linker 
The cyclo[DKP-RGD] peptidomimetic was linked to MMAE via a self-immolative spacer, a 
cathepsin B-cleavable dipeptide linker (Val-Ala), a triazole linkage and a PEG-4 spacer, 
leading to SMDC 145 (Fig. 43). The secondary amine at the N-terminus of MMAE drug was 
used as anchoring point for the linker: this choice resulted in the formation of a stable 
carbamate bond between the drug and a p-aminobenzyl alcohol self-immolative spacer (Fig. 
43). Unlike the PTX conjugates described in the previous Chapters, this layout allows the 
release of MMAE upon a single and fast 1,6-elimination step, avoiding the slow cyclization of 
the diamine spacer (the detailed mechanism is depicted in Fig. 42 on Chapter III). In analogy 
to the previous RGD-PTX conjugates described in Chapter II and III, the formation of a triazole 
ring between the linker-drug module and the ligand was chosen as the last conjugation step: 
this chemoselective methodology does not require specific protecting groups at the amino acid 
side chains and it is adaptable to several linker-drug combinations. 
The synthesis of the cyclo[DKP-RGD]-PEG-4-VA-MMAE 145 is shown in Scheme 15. Similarly 
to what described by or group for SMDC 77,[130] the Val-Ala dipeptide was coupled to p-
aminobenzyl alcohol (151). The fast deprotection of the valine residue, followed by coupling 
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with 4-pentynoic acid, afforded the terminal alkyne-functionalized compound 152. The latter 
was activated as 4-nitrophenyl carbonate (Scheme 15, compound 153). MMAE was attached 
to the linker by reaction of its secondary amine with electrophile 153, leading to carbamate 
154. The final conjugate 145 was obtained after copper-catalyzed azide-alkyne cycloaddition 
(CuAAC) between alkyne 154 and cyclo[DKP-RGD]-PEG-4-N3 86, whose synthesis is 
described in Chapter II (Scheme 4). The latter reaction was also used to produce control 
compound 147 (devoid of the targeting ligand) by reacting alkyne 154 and HOOC-PEG-4-N3 
91 (Scheme 4, Chapter II) through the same CuAAC “click reaction” (Scheme 15). Both 
products (145 and 147) were then purified by semi-preparative HPLC and lyophilized. 
 
Scheme 15. Synthesis of cyclo[DKP-RGD]-PEG-4-VA-MMAE conjugate (145) and HOOC-PEG-4-VA-MMAE (147). 
Reagents and conditions: a) 1) piperidine, DMF, r.t., 2 h; 2) 4-pentynoic acid, HATU, HOAt, iPr2NEt, DMF, r.t., 
overnight; b) 4-nitrophenyl chloroformate, pyridine, r.t., THF, 2 h, c) MMAE, HOBt, iPr2NEt, r.t., DMF:pyridine (4:1), 
over-weekend; d) cyclo[DKP-RGD]-PEG-4-N3 (86), CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 35 ºC, overnight; e) 
HOOC-PEG-4-N3 (91), CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 35 ºC, overnight. 
In addition to compounds 145 and 147, a third conjugate (compound 148, Fig 43) was 
prepared, in which the cleavable linker moiety (Val-Ala) is replaced by a tertiary amide bond. 
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Similarly to conjugate 124 (Chapter III, Fig.38), the synthesis of the RGD-MMAE conjugate 
featuring the “uncleavable” linker (148) is reported in Scheme 16. 
 
Scheme 16. Synthesis of cyclo[DKP-RGD]-Uncleavable-MMAE conjugate (148) and HOOC-Uncleavable-MMAE 
(156). Reagents and conditions: a) MMAE, HATU, HOAt, iPr2NEt, DMF, r.t., overnight; b) cyclo[DKP-RGD]-PEG-4-
N3 (86), CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 35 ºC, overnight; e) HOOC-PEG-4-N3 (91), CuSO4∙5H2O, NaAsc, 
DMF/H2O (1:1), 35 ºC, overnight. 
Herein, 4-pentynoic 87 acid was reacted with the secondary amine of MMAE affording tertiary 
amide 155. Also in this case, a final CuAAC afforded cyclo[DKP-RGD]-uncleavable-MMAE 
(148). Finally, compound 156 was also prepared, consisting in an analog compound of 
uncleavable conjugate 148, devoid of the targeting unit. This exhaustive panel of SMDC 
compounds and relative controls would facilitate the rationalization of in vitro data, providing 
important information for the determination of the mechanism of action of our RGD-MMAE 
conjugates. 
4.3. Synthesis of cyclo[DKP-RGD]-PEG-4-VA-MMAF Conjugates 
bearing a Lysosomally-Cleavable Linker  
As previously mentioned, another group of compounds was prepared, being structurally similar 
to cyclo[DKP-RGD]-MMAE-containing conjugates (145 and 148, Fig. 43), but possessing the 
MMAF cytotoxic payload (146 and 149, Fig. 43).[185] 
According to the synthetic pathway used for the development of cyclo[DKP-RGD]-MMAE-
containing conjugates, cyclo[DKP-RGD]-MMAF conjugates (146 and 149) were synthesized 
as it is described in Schemes 17 and 18. 
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Scheme 17. Synthesis of cyclo[DKP-RGD]-PEG-4-VA-MMAF conjugate (146). Reagents and conditions: a) 
MMAF·TFA, HOBt, iPr2NEt, r.t., DMF:pyridine (4:1), over-weekend; b) cyclo[DKP-RGD]-PEG-4-N3 86, 
CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 35 ºC, overnight. 
Likewise, the synthesis of cyclo[DKP-RGD]-PEG-4-VA-MMAE (145) was performed following 
the same pathway for the development of cyclo[DKP-RGD]-PEG-4-VA-MMAF (146). 
Carbamate 157 was prepared reacting carbonate 153 with the commercial TFA salt of MMAF, 
in the presence of 1-Hydroxybenzotriazole (HOBt) and excess of base. The resulting alkyne 
was reacted with azide 86 through the same CuAAC “click reaction” to give the final conjugate 
146, after purification by semi-preparative HPLC and lyophilization. 
 
Scheme 18. Synthesis of cyclo[DKP-RGD]-Uncleavable-MMAF (149) conjugate. Reagents and conditions: a) 
MMAF·TFA, HATU, HOAt, iPr2NEt, DMF, r.t., overnight; b) cyclo[DKP-RGD]-PEG-4-N3 86, CuSO4∙5H2O, NaAsc, 
DMF/H2O (1:1), 35 ºC, overnight. 
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Furthermore, the synthesis of the uncleavable conjugate cyclo[DKP-RGD]-uncleavable-MMAF 
(149, Scheme 18) was performed in analogy to the one used for cyclo[DKP-RGD]-uncleavable-
MMAE (148, Scheme 15). Conjugate 149 was successfully synthesized, purified by semi-
preparative HPLC and freeze-dried. 
 
4.4. Synthesis of cyclo[DKP-RGD]-PEG-4-NPV-MMAE Conjugate 
bearing an Extracellularly-Cleavable Linker 
Conjugate 150 (Scheme 19) carrying the elastase-cleavable linker Asn-Pro-Val (NPV) 
represents an analog of conjugate 121 (Chapter III). Here, the αvβ3 integrin ligand cyclo[DKP-
RGD] is connected to MMAE via a self-immolative spacer, an elastase-cleavable tripeptide 
linker (Asn-Pro-Val), a triazole linkage and a PEG-4 spacer. The synthesis of conjugate 150 is 
reported in Scheme 19. 
 
Scheme 19. Synthesis of cyclo[DKP-RGD]-PEG-4-NPV-MMAE (150). Reagents and conditions: a) 1) piperidine, 
DMF, r.t., 2 h; 2) 4-pentynoic acid, HATU, HOAt, iPr2NEt, DMF, r.t., overnight; b) 4-nitrophenyl chloroformate, 
pyridine, r.t., THF, 2 h; c) MMAE, HOBt, DIPEA, RT, DMF:pyridine (4:1), over-weekend; d) 1) TFA, Et3SiH, CH2Cl2, 
r.t., 45’; 2) cyclo[DKP-RGD]-PEG-4-N3 86, CuSO4∙5H2O, NaAsc, DMF/H2O (1:1), 35 ºC, overnight. 
Intermediate 159, previously synthesized for the development of conjugate 121, was Fmoc-
deprotected in the presence of piperidine and the resulting amine was treated with 4-pentynoic 
acid, leading to amide 160. The latter was converted into the corresponding 4-nitrophenyl 
carbonate (161) and reacted with commercial MMAE, leading to carbamate 162. Finally, 
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conjugate cyclo[DKP-RGD]-PEG-4-NPV-MMAE 150 was isolated after CuAAC reaction with 
cyclo[DKP-RGD]-PEG-4-N3 86. 
4.5. In vitro Biological Evaluation  
4.5.1. Integrin Receptor Competitive Binding Assays 
Also in this case, the newly synthesized cyclo[DKP-RGD]-MMAE/MMAF 145, 148, 146 and 
149 conjugates were evaluated in competitive assays for the binding to the purified αvβ3 
integrin, in the presence of biotinylated vitronectin. The IC50 values obtained are shown in 
Table 8. 
 
Table 8. Inhibition of biotinylated vitronectin binding to isolated αvβ3 receptor. 
Cpd Structure 
v3 
IC50 [nM][a] 
145 cyclo[DKP-RGD]-PEG-4-VA-MMAE 58.5 ± 10.5 
147 HOOC-PEG-4-VA-MMAE 3200 ± 2.4 
148 cyclo[DKP-RGD]-Uncleavable-MMAE 40.0 ± 16.1 
156 HOOC-Uncleavable-MMAE > 10000 
146 cyclo[DKP-RGD]-PEG-4-VA-MMAF 57.9 ± 17.9 
149 cyclo[DKP-RGD]-Uncleavable-MMAF 30.3 ± 7.4 
 
 
In the same frame to the SMDCs described in the previous Chapters, the results showed that 
despite their remarkable steric bulk, the conjugates’ affinity for the purified αvβ3 receptor is 
comparable to that of the free ligand 69. Remarkably, the high affinity observed towards the 
αvβ3 receptor (IC50 = 30.3-58.5 nM), demonstrates that the use of a new tripeptide sequence 
as cleavable linker in the presence of this type of constructs does not impair the binding to the 
integrin receptor. In addition, compounds 147 and 156 (devoid of the targeting ligand) did not 
show binding affinity to the isolated αvβ3 receptor (IC50 values in the micromolar range), proving 
the importance of the cyclo[DKP-RGD] targeting ligand for the binding avidity to αvβ3 integrin. 
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4.5.2. Cell Proliferation Assays 
Preliminary cytotoxicity assays were performed in collaboration with Italfarmaco, Milan (Dr. 
Christian Steinkühler and Msc. Ana Martins). These assays were carried out in parallel with 
other four conjugates (163-166) synthesized by Prof. Umberto Piarulli’s research group 
(University of Insubria, Como - Italy), bearing the cyclo[DKP-isoDGR] integrin ligand (Fig. 45). 
Such ligand was developed as analog of the well-known RGD-bearing peptidomimetics, in 
which the RGD sequence is substituted with an isoaspartate-glycine-arginine tripeptide 
(isoDGR). The latter is also recognized by integrins and the cyclo[DKP-isoDGR] was found to 
bind αVβ3 receptor with low nanomolar affinity.[133] The resulting cyclo[DKP-isoDGR]-
MMAE/MMAF conjugates were structurally similar to the RGD-bearing analogs 145-146 and 
148-149. In particular, the ligand and the MMAE/MMAF cytotoxic payloads were connected 
through either a Val-Ala dipeptide or an uncleavable nonpeptide linker (in compound 163-164 
and 165-166, respectively) – Figure 45. 
 
Figure 45. Structures of cyclo[DKP-isoDGR]-PEG-4-VA-MMAE (163), cyclo[DKP-isoDGR]-PEG-4-VA-MMAF 
(164), cyclo[DKP-isoDGR]-Uncleavable-MMAE (165) and cyclo[DKP-isoDGR]-Uncleavable-MMAF (166). 
All synthesized compounds have been tested against αvβ3-expressing cell line (human 
glioblastoma cell line U87). In this experiment, αvβ3-negative cells were not included, in order 
to gain information on the integrin-targeting ability of (RGD / isoDGR)-MMAE/MMAF 
conjugates by comparing their anticancer activity with the one of their relative control 
compounds (devoid of the targeting ligand) against the same cancer cells.  
In a first set of experiments, cells were incubated with increasing doses of free MMAE (29) and 
MMAE-containing compounds (145, 147-148, 156, 163 and 165). After 72 hours, the cell 
viability was analyzed by MTT assay. 
The measured IC50 values are shown in Table 9. 
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Table 9. Cytotoxicity assays of compounds 145, 147-148, 156, 163 and 
165 and free MMAE in U87 cell line. 
 
 
 
 
 
 
[a] IC50 values were calculated as the concentration of compound 
required for 50% inhibition of cell viability. U87 cell line was treated 
with different concentrations of MMAE and compounds 145, 147-
148, 156, 163 and 165 for 72 hours. The samples were measured in 
triplicate. 
 
From these first set of in vitro assays arose that lysosomally-cleavable cyclo[DKP-RGD]-PEG-
4-VA-MMAE (145) and cyclo[DKP-isoDGR]-PEG-4-VA-MMAE (163) conjugates show IC50 
values 2-3 order of magnitude (100-1000) higher than MMAE 29, Table 9. This could be 
ascribed by a non-efficient αVβ3-mediated endocytosis process. However, this test revealed 
the high absolute potency of conjugates 145 and 163 against U87 cells (IC50 in the low 
nanomolar range), resulting much more effective than its analog cyclo[DKP-RGD]-PEG-4-VA-
PTX conjugate 97, described in Chapter II. This expected result proved that the use of more 
potent cytotoxic payloads also increases the potency of the SMDC constructs, and conjugates 
145 and 163 can be now considered a promising compound for further tests. 
As for the control compounds, conjugates 148 and 165, bearing an uncleavable linker, showed 
IC50 values 4 order of magnitude (~10000) higher than MMAE (IC50 = 571.80 nM and 685.50 
nM, respectively), proving that the payload is not active when it is not released from the 
targeting vehicle. Furthermore, it can be observed that the absence of targeting ligand (147) 
led to a slightly less potent construct than conjugates 145 and 163 (IC50 = 77.32 nM VS IC50 = 
38.99 nM and 11.50 nM, respectively). The high lipophilicity of compound 147 (especially when 
compared to 145 and 163) may account for its significant anticancer activity: indeed, this 
compound may behave as a “non-targeted” prodrug, capable of penetrating the cell by passive 
diffusion and undergo intracellular linker cleavage. A more representative control compound is 
now being developed by our group (e.g. a cyclopeptide bearing the Arg-Ala-Asp “non-
targeting” sequence or a more hydrophilic spacer such as peptidoglycan-based structure, see 
Figure 10 in Chapter I), in order to minimize non-specific internalization of the prodrug. 
Later on, cells were incubated with increasing doses of free MMAF and conjugates (146, 149, 
164 and 166). After 72 hours, the cell viability was analyzed by MTT assay. 
The measured IC50 values are shown in Table 10. 
Cpd Structure 
IC50 (nM)[a] 
U87 (v3 +) 
29 MMAE 0.076 ± 0.08 
145 cyclo[DKP-RGD]-PEG-4-VA-MMAE 38.99 ± 0.11 
147 HOOC-PEG-4-VA-MMAE 77.32 ± 0.07 
148 cyclo[DKP-RGD]-Uncleavable-MMAE 571.80 ± 0.21 
156 HOOC-Uncleavable-MMAE > 10000 
163 cyclo[DKP-isoDGR]-PEG-4-VA-MMAE 11.50 ± 0.13 
165 cyclo[DKP-isoDGR]-Uncleavable-MMAE 685.50 ± 0.08 
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Table 10. Cytotoxicity assays of compounds 146, 149, 164, 166 and free 
MMAF in U87 cell line. 
 
 
 
 
 
 
[a] IC50 values were calculated as the concentration of compound 
required for 50% inhibition of cell viability. U87 cell line was treated 
with different concentrations of MMAF and compounds 146, 149, 
164, 166 for 72 hours. The samples were measured in triplicate. 
 
Since free MMAF shows weak membrane diffusion properties, internalizing ligands would 
increase its anticancer activity. However, from the results presented in Table 10, it can be 
observed that the conjugates displayed reduced cytotoxicity when compared with the free drug 
MMAF, which can be ascribed to a non-efficient αVβ3-mediated endocytosis process. In 
particular, cleavable MMAF-conjugates (146 and 164) show IC50 values 2-4 times higher than 
MMAF, by means that there is no advantage with the conjugation. Finally, the cyclo[DKP-
isoDGR]-PEG-4-VA-MMAF (164) conjugate proved slightly more potent (ca. 2 times) than the 
cyclo[DKP-RGD]-PEG-4-VA-MMAF (146), which may indicate that the internalization of the 
isoDGR could be more pronounced. 
 
Additional in vitro cytotoxicity assays with MMAE-containing conjugates are now being handled 
in presence of an αvβ3-negative cell line, in order to gain insights into the targeting performance 
of these constructs. 
Finally, the biological evaluation of conjugate cyclo[DKP-RGD]-PEG-4-NPV-MMAE (145), 
bearing the elastase-cleavable linker NPV, is still in progress. 
Hopefully, with all data in our hands, it will be possible to rationalize the mechanism of action 
of our (RGD / isoDGR)-MMAE/MMAF conjugates. This will facilitate the choice of the most 
suitable linker (e.g. to mediate an intra- or extracellular drug release) to consider future in vivo 
antitumor applications. 
Cpd Structure 
IC50 (nM)[a] 
U87 (v3 +) 
26 MMAF 94.40 ± 0.06 
146 cyclo[DKP-RGD]-PEG-4-VA-MMAF 385.90 ± 0.09  
149 cyclo[DKP-RGD]-Uncleavable-MMAF > 10000  
164 cyclo[DKP-isoDGR]-PEG-4-VA-MMAF 165.90 ± 0.05 
166 cyclo[DKP-isoDGR]-Uncleavable-MMAF 763.70 ± 0.08 
  
 
Chapter V 
Conclusions and Future Perspectives 
 
  
 
Conclusions and Future Perspectives 
The work presented in this thesis mainly focused on potentialities of the peptidomimetic 
cyclo[DKP-RGD] as targeting device, for specific release of payloads against integrin-
expressing cancer cells. The chemical properties of such cyclo[DKP-RGD] ligand allowed its 
covalent connection to a wide range of chemical compounds and, due to the hydrophilic nature 
of the RGD peptide, the final constructs of these conjugation reactions exhibited better 
solubility in aqueous solutions compared to highly lipophilic anticancer drugs and peptide 
linkers. Generally, the attachment of the RGD peptidomimetic to the N-termini of such di- or 
tripeptide linkers was found to affect neither the affinity of the RGD moiety for the isolated αvβ3 
receptor, nor the enzymatic cleavage at the linkers’ C-termini. A previous SMDC developed in 
our group, the cyclo[DKP-RGD]-VA-PTX conjugate (77), showed a 66.9-fold higher cytotoxic 
activity against αvβ3+ cancer cells, compared to antigen-negative isogenic cells (TI = 9.0 shown 
by 77, calculated considering the intrinsic selectivity of free PTX).[130] The present thesis 
describes the multimerization of conjugate 77, representing a logical upgrade of the previous 
research activity and devised in order to increase the binding affinity and the TI of such SMDC 
against αVβ3-overexpressing cells. We synthesized three new multimeric (cyclo[DKP-RGD]-
PEG-4)n-VA-PTX conjugates (n = 2-4) and we compared them against two other monomeric 
analogs. Our new conjugates were tested for their ability to compete with biotinylated 
vitronectin for the binding to the purified αvβ3 integrin: it was observed that when the number 
of cyclo[DKP-RGD] units increases, the binding affinity raises to a plateau achieved by the 
trimeric (cyclo[DKP-RGD]-PEG-4)3-VA-PTX conjugate 104 (IC50 αvβ3 = 1.2 ± 0.5 nM), which 
exhibits higher binding affinity than the free ligand cyclo[DKP3-RGD] (IC50 αvβ3 = 4.5 ± 0.1 nM). 
Later on, all conjugates (77, 97, 102-105) were subjected to cell viability assays against two 
non-isogenic cell lines: human colorectal adenocarcinoma cell line HT29 (αvβ3 −) and, the 
human glioblastoma cell line U87 (αvβ3 +). Unfortunately, while all conjugates showed reduced 
potency when compared to free PTX (for U87 and HT29 cell lines), we observed that the 
increase of the valency of the conjugates leads to a progressive loss of cytotoxic activity. This 
trend may be ascribed to the increased steric bulk around the linker system, which hinders the 
enzymatic cleavage. However, despite the potency issue, remarkable TI values were observed 
for monomeric conjugates 77 (TI = 43) and 94 (TI = 94-533). These results can be considered 
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as a valuable reference in the field of αvβ3-targeted chemotherapeutics. Furthermore, from our 
research activity two main issues emerged: 
1) the central role of the biological system chosen to test and compare the synthesized 
compounds (e.g. isogenic or non-isogenic cell lines, integrin expressing or non-
expressing cells etc.). The in vitro variability shown by 77 on CCRF-CEM cells[130] and 
U87 cells (Table 1 and Table 3, Chapter II) and then by 97 (Table 3 and Table 5, 
Chapter II), together with the different cytotoxic activity detected for the free payload 
itself, prompted our group to prepare different chemical tools as negative controls in 
biological investigations (i.e. nontargeting-RAD ligand or conjugates lacking the ligand 
moiety); 
2)  the significant reduced potency shown by our conjugates. This drawback limits 
substantially the escalation of our products to in vivo therapy experiments. 
Thus, following efforts focused on the development of new SMDCs bearing extracellularly-
cleavable linkers (Chapter III) and highly potent payloads (Chapter IV). The first project was 
devised to evaluate whether the extracellular release of PTX and its subsequent passive 
diffusion into the cancer cell would raise the potency of our SMDC system. Indeed, the 
cyclo[DKP-RGD]-NPV-PTX (121) was synthesized to be cleaved in the extracellular 
environment by the tumor-associated enzyme elastase at the C-terminus of NPV linker. 
Although the biological evaluation of this latter compound is still in progress, some interesting 
preliminary results emerged from the in vitro investigation of 121. Besides showing good 
binding affinity for the αvβ3 isolated receptor, conjugate 121 displayed a 256-fold increment of 
antiproliferative activity (IC50 = 19.6 ± 4.1 nM) against 786-O renal cancer cell line, in the 
presence of elastase. By contrast, when elastase was not added to the cellular medium, the 
antiproliferative activity of 121 is substantially decreased (IC50 > 5000 nM). This result proved 
that the release of the payload within the tumor stroma can be a valuable tool to raise the 
potency of our constructs. Given that the enzyme effector is present at significantly high 
concentrations at the tumor site, conjugate 121 may be indicated as attractive candidate for in 
vivo anticancer applications, in order evaluate the payload accumulation at the tumor site 
mediated by the cyclo[DKP-RGD] ligand. 
The last project consisted in the modification of the payload: we used the same construct 
system (i.e. same ligand and same linkers), replacing PTX with MMAE or MMAF. The 
conjugation of the cyclo[DKP-RGD] integrin ligand to ultrapotent cytotoxic agents represent a 
logical strategy to increase the potency of ADC and SMDC products. Several cyclo[DKP-
RGD]-linker-drug conjugates were synthesized (i.e. combination between VA or NPV linkers 
and MMAE or MMAF drugs, Chapter IV) in order to evaluate their antiproliferative activity. 
Moreover, analog versions of such conjugates, lacking the homing device, were also 
synthesized as a negative control to assess the cyclo[DKP-RGD] targeting ability. While some 
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clear preliminary data were provided, cytotoxicity assays on αvβ3-overexpressing cells (U87) 
and αvβ3-nonexpressing cells (HT29) are currently still under evaluation. 
In conclusion, the significant decrease of drug’s potency displayed by our lysosomally-
cleavable SMDCs revealed to be a major issue during this project, which was addressed both 
by modifications of the payload component and by forcing the extracellular payload release. 
The latter approach overcomes the need for antigen internalization. Moreover, it remains to be 
understood if our cyclo[DKP-RGD] ligand can mediate an effective integrin-mediated 
endocytosis and if literature data are confirmed (mentioning that the internalization process is 
stimulated by ligand multimerization), the development of ‘theranostic’ SMDCs or multimeric 
cyclo[DKP-RGD]-dyes can be a valuable tool to confirm that the loss of potency is related to 
ineffective internalization. This analysis, together with an exhaustive linker screening, might 
hopefully lead to a significant increase of the potency and selectivity of our constructs. 
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Experimental Section 
General Remarks and Procedures 
Materials and Methods 
All manipulations requiring anhydrous conditions were carried out in flame-dried glassware, 
with magnetic stirring and under a nitrogen atmosphere. All commercially available reagents 
were used as received. Anhydrous solvents were purchased from commercial sources and 
withdrawn from the container by syringe, under a slight positive pressure of nitrogen. 
cyclo[DKP-RGD] (75),[127] azido-tetraethylene glycol-acid (91),[188] azido-tetraethylene glycol-
N-hydroxysuccinimidyl ester (92),[188] Fmoc-Val-Ala-N-[4-[[[(N-(Boc)-N,N’-dimethylethylenedi-
amine)carbonyl]oxy]methyl]phenyl] (93),[130] 2’-(4-nitrophenoxycarbonyl) paclitaxel (95),[130] 4-
(Prop-2-yn-1-yloxy)benzoic acid (109)[189] and intermediates, Fmoc-Asn(Trt)-Pro-OH (126)[190] 
and Fmoc-[D]-Val-PABA (132)[191] were prepared according to literature procedures, and their 
analytical data were in agreement with those already published. Reactions were monitored by 
analytical thin-layer chromatography (TLC) using silica gel 60 F254 pre-coated glass plates 
(0.25 mm thickness). Visualization was accomplished by irradiation with a UV lamp and/or 
staining with a potassium permanganate alkaline solution or ninhydrin. Flash column 
chromatography was performed according to the method of Still and co-workers[192] using 
Chromagel 60 ACC (40-63 µm) silica gel. Proton NMR spectra were recorded on a 
spectrometer operating at 400.16 MHz. Proton chemical shifts are reported in ppm (δ) with the 
solvent reference relative to tetramethylsilane (TMS) employed as the internal standard (CDCl3 
δ = 7.26 ppm; CD2Cl2, δ = 5.32 ppm; D2O, δ = 4.79 ppm; [D]6DMSO, δ = 2.50 ppm; CD3OD, δ 
= 3.33 ppm).[193] The following abbreviations are used to describe spin multiplicity: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of doublet, 
ddd = doublet of doublet of doublet, ddt = doublet of doublet of triplet. Carbon NMR spectra 
were recorded on a spectrometer operating at 100.63 MHz, with complete proton decoupling. 
Carbon chemical shifts are reported in ppm (δ) relative to TMS with the respective solvent 
resonance as the internal standard (CDCl3, δ = 77.16 ppm; CD2Cl2, δ = 54.00 ppm; [D]6DMSO, 
δ = 39.51 ppm; CD3OD, δ = 49.05 ppm). 
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ESI-MS spectra were recorded on the ion trap mass spectrometer Finnigan LCQ Advantage 
or Micro Waters Q-Tof (ESI source). MALDI-TOF-MS spectra were recorded on the instrument 
Bruker Microflex™ LT, supporting the sample on the 2,5-dihydroxybenzoic acid (DHB), α-
cyano-4-hydroxycinnamic acid (HCCA) and sinapinic acid (SIN) matrices. The peptide 
calibration standard (300-6000 Da range), which consisted of Angiotensin II, Angiotensin I, 
Substance P, Bombesin; ACTH clip 1-17, ACTH clip 18-39, Somatostatin 28, was purchased 
from Bruker Daltonics® and used to calibrate the MALDI-TOF-MS instrument. The sample was 
mixed in equal volumes with the matrix solution: a small amount (1 μL) of this mixture was 
spotted on the target surface. The target matrix was dried at room temperature and then 
analyzed. 
High-resolution mass spectra (HRMS) were performed with a Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) Mass Spectrometer APEX II & Xmass software (Bruker Daltonics) – 4.7 
T Magnet (Magnex) equipped with ESI source, available at CIGA (Centro Interdipartimentale 
Grandi Apparecchiature), University of Milan. 
HPLC purifications and HPLC traces of final products were performed on Dionex Ultimate 3000 
equipped with Dionex RS Variable Wavelength Detector (column: Atlantis Prep T3 OBDTM 5 
m 19 × 100 mm; flow 15 mL/min unless stated otherwise). The crude reaction mixture was 
dissolved in H2O or, if the compound was insoluble in water, adding first DMF, then diluting 
slowly with H2O until reaching a 1:1 mixture DMF/H2O (ultrasonic sonicator was used to assist 
the dissolution). The solution so obtained was filtered (polypropylene, 0.45 μm, 13 mm ø, 
PK/100) and injected in the HPLC, affording purified products. Purity analyses were carried on 
a Dionex Ultimate 3000 instrument equipped with a Dionex RS Variable Wavelength detector 
(column: Waters Atlantis® 5 μm 21 mm × 10 cm column). 1 mg of analyte was dissolved in 1 
mL of H2O and was injected using the same gradient used in the purification step. The analysis 
of the integrals and the relative percentage of purity was performed with the software 
Cromeleon 6.80 SR11 Build 3161. 
Freeze-drying: The products were dissolved in water and frozen with dry ice. Later on, the 
freeze-drying was carried out at least for 48 h at -50 °C using the instrument 5Pascal Lio5P 
DGT. 
General Procedures 
GENERAL PROCEDURE FOR Boc DEPROTECTION REACTIONS: 
GP1: To a 0.03 M CH2Cl2 solution of the N-Boc-protected compound half volume of TFA was 
added, and the reaction was stirred at r.t. for 1 h. The solvent was evaporated and then for two 
times CH2Cl2 was added to the residue followed by evaporation under vacuum, to afford the 
amine TFA salt. 
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GENERAL PROCEDURE FOR Fmoc DEPROTECTION REACTIONS: 
GP2: A 0.01 M solution of the N-Fmoc-protected compound (1 equiv) in DMF was cooled to 0 
°C under nitrogen atmosphere. Piperidine (5 equiv) was added and the reaction was stirred at 
room temperature for 2 h. The mixture was diluted with AcOEt (20  volume of DMF) and 
washed twice with a saturated aqueous solution of NaHCO3. The organic phase was dried 
over Na2SO4 and concentrated at rotavapor. CH2Cl2 was added to the residue and evaporated 
to afford a yellow solid. The crude was left under vacuum for 2 h and then used as starting 
material for the subsequent step. 
GENERAL PROCEDURE FOR CuAAC (“click reaction”) REACTIONS: 
GP3: Alkyne (1 - 1.5 equiv) and azide (1 - 4.8 equiv) were dissolved in a degassed 1:1 mixture 
of H2O/DMF (0.01 M) under a nitrogen atmosphere. Degassed aqueous solutions of 
CuSO4∙5H2O (0.5 equiv per unit of alkyne) and sodium ascorbate (0.6 equiv per unit of alkyne) 
were added at room temperature and the mixture was stirred overnight at 35 ºC. The solvent 
was removed under vacuum, and the crude residue was purified by semipreparative HPLC 
[Waters Atlantis 21 mm x 10 cm column; gradient: 90% (H2O+0.1% CF3COOH)/10% 
(CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% CF3COOH)]. After purification, the final 
product was then freeze-dried. 
Biological Assays 
SOLID-PHASE RECEPTOR BINDING ASSAY: 
Recombinant human integrin αvβ3 receptor (R&D Systems, Minneapolis, MN, USA) was diluted 
to 0.5 µg/mL in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MnCl2, 
2 mM CaCl2, and 1 mM MgCl2. An aliquot of diluted receptor (100 µL/well) was added to 96-
well microtiter plates (Nunc MaxiSorp) and incubated overnight at 4 °C. The plates were then 
incubated with blocking solution (coating buffer plus 1% bovine serum albumin) for 2 h at r.t. 
to block nonspecific binding. After washing 2 times with blocking solution, plates were 
incubated shaking for 3 h at r.t., with various concentrations (10-5-10-12 M) of test compounds 
in the presence of 1 µg/mL biotinylated vitronectin (Molecular Innovations, Novi, MI, USA). 
Biotinylation was performed using an EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, Rockford, 
IL, USA). After washing 3 times, the plates were incubated shaking for 1 h at r.t., with 
streptavidin-biotinylated peroxidase complex (Amersham Biosciences, Uppsala, Sweden). 
After washing 3 times with blocking solution, plates were incubated with 100 µL/well of 
Substrate Reagent Solution (R&D Systems, Minneapolis, MN, USA) for 30 min, in the dark, 
with shaking. After stopping the reaction with the addition of 50 µL/well 2 N H2SO4, absorbance 
at λ = 415 nm was read in a SynergyTM HT Multi-Detection Microplate Reader (BioTek 
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Instruments, Inc.). Each data point represents the average of triplicate wells; data analysis was 
carried out by nonlinear regression analysis with GraphPad Prism software (GraphPad Prism, 
San Diego, CA, USA). Each experiment was repeated in duplicate. 
DETERMINATION OF INTEGRIN αvβ3 RECEPTOR EXPRESSION BY FLUORESCENCE 
ACTIVATED CELL SORTER (FACS) 
U87 and HT29 cells were seeded in T25 flasks with ventilation cap and incubated at 37 °C in 
a humidified atmosphere with 5% CO2 for 48 h. Cells were harvested and fixed with 4% PFA 
(Paraformaldehyde). With 3% BSA (Bovine Serum Albumin) were blocked all possible non-
specific binding sites on the cell, and cells were exposure with LM609 anti integrin αVβ3 
antibody conjugated with FITC (Merck Millipore, Darmstadt, Germany). In control samples cells 
were not stained with antibody, and auto-fluorescence intensity of cells was measured. 
Fluorescent intensity of stained samples was measured by flow cytometer Beckman Coulter, 
and compared with auto-fluorescence intensity of control samples. 
 
Figure 46. Flow cytometry analysis of integrin αvβ3 in U87 and HT29 cell lines. Black: auto-fluorescence of the 
cell; Red: fluorescence of αVβ3 integrin antibody. 
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Figure 47. Mean fluorescence intensity of αvβ3 receptors expression in U87 and HT29 cell lines. 
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U87 AND HT29 CELL LINES AND CULTURE CONDITIONS: 
U87 (human glioblastoma) and HT29 (human colorectal adenocarcinoma) cell lines obtained 
from ATCC and were cultured in sterile T25 flasks with ventilation cap (Sarstedt, Nümbrecht, 
Germany) at 37 °C in a humidified atmosphere with 5% CO2. For U87 cells, DMEM medium 
(Dulbecco's Modified Eagle's Medium) (Lonza, Basel, Switzerland) containing 4500 mg·L−1 
glucose and supplemented with 10% heat-inactivated and filtered FBS (Fetal Bovine Serum) 
(Lonza, Basel, Switzerland) and 1% Penicillin-Streptomycin (Lonza, Basel, Switzerland) was 
used. HT29 cells were grown in RPMI 1640 medium supplemented with 10% FBS and 1% 
Penicillin-Streptomycin. 
ANTIPROLIFERATIVE ACTIVITY OF CONJUGATES 97, 103-105 
Cell viability was determined by MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) obtained from Sigma Aldrich (St. Louis, MO, USA). After standard 
trypsinization, cells were seeded at 3 × 103 cells (U87) and 4 × 103 cells (HT29) per well in a 
96-well plate and incubated. After 24 h, cells were treated with various concentrations of 
conjugates 97, 103-105 and free drug PTX (paclitaxel) and incubated in appropriate serum-
containing growth medium for 96 h under standard growth conditions. Control wells were 
untreated. Subsequently, MTT assay was performed by adding 20 μL of MTT solution (5 mg·L−1 
in PBS) to each well and after 4 h of incubation at 37 °C, the supernatant was removed. The 
formazan crystals were dissolved in 100 μL of a 1:1 solution of DMSO (Sigma Aldrich, St. 
Louis, MO, USA) and EtOH (Molar Chemicals Kft. Hungary) and the absorbance was 
measured after 15 min at λ = 570 nm by using a microplate reader (BIO-RAD, model 550). 
Average background absorbance of DMSO-EtOH only, was subtracted from absorbance 
values of control and treated wells, and cell viability was determined relative to untreated 
(control) wells where cell viability was arbitrarily set to 100%. Absorbance values of treated 
samples were normalized versus untreated control samples and interpolated by nonlinear 
regression analysis with GraphPad Prism software to generate dose-response curves. The 
50% inhibitory concentration (IC50) was determined from the dose-response curves by using 
sigmoidal interpolation curve fitting. The experiments were done in triplicate. 
 
 
 
 
 
 
 
 
 
H T -2 9  9 6 h
C o n c e n tra t io n  [M ]
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
1 0 -1 4 1 0 -1 2 1 0 -1 0 1 0 -8 1 0 -6 1 0 -4
0
5 0
1 0 0
9 7
1 0 3
1 0 4
1 0 5
P T X
U 8 7 M G  9 6 h
C o n c e n tra t io n  [M ]
C
e
ll
 v
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l)
1 0 -1 4 1 0 -1 2 1 0 -1 0 1 0 -8 1 0 -6 1 0 -4
0
5 0
1 0 0
9 7
1 0 3
1 0 4
1 0 5
P T X
Figure 48. Dose-response curves of conjugates 97, 103-105 and PTX. 
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DIGESTION OF 121 WITH ELASTASE AND LYSOSOMAL ENRICHED EXTRACT 
100 µM solution of conjugate 121 was digested in PBS/ 10% CH3CN at 37 °C for 2 h with 25 
mUnits of Elastase from human leucocytes (ELANE, E-8140, Sigma-Aldrich). 
0.2 mM solutions of conjugate 121 were digested in 200 mM sodium acetate (pH 5.5)/1 mM 
EDTA containing 1 mM cysteine at 37 °C for 2 h with 0.5 mg mL−1 of lysosomal enriched extract 
(prepared from a rat liver as previously described in the literature) in the presence or absence 
of 20 µM E-64 protease inhibitors (Enzo Life Sciences). 
Control samples were prepared by diluting the compounds in the same reaction mixture 
acidified with TFA to inactivate elastase and the lysosomal enzymes. 
All samples were analyzed by ESI-LC/MS on a PLRP-S column (Agilent Technologies; 2.1  
150 mm, 8 µm, 1000 Å) with an Agilent 1100 HPLC system equipped with a diode array 
detector with an electrospray ion source. Mobile phase A was composed of 0.05% TFA in 
water, and mobile phase B was 0.05% TFA in CH3CN. Samples (45 µM) were eluted at 0.25 
mL min−1 by using a gradient from 20 to 50% B in 30 min, raised to 80% B and held at 80% B 
for 5 min; the UV signal was recorded at 220 and 280 nm, and MS detection was set in full-
scan mode from 300–2000 amu. 
PLASMA STABILITY OF CONJUGATE 121 
A 1 mM solution of conjugate 121 in DMSO was diluted to 5 μM with blank mouse plasma and 
incubated at 37 °C under mixing for 24 h. Aliquots of 20 μL were double collected at the time 
points 0, 0.25, 0.50, 1, 2, 4, 6 and 24 h and frozen up to analysis. Sample plasma proteins 
were precipitated by adding 180 mL of CH3CN/MeOH (9:1) to the unfrozen aliquots. After 
mixing for 15 minutes, the aliquots were centrifuged for 5 minutes at 12000 rpm; the 
supernatants were collected and transferred into 96-well plate; the plate was further 
centrifuged for 5 minutes at 4000 rpm. The samples were analyzed against standard 
appropriately diluted for calibration line in CH3CN /MeOH (9:1). 
 
Figure 49. Plasma stability of conjugate 121: the calculated half-life (t1/2) is 35.27 hours. 
 
  
105 Experimental Section 
All samples were analyzed by UPLC-LC-MS/MS on a BEH C18 column (Waters Acquity BSM; 
2.1  50 mm, 1.7 µm) with an Waters UPLC system equipped with a diode array detector with 
an electrospray ion source. Mobile phase A was composed of 5% CH3CN in 5 mM Ammonium 
Formate pH 3.5, and mobile phase B was 5% 5 mM Ammonium Formate pH 3.5 in CH3CN; 
the UV signal was recorded at 220 and 280 nm, and MS detection was set in full-scan mode 
from 300–2000 amu. The software used to analyze all the data was Mass Lynx 4.1 SCN919.  
After linear regression analysis, the calculated half-life (t1/2) is 35.27 hours. 
STABILITY TEST OF PRO-PTX 142 
Paclitaxel drug release was investigated by incubation of Pro-PTX TFA salt 142 (250 µM) in 
DMSO:PBS (1:1), pH 7.5  at 37 ºC. Aliquots (100 μL) were taken at several time points and 
analyzed by HPLC after dilution with eluent (300 μL). HPLC conditions: analysis was carried 
out on a reverse-phase column (Waters Atlantis 21 mm x 10 cm column, gradient from 90% 
(H2O + 0.1% CF3COOH) / 10% (CH3CN + 0.1% CF3COOH) to 100% (CH3CN + 0.1% 
CF3COOH) in 20 min). The data were extracted from the software Cromeleon 6.80 SR11 Build 
3161 and analyzed by Excel™ 2016. 
 
Figure 50. Pro-PTX 142 cyclization and PTX release during the time. A representative curve was treated for each 
HPLC run. X-axis shows the retention time of each specie; Y-axis shows the area of each peak. 
 
ANTIPROLIFERATIVE ACTIVITY OF 121-124 AND 142 
786-O renal cancer cell line (NCI) was cultured in RPMI 1640 medium supplemented with 10% 
fetal calf serum (FCS) at 37°C and 5% CO2. Cells were seeded at a density of 2000 cells/well 
(200 l/well) in 96-well plates and, 24 hours after seeding. Cells were treated in duplicate with 
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serial dilutions of 121-124 in the range 5.0 μM - 9.8 nM and with serial dilutions of PTX and Pro-
PTX 142 in the range 0.1 M – 0.2 nM, in the presence or absence of Elastase from human 
leucocytes (ELANE, 324681, Millipore). In the case of presence of elastase, the latter was 
added immediately after compound treatment at a final concentration of 50 nM in half of 
replicates, then the plates were incubated for 96 hours at 37°C. 
Cell viability was assessed with the CellTiter-Glo luciferase-based ATP detection assay 
(Promega) and Envision (PerkinElmer) microplate reader. Growth inhibitory activity was 
evaluated at the end of incubation by using GraphPad Prism software. Experimental data were 
normalized versus untreated control samples and interpolated by nonlinear regression analysis 
with GraphPad Prism software to generate dose-response curves. IC50 values were calculated 
by using sigmoidal interpolation curve fitting. 
 
ANTIPROLIFERATIVE ACTIVITY OF RGD-MMAE/MMAF CONJUGATES (145-149, 156 and 
163-166) 
To evaluate the cytotoxicity of (RGD/isoDGR)-MMAE/MMAF conjugates against U-87 MG 
glioblastoma cells obtained from American Type Culture Collection (ATCC, Bethesda, MD, 
USA). Cell viability was quantified by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. Briefly, cells in EMEM supplemented with 10% FBS, 1% L-glutamine and 1% 
penicillin/streptomycin, were seeded in 96-well culture plates (5 × 104 cells/well) and incubated 
in a humidified, 37 °C, 5% CO2 atmosphere overnight to allow adherence. The following day 
cells were treated with serial dilutions of each compound starting at 500 nM for MMAE or MMAF 
and 5000 nM for each conjugate, or 0.1% DMSO as a control, and incubated as described for 
72h. At the end of treatment, 5 µL of MTT (5 mg/mL in deionized H2O, Sigma #M5655) was 
added to each well. The cells were incubated for another 2 hours, and 100 µL of lysis buffer 
(10% SDS, 10 mM HCl) were added, and placed in the incubator overnight for the formazan 
crystal solubilization. Absorbance at 540 nm was measured and the growth inhibition ratio was 
calculated. Blank controls detecting cell-free media absorbance were performed in parallel. 
Three experimental replicates were used. The half-maximal inhibitory concentration values 
(IC50) were obtained from viability curves using GraphPad Prism 6 (Figure 51). The cell viability 
was expressed as percentage relative to the respective control conditions (0.1% of DMSO). 
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Figure 51. Dose-response curves of MMAE-containing compounds (left), MMAF-containing compounds (right), 
MMAE and MMAF. 
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Synthesis of cyclo[DKP-RGD]-Drug Conjugates 
cyclo[DKP-RGD]-PEG-4-Azide (86) 
14-Azido-3,6,9,12-tetraoxatetradecanoic acid (91) 
 
Commercially available tetraethylene glycol (4.58 g, 23.6 mmol, 3 equiv) was dissolved in dry 
CH2Cl2 (80 mL) under inert atmosphere. Then DMAP (0.19 g, 1.58 mmol, 0.2 equiv) and Et3N 
(3.3 mL, 23.6 mmol, 3 equiv) were added. The mixture was cooled at 0 °C and a solution of 
TsCl (1.5 g, 7.9 mmol, 1 equiv) in dry CH2Cl2 (40 mL) was added dropwise. The reaction was 
stirred at r.t. for 2 h. Hence, 100 mL of CH2Cl2 were added and the mixture was washed with 
a solution of HCl 1 M (2 × 40 mL) and brine (1 × 50 mL). The organic phase was dried over 
Na2SO4 and concentrated. Then the crude was dissolved in dry DMF (15 mL) and NaN3 (1.03 
g, 15.8 mmol, 2 equiv) was added under inert atmosphere. The suspension was stirred at 80 
°C overnight. The solvent was removed and the crude was purified by flash chromatography 
on silica gel (gradient from 1% MeOH to 5% MeOH in AcOEt) affording the corresponding 
azide. Later on, to a suspension of NaH (0.6 g, 25 mmol, 5 equiv) in dry THF (25 mL), azido-
tetraehtylene glycol (1.09 g, 5 mmol, 1 equiv) dissolved in dry THF (25 mL) was added 
dropwise over a period of 30 min under inert atmosphere. The reaction was stirred for 1 h more 
at room temperature. Later, a solution of bromoacetic acid (1.387 g, 10 mmol, 2 equiv) in dry 
THF (21 mL) was added dropwise over a period of 1 h and then the reaction was stirred 
overnight at r.t. After addition of cold water, THF was removed under vacuum and a solution 
of HCl 1 M was added until pH = 1. The mixture was extracted with AcOEt (5 × 80 mL) and the 
collected organic phases were washed with brine (1 × 150 mL). The organic phase was dried 
over Na2SO4 and concentrated, then the crude was purified by flash chromatography on silica 
gel (eluent: CH2Cl2/MeOH, 9:1 + 0.1% CH3COOH) affording the corresponding carboxylic acid 
91 as a pale-yellow oil (1.09 g, 79% yield). 
Rf = 0.25 (9:1, CH2Cl2/MeOH + 0.1% CH3COOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 3.96 (s, 
2H), 3.70-3.61 (m, 14H), 3.39 (t, J = 5.0 Hz, 2H). 
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Azido-tetraethylene glycol-N-hydroxysuccinimidyl ester (92) 
 
Carboxylic acid 91 (77 mg, 0.28 mmol, 1 equiv) was dissolved in dry THF and cooled down to 
0 °C under a nitrogen atmosphere. EDC∙HCl (69 mg, 0.36 mmol, 1.3 equiv) and N-
hydroxysuccinimide (41 mg, 0.36 mmol, 1.3 equiv) were added and the mixture was allowed 
to reach r.t. and stirred overnight. The solvent was removed and the crude was purified over a 
pad of silica [eluent: AcOEt/hexane, 8:2] affording ester 92 as a colorless oil (67 mg, 64% 
yield).  
Rf = 0.43 (9:1, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 4.50 (s, 2H), 3.78-3.73 (m, 
2H), 3.68-3.59 (m, 12H), 3.37 (t, J = 5.1 Hz, 2H), 2.83 (s, 4H); MS (ESI+): m/z calcd for 
[C14H22N4NaO8]+: 397.13 [M + Na]+; found: 397.19. 
cyclo[DKP-RGD]-PEG-4-N3 (86) 
 
To a solution of 92 (17 mg, 0.045 mmol, 1.3 equiv) in CH3CN (2 mL) under a nitrogen 
atmosphere, cyclo[DKP-RGD] 75 (30 mg, 0.035 mmol, 1 equiv) dissolved in pH 7.5 PBS 
solution (1.5 mL) was added at 0 °C under a nitrogen atmosphere. The reaction mixture was 
allowed to reach r.t. and stirred overnight. During the first 3 h the pH value was kept close to 
7.3-7.5 adding 0.2 M aqueous NaOH aq. when necessary. The crude was then purified by 
semipreparative-HPLC [Waters Atlantis 21 mm  10 cm column, flow: 9 mL/min, gradient: 90% 
(H2O + 0.1% CF3COOH) / 10% (CH3CN + 0.1% CF3COOH) to 55% (H2O + 0.1% CF3COOH) 
/ 45% (CH3CN + 0.1% CF3COOH) in 10 min; tR (product): 8.3 min]. The purified product was 
then freeze-dried giving the desired 86 as a white solid (27 mg, 77% yield). 
1H NMR (400 MHz, D2O) δ 7.36 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 5.12 (d, J = 15.4 
Hz, 1H), 4.90 (t, J = 7.1 Hz, 1H), 4.59 (dd, J = 7.9, 5.4 Hz, 1H), 4.48 (s, 2H), 4.34 (d, J = 17.1 
Hz, 1H), 4.22 (dd, J = 9.6, 5.2 Hz, 1H), 4.19-4.11 (m, 4H), 4.01 (d, J = 14.6 Hz, 1H), 3.80-3.75 
(m, 3H), 3.75-3.69 (m, 3H), 3.69-3.59 (m, 10H), 3.47-3.43 (m, 2H), 3.25 (t, J = 6.8 Hz, 2H), 
3.01-2.88 (m, 2H), 2.81 (dd, J = 16.9, 7.1 Hz, 1H), 2.67 (dd, J = 14.0, 5.4 Hz, 1H), 2.08-1.97 
(m, 1H), 1.90-1.78 (m, 1H), 1.77-1.60 (m, 2H); 13C NMR (101 MHz, D2O) δ 174.1, 173.9, 173.1, 
172.8, 172.7, 170.9, 170.1, 168.6, 156.8, 137.8, 134.1, 128.1, 127.8, 70.5, 69.5, 69.2, 59.3, 
54.0, 52.1, 50.1, 49.4, 47.6, 42.5, 42.2, 40.6, 39.2, 38.0, 34.6, 25.8, 24.7; MS (ESI+) m/z calcd 
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for [C37H56N13O13]+: 890.41 [M + H]+; found: 890.47; m/z calcd [C37H55N13NaO13]+: 912.39 [M + 
Na]+; found: 912.45. 
cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX aliphatic scaffold (97) 
Aliphatic alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (94) 
 
N-Fmoc-protected compound 93 (150 mg, 0.206 mmol, 1 equiv) was deprotected following 
General Procedure GP2. A solution of commercial 4-pentynoic acid (31 mg, 0.31 mmol, 1.5 
equiv) in dry DMF (7 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (134 mg, 
0.35 mmol, 1.7 equiv), HOAt (48 mg, 0.35 mmol, 1.7 equiv) and iPr2NEt (145 µL, 0.83 mmol, 
4 equiv) were added and the mixture was stirred for 20 min at 0 °C. A solution of 93-NH (105 
mg, 0.206 mmol, 1 equiv) in dry DMF (3 mL) was added to the stirred mixture. The reaction 
was allowed to slowly reach room temperature and stirred overnight. The mixture was diluted 
with an AcOEt/CH2Cl2, 4:1 mixture (100 mL) and washed with 1 M aqueous solution of KHSO4 
(2 × 15 mL), a saturated aqueous solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The 
organic phase was dried over Na2SO4 and concentrated. The solid was suspended in Et2O. 
The product was collected by centrifugation and purified by flash chromatography [gradient: 
from 99:1 CH2Cl2/MeOH to 97:3 CH2Cl2/MeOH] to afford amide 94 as a white solid (106 mg, 
88% yield over two steps). 
Rf = 0.39 (9:1, CH2Cl2/MeOH); 1H NMR (500 MHz, [D]6DMSO) δ 9.71 (s, 1H), 7.93 (d, J = 7.2 
Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 5.00 (s, 
2H), 4.44 (p, J = 7.0 Hz, 1H), 4.21 (dd, J = 8.4, 6.5 Hz, 1H), 3.38-3.29 (m, 4H), 2.87 (s, 3H), 
2.75 (s, 3H), 2.62 (t, J = 2.4 Hz, 1H), 2.46-2.32 (m, 4H), 2.09-1.99 (m, 1H), 1.39 (s, 9H), 1.34 
(d, J = 7.1 Hz, 3H), 0.90 (dd, J = 11.3, 6.8 Hz, 6H); 13C NMR (126 MHz, [D]6DMSO) δ 171.41, 
171.23, 171.14, 155.93, 155.28, 139.02, 132.35, 128.64, 121.72, 120.36, 119.73, 84.25, 78.98, 
71.33, 66.47, 58.45, 49.56, 34.73, 34.48, 30.77, 19.58, 18.53, 18.36, 14.79. MS (ESI+) m/z 
calcd for [C30H46N5O7]+: 588.75 [M + H]+; found: 588.77; m/z calcd [C30H45NaN5O7]+: 610.72 [M 
+ Na]+; found: 610.70. 
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Aliphatic alkyne-Val-Ala-PTX (96) 
 
A solution of Boc-protected compound 94 (20 mg, 0.034 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained TFA salt was dissolved in dry DMF (500 μL) 
and iPr2NEt (25 µL, 0.136 mmol, 4 equiv). The resulting solution was added at 0 °C to a stirred 
solution of 95 (52 mg, 0.051 mmol, 1.5 equiv) in dry DMF (500 μL), under a nitrogen 
atmosphere. The reaction was then allowed to reach room temperature and stirred overnight. 
AcOEt (100 mL) was added and the solution was washed with a 1 M aqueous solution of 
KHSO4 (2 × 10 mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 and 
concentrated, then the crude was purified by flash chromatography [gradient: from 9:1 
CH2Cl2/AcOEt to 7:3 CH2Cl2/AcOEt] to afford carbamate 96 as a white solid (30 mg, 66% yield). 
Rf = 0.33 (CH2Cl2/AcOEt, 9:1); MS (MALDI-TOF): m/z calcd for [C73H86NaN6O20]+: 1389.98 [M 
+ Na]+; found: 1389.70 (HCCA matrix), 1390.08 (SA matrix); HRMS (ESI+): m/z calcd for 
[C73H86NaN6O20]+: 1389.98 [M + Na]+; found: 1389.57; m/z calcd for [C73H86Na2N6O20]2+: 
706.14, [M + 2Na]2+; found: 706.28. 
cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX aliphatic scaffold (97) 
 
Alkyne 96 (10 mg, 0.0075 mmol, 1.5 equiv) and azide 86 (5 mg, 0.005 mmol, 1 equiv) were 
reacted following the General Procedure GP3. Crude was purified by semipreparative HPLC 
[Waters Atlantis 21 mm x 10 cm column; gradient: 90% (H2O+0.1% CF3COOH)/10% 
(CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% CF3COOH) in 20 min; tR (product)=11.9 
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min]. The purified product was then freeze-dried to give the desired compound 97 as a white 
solid (9 mg, 81% yield).  
MS (MALDI-TOF): m/z calcd for [C110H142N19O33]+: 2258.40 [M + H]+; found: 2258.30 (HCCA 
matrix), 2258.34 (SA matrix); HRMS (ESI+): m/z calcd for [C110H140Na3N19O33]2+: 1161.90, [M 
+ 3Na - H]2+; found: 1161.97; m/z calcd for [C110H141Na2N19O33]2+: 1150.90, [M + 2Na]2+ found: 
1150.98. 
cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX aromatic scaffold (102) 
Methyl 4-hydroxybenzoate (107) 
 
Commercial 4-hydroxybenzoic acid 106 (100 mg, 0.724 mmol, 1 equiv) was dissolved in MeOH 
(1.3 mL), and H2SO4 (19 μL, 0.362 mmol, 0.5 equiv) was added thereto, and stirred for 4 hours 
under reflux. The reaction mixture was concentrated, diluted in water, and extracted with 
EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. Then, the residue was purified by flash chromatography on silica gel (1:1 
Et2O/n-Hexane) affording the desired product 107 as a white solid (110 mg, yield: quantitative). 
Rf = 0.48 (1:1, Et2O/n-Hexane); 1H NMR (400 MHz, CD2Cl2-d2) δ 7.98 (d, J = 8.8 Hz, 2H), 6.92 
(d, J = 8.7 Hz, 2H), 5.90 (s, 1H), 3.90 (s, 3H); MS (ESI+) m/z calcd for [C8H9O3]+: 153.03 [M + 
H]+; found: 153.08. 
Methyl 4-(prop-2-yn-1-yloxy)benzoate (108) 
 
Compound 107 (110 mg, 0.723 mmol, 1 equiv) was dissolved in dry acetone (7 mL) under 
nitrogen atmosphere. The solution was cooled in an ice bath. Propargyl bromide (250 μL, 2.9 
mmol, 4 equiv) and K2CO3 (400 mg, 2.9 mmol, 4 equiv) were added, and the mixture was 
stirred at room temperature for 24 h at 30 ºC. The mixture was concentrated, the crude was 
dissolved in AcOEt (70 mL) and washed with water (3 × 10 mL). The organic phase was dried 
over Na2SO4 and concentrated, affording the desired product 108 as an orange solid (135 mg, 
yield: 99%). 
Rf = 0.77 (1:1, n-Hexane/EtOAc); 1H NMR (400 MHz, CD2Cl2-d2) δ 7.99 (d, J = 9.0 Hz, 2H), 
7.01 (d, J = 8.9 Hz, 2H), 4.76 (d, J = 2.4 Hz, 2H), 3.86 (s, 3H), 2.61 (t, J = 2.4 Hz, 1H); MS 
(ESI+) m/z calcd for [C11H11O3]+: 191.06 [M + H]+; found: 191.08. 
  
113 Experimental Section 
4-(Prop-2-yn-1-yloxy)benzoic acid (109) 
 
Compound 108 (135 mg, 0.710 mmol, 1 equiv) was dissolved in MeOH (6 mL) under a nitrogen 
atmosphere. The solution was cooled to 0 °C, then NaOH (142 mg, 3.6 mmol, 5 equiv) in H2O 
(2 mL) was added. The mixture was stirred 5 h at room temperature. The mixture evaporated 
until the dryness under reduced pressure and later acidified to ca. pH = 1 with a 1 M KHSO4 
aqueous solution and extracted with EtOAc (4 × 20 mL). The organic phase was dried over 
Na2SO4 and concentrated, affording 109 as an orange solid (120 mg, yield: 98%). 
Rf = 0.15 (3:2, n-Hexane/EtOAc); 1H NMR (400 MHz, CD3OD) δ 7.98 (d, J = 8.9 Hz, 2H), 7.05 
(d, J = 8.9 Hz, 2H), 4.81 (d, J = 2.4 Hz, 2H), 2.99 (t, J = 2.4 Hz, 1H). MS (ESI+) m/z calcd for 
[C10H9O3]+: 177.05 [M + H]+; found: 177.06; m/z calcd [C10H8NaO3]+: 199.39 [M + Na]+; found: 
199.45. 
Aromatic alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118a) 
 
N-Fmoc-protected compound 93 (70 mg, 0.096 mmol, 1 equiv) was deprotected following 
General Procedure GP2. A solution acid 109 (26 mg, 0.15 mmol, 1.5 equiv) in dry DMF (4 mL) 
was cooled to 0 °C under a nitrogen atmosphere. HATU (93 mg, 0.25 mmol, 1.7 equiv), HOAt 
(34 mg, 0.25 mmol, 1.7 equiv) and iPr2NEt (67 µL, 0.39 mmol, 4 equiv) were added and the 
mixture was stirred for 20 min at 0 °C. A solution of 93-NH (49 mg, 0.096 mmol, 1 equiv) in dry 
DMF (2 mL) was added to the stirred mixture. The reaction was allowed to slowly reach room 
temperature and stirred overnight. The mixture was diluted with an AcOEt/CH2Cl2, 4:1 mixture 
(100 mL) and washed with 1 M aqueous solution of KHSO4 (2 × 15 mL), a saturated aqueous 
solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic phase was dried over 
Na2SO4 and concentrated. The solid was solubilized in DCM/MeOH (95:5) and purified by flash 
chromatography [gradient: from 100% CH2Cl2 to 95:5 CH2Cl2/MeOH] to afford amide 118a as 
a white solid (55 mg, 86% yield over two steps). 
Rf = 0.35 (95:5, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.73 (s, 1H), 7.82 (d, J = 8.8 
Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 7.13 (t, J = 6.4 Hz, 1H), 6.99 (d, J = 
8.8 Hz, 2H), 6.90 (d, J = 7.7 Hz, 1H), 5.04 (s, 2H), 4.74 (d, J = 2.4 Hz, 2H), 4.66 (p, J = 7.1 Hz, 
1H), 4.50 (t, J = 7.2 Hz, 1H), 3.38-3.27 (m, 4H), 2.91 (s, 3H), 2.76 (s, 3H), 2.61 (t, J = 2.4 Hz, 
1H), 2.24 (q, J = 6.8 Hz, 1H), 1.43 (d, J = 11.8 Hz, 12H), 1.01 (dd, J = 6.8, 4.0 Hz, 6H). 13C 
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NMR (101 MHz, CD2Cl2-d2) δ 171.86, 170.91, 167.23, 160.23, 138.02, 132.73, 129.23, 128.66, 
128.44, 127.08, 119.82, 114.50, 79.11, 77.96, 75.83, 66.59, 66.47, 59.13, 55.83, 49.66, 46.55, 
38.37, 29.67, 28.08, 19.10, 18.50, 18.02. MS (ESI+) m/z calcd for [C35H48N5O8]+: 666.34 [M + 
H]+; found: 666.71; m/z calcd [C35H47NaN5O8]+: 711.35 [M + Na]+; found: 711.23. 
Aromatic alkyne-Val-Ala-PTX (119a) 
 
A solution of Boc-protected compound 118a (20 mg, 0.03 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained TFA salt was dissolved in dry DMF (500 μL) 
and iPr2NEt (21 µL, 0.12 mmol, 4 equiv). The resulting solution was added at 0 °C to a stirred 
solution of 95 (46 mg, 0.045 mmol, 1.5 equiv) in dry DMF (500 μL), under a nitrogen 
atmosphere. The reaction was then allowed to reach room temperature and stirred overnight. 
AcOEt (100 mL) was added and the solution was washed with a 1 M aqueous solution of 
KHSO4 (2 × 10 mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 and 
concentrated, then the crude was purified by flash chromatography [eluent: 9:1 CH2Cl2/AcOEt] 
to afford carbamate 119a as a white solid (39 mg, 93% yield). 
Rf = 0.30 (9:1, CH2Cl2/AcOEt); MS (MALDI-TOF): m/z calcd for [C78H88NaN6O21]+: 1467.99 [M 
+ Na]+; found: 1469.02 (HCCA matrix), 1469.09 (SA matrix); HRMS (ESI+): m/z calcd for 
[C78H88NaN6O21]+: 1467.99, [M + Na]+; found 1467.58; m/z calcd for [C78H88Na2N6O21]2+: 
745.25, [M + 2Na]2+; found: 745.28. 
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cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX aromatic scaffold (102) 
 
Alkyne 119a (6.5 mg, 0.005 mmol, 1.5 equiv) and azide 86 (3 mg, 0.003 mmol, 1 equiv) were 
reacted following the General Procedure GP3. Crude residue was purified by semipreparative 
HPLC [Waters Atlantis 21 mm x 10 cm column; gradient: 90% (H2O+0.1% CF3COOH)/10% 
(CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% CF3COOH) in 20 min; tR (product)=12.9 
min]. The purified product was then freeze-dried to give the desired compound 102 as a white 
solid (5 mg, 70% yield).  
MS (MALDI-TOF): m/z calcd for [C115H144N19O34]+: 2336.47 [M + H]+; found: 2236.54 (HCCA 
matrix), 2236.09 (SA matrix); HRMS (ESI+): m/z calcd for [C115H144NaN19O34]2+: 1178.98 [M + 
H + Na]2+; found: 1179.00; m/z calcd for [C115H143Na2N19O34]2+: 1189.96 [M + 2Na]2+; found: 
1189.99; m/z calcd for [C115H142Na3N19O34]2+ 1200.86 [M + 3Na - H]2+; found: 1200.98. 
(cyclo[DKP-RGD]-PEG-4)2-Val-Ala-PTX (103) 
Methyl 3,5-bis(propynyloxy)phenyl acetate (111) 
 
Commercial methyl 3,5-hydroxyphenyl acetate 110 (200 mg, 1.09 mmol, 1 equiv) was 
dissolved in dry acetone (11 mL) under nitrogen atmosphere. The solution was cooled in an 
ice bath. Propargyl bromide (760 μL, 8.8 mmol, 8 equiv) and K2CO3 (1.2 g, 8.8 mmol, 8 equiv) 
were added, and the mixture was stirred at room temperature 72 h. The mixture was 
concentrated, then the crude was dissolved in AcOEt (70 mL) and washed with water (3 × 10 
mL). The organic phase was dried over Na2SO4 and concentrated. The crude residue was 
purified by a Grace Reveleris system (column: Reveleris Silica 12 g; dry load; flow rate: 30 mL 
min−1; ramp: from 100% hexane to 100% AcOEt in 18 min) to afford 111 as a white solid (167 
mg, yield: quantitative). 
Rf = 0.58 (1:1, n-Hexane/AcOEt,); 1H NMR (400 MHz, CDCl3) δ 6.53 (bs, 3H), 4.65 (d, J = 2.4 
Hz, 4H), 3.68 (s, 3H), 3.56 (s, 2H), 2.53 (t, J = 2.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 171.6, 
158.7, 136.2, 109.1, 101.0, 78.4, 75.8, 55.9, 52.2, 41.4. 
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3,5-bis(Propynyloxy)phenyl acetic acid (88) 
 
Compound 111 (165 mg, 0.64 mmol, 1 equiv) was dissolved in THF (20 mL) under a nitrogen 
atmosphere. The solution was cooled to 0 °C, then a solution of LiOH∙H2O (67 mg, 1.6 mmol, 
2.5 equiv) in H2O (10 mL) was added. The mixture was stirred 1.5 h at 0 °C. The mixture was 
acidified to ca. pH = 2 with a 1 M KHSO4 aqueous solution and extracted with CH2Cl2 (4 × 20 
mL). The organic phase was dried over Na2SO4 and concentrated, affording 88 as a white solid 
(158 mg, quantitative yield). 
Rf = 0.36 (1:1, n-Hexane/AcOEt,); 1H NMR (400 MHz, CD3OD) δ 6.59-6.51 (m, 3H), 4.70 (d, J 
= 2.4 Hz, 4H), 3.54 (s, 2H), 2.92 (t, J = 2.4 Hz, 2H). 
[3,5-bis(Propynyloxy)phenylacetyl]-Val–Ala-N-[4-[[[(N-(Boc)-N,N’-
dimethylethylenediamine)carbonyl]oxy]methyl]phenyl] (118b) 
 
N-Fmoc-protected compound 93 (160 mg, 0.219 mmol, 1 equiv) was deprotected following 
General Procedure GP2. A solution of acid 88 (68 mg, 0.28 mmol, 1.5 equiv) in dry DMF (2.3 
mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (114 mg, 0.3 mmol, 1.6 equiv), 
HOAt (41 mg, 0.3 mmol, 1.6 equiv) and iPr2NEt (100 µL, 0.57 mmol, 3 equiv) were added and 
the mixture was stirred for 20 min at 0 °C. A solution of 93-NH (96 mg, 0.19 mmol, 1 equiv) in 
dry DMF (2.3 mL) was added to the stirred mixture. The reaction was allowed to slowly reach 
room temperature and stirred overnight. The mixture was diluted with a AcOEt/CH2Cl2, 4:1 
mixture (100 mL) and washed with 1 M aqueous solution of KHSO4 (2 × 15 mL), a saturated 
aqueous solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic phase was dried 
over Na2SO4 and concentrated. The solid was suspended in Et2O. The product was collected 
by centrifugation and purified by flash chromatography [gradient: from 99:1 CH2Cl2/MeOH to 
97:3 CH2Cl2/MeOH] to afford amide 118b as a white solid (101 mg, 71% yield). 
Rf = 0.3 (100 %, AcOEt); 1H NMR (400 MHz, CD3OD + [D]6DMSO) δ 7.57 (m, 2H), 7.32 (m, 
2H), 6.60 (d, J = 2.2 Hz, 2H), 6.53 (t, J = 2.2 Hz, 1H), 5.06 (s, 2H), 4.70 (d, J = 2.4 Hz, 4H), 
4.46 (q, J = 7.1 Hz, 1H), 4.20 (d, J = 7.2 Hz, 1H), 3.56 (s, 1H), 3.41 (m, 4H), 3.03 (t, J = 2.4 
Hz, 2H), 2.95 (m, rotamer A+B, 3H), 2.85 (bs, rotamer A, 3H), 2.75 (bs, rotamer B, 3H), 2.11 
(m, 1H), 1.42 (m, 12H), 0.99 (d, J = 6.9 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, 
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CD3OD + [D]6DMSO) δ 173.6, 173.3, 172.9, 160.2, 139.3, 130.0, 129.7, 121.0, 110.0, 101.8, 
79.9, 77.2, 68.1, 67.9, 60.4, 56.7, 51.0, 43.6, 35.6, 35.3, 34.7, 31.9, 28.8, 19.8, 18.7, 18.1. 
[3,5-bis(Propynyloxy)phenylacetyl]-Val–Ala-PTX (119b) 
 
A solution of Boc-protected compound 118b (75 mg, 0.1 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained TFA solid was dissolved in dry DMF (2 mL) 
and iPr2NEt (52 µL, 0.3 mmol, 3 equiv). The resulting solution was added at 0 °C to a stirred 
solution of 95 (204 mg, 0.2 mmol, 2 equiv) in dry DMF (1 mL), under a nitrogen atmosphere. 
The reaction was then allowed to reach room temperature and stirred overnight. AcOEt (100 
mL) was added and the solution was washed with a 1 M aqueous solution of KHSO4 (2 × 10 
mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 and concentrated, then 
the crude was purified by a Grace Reveleris system (column: Reveleris Silica HP 12 g, dry 
load, flow rate: 25 mL/min., ramp from 0% to 15% of MeOH in CH2Cl2 in 15 min) to afford 
carbamate 119b as a white solid (116 mg, 77% yield). 
Rf = 0.22 (100%, AcOEt); MS (ESI+) m/z calcd for [C82H92N6NaO22]+: 1535.62 [M + Na]+; found: 
1535.89. MS (MALDI-TOF): m/z calcd for [C82H92N6NaO22]+: 1535.62 [M + Na]+; found: 1536.00 
(HCCA matrix), 1536.08 (SA matrix); HRMS (ESI+): m/z calcd for [C82H92N6NaO22]+: 1535.62, 
[M + Na]+; found: 1535.68; m/z calcd for [C82H92N6Na2O22]2+: 779.01, [M + 2Na]2+; found: 
779.02.  
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(cyclo[DKP-RGD]-PEG-4)2-Val-Ala-PTX (103) 
 
The bis-alkyne 119b (5 mg, 33.2×10−2 mmol, 1 equiv) and azide 86 (10 mg, 99.6×10−2 mmol, 
3 equiv) were reacted following the General Procedure GP3. The solvent was removed under 
vacuum, and the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm 
x 10 cm column; gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 
100% (CH3CN+0.1% CF3COOH) in 26 min; tR (product) = 14.9 min]. The purified product was 
then freeze-dried to give the desired compound 103 as a white solid (11 mg, quantitative yield). 
MS (ESI+): m/z calcd for [C156H204N32O48]2+: 1646.73 [M + 2H]2+; found: 1647.02; m/z calcd for 
[C156H203N32NaO48]2+: 1657.72 [M + H + Na]2+; found: 1658.01; MS (MALDI): m/z calcd for 
[C156H203N32O48]+: 3294.47 [M + H]+; found: 3291.00 (HCCA matrix), 3294.00 (SA matrix); 
HRMS (ESI+): m/z calcd for [C156H204N32O48]2+: 1646.725 [M + 2H]2+; found: 1646.726; m/z 
calcd for [C156H205N32O48]3+; 1098.152 [M + 3H]3+; found: 1098.148. 
(cyclo[DKP-RGD]-PEG-4)3-Val-Ala-PTX (104) 
Methyl 2-(3,5-bis(2-((tert-butoxycarbonyl)amino)ethoxy)phenyl)acetate (112) 
  
Methyl 3,5-hydroxyphenyl acetate 110 (500 mg, 2.75 mmol, 1 equiv) was dissolved in dry 
acetone (20 mL) under nitrogen atmosphere. 2-(Boc-amino)ethyl bromide (3.7 g, 16.5 mmol, 
6 equiv) in dry acetone (7 mL) was added to the starting material at 0 ºC together with K2CO3 
(2.3 g, 16.5 mmol, 6 equiv), and the mixture was stirred under reflux, overnight. The mixture 
was concentrated, and later diluted in AcOEt (70 mL). The organic layer was washed with H2O 
(2 × 30 mL) and brine (1 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated, then the crude was purified by flash chromatography [eluent: 9:1 CH2Cl2/AcOEt] 
to afford protected diamine 112 as a transparent oil (1.12 g, 87% yield). 
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Rf = 0.38 (9:1, CH2Cl2/AcOEt); 1H NMR (400 MHz, CDCl3) δ 6.42 (d, J = 2.2 Hz, 2H), 6.34 (t, J 
= 2.2 Hz, 1H), 4.99 (s, 2H), 3.97 (t, J = 5.1 Hz, 4H), 3.68 (s, 3H), 3.53 (s, 2H), 3.51-3.46 (m, 
4H), 1.44 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 171.62, 159.82, 155.86, 136.23, 108.31, 
100.14, 67.26, 52.06, 41.30, 40.09, 28.39, 27.34. 
Methyl 2-(3-(2-(2-(3,5-bis(prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)-5-(2-(4-(prop-2-
yn-1-yloxy)benzamido)ethoxy)phenyl)acetate (116) 
 
A solution of Boc-protected compound 112 (550 mg, 2.05 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained solid (550 mg, 2.05 mmol, 5 equiv) was 
dissolved in a pre-flame dry flask with DMF (14 mL) and Et3N (57 μL, 0.41 mmol, 1 equiv) and 
stirred about 20 min at r.t. Then, the acyl chloride 114 (110 mg, 0.410 mmol, 1 equiv) dissolved 
in DMF (5 mL) was slowly added (dropwise) to the TFA salt 113 at 0 ºC and the reaction 
mixture was stirred overnight at r.t. AcOEt (100 mL) was added and the solution was washed 
with NaHCO3 (2 × 30 mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 
and concentrated, giving a yellow crude as amine 115 (MS (ESI+): m/z calcd for [C27H31N2O7]+: 
495.21 [M + H]+; found: 495.25). Without isolation, the amine 115 was directly used in the next 
coupling. A solution of acid 109 (109 mg, 0.62 mmol, 1.5 equiv) in dry DMF (15 mL) was cooled 
to 0 °C under a nitrogen atmosphere. HATU (265 mg, 0.70 mmol, 1.7 equiv), HOAt (95 mg, 
0.70 mmol, 1.7 equiv) and iPr2NEt (286 µL, 1.64 mmol, 4 equiv) were added and the mixture 
was stirred for 20 min at 0 °C. A solution of 115 (203 mg, 0.410 mmol, 1 equiv) in dry DMF (5 
mL) was added to the stirred mixture. The reaction was allowed to slowly reach room 
temperature and stirred overnight. The mixture was diluted with AcOEt (200 mL) and washed 
with aqueous solution of NaHCO3 sat. (2 × 30 mL), a saturated aqueous solution of K2CO3 (1 
× 30 mL) and brine (2 × 20 mL). The organic phase was dried over Na2SO4 and concentrated. 
The crude was purified by flash chromatography [gradient: from 3:2 AcOEt/Petroleum Ether to 
4:1 AcOEt/Petroleum Ether] to afford carbamate 116 as a light orange solid (80 mg, 30% yield 
over three steps). 
Rf = 0.29 (25:75, Petroleum Ether/AcOEt); 1H NMR (600 MHz, CD2Cl2-d2) δ 7.77 (d, J = 8.8 
Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.87 (t, J = 5.5 Hz, 1H), 6.51 (d, J = 3.5 Hz, 3H), 6.43 (t, J = 
1.8 Hz, 1H), 6.35 (dt, J = 13.6, 2.1 Hz, 2H), 6.28 (t, J = 5.3 Hz, 1H), 4.73 (d, J = 2.4 Hz, 2H), 
4.62 (d, J = 2.5 Hz, 4H), 4.08 (t, J = 5.3 Hz, 2H), 3.95 (t, J = 5.3 Hz, 2H), 3.78 (q, J = 5.4 Hz, 
2H), 3.66 (s, 3H), 3.55 (q, J = 5.6 Hz, 2H), 3.52 (s, 2H), 3.48 (s, 2H), 2.62 (t, J = 2.4 Hz, 1H), 
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2.58 (t, J = 2.5 Hz, 2H). 13C NMR (151 MHz, CD2Cl2-d2) δ 172.19, 171.03, 167.36, 160.54, 
160.36, 160.27, 159.40, 138.15, 137.02, 129.34, 128.12, 115.07, 109.51, 109.01, 108.82, 
101.42, 100.45, 78.91, 78.59, 76.34, 76.14, 67.36, 67.21, 56.40, 52.49, 44.15, 41.58, 39.92, 
39.51, 38.92; MS (MALDI): m/z calcd for [C37H37N2O9]+: 653.24 [M + H]+; found: 653.27 (DHB 
matrix); m/z calcd for [C37H36NaN2O9]+: 675.24 [M + Na]+; found: 675.56 (DHB matrix). 
2-(3-(2-(2-(3,5-bis(Prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)-5-(2-(4-(prop-2-yn-1-
yloxy)benzamido)ethoxy)phenyl)acetic acid (89) 
 
Compound 116 (71 mg, 0.11 mmol, 1 equiv) was dissolved in THF (4 mL) under a nitrogen 
atmosphere. The solution was cooled to 0 °C, then a solution of LiOH∙H2O (12 mg, 0.27 mmol, 
2.5 equiv) in H2O (2 mL) was added. The mixture was stirred 1.5 h at 0 °C. The mixture was 
acidified to ca. pH = 2 with a 1 M KHSO4 aqueous solution and extracted with CH2Cl2 (4 × 20 
mL). The organic phase was dried over Na2SO4 and concentrated, affording 89 as a white solid 
(158 mg, 99% yield). 
Rf = 0.39 (9:1, CH2Cl2/MeOH); 1H NMR (500 MHz, CD3OD) δ 7.80 (d, J = 8.8 Hz, 2H), 7.01 (d, 
J = 8.9 Hz, 2H), 6.53 (d, J = 2.3 Hz, 2H), 6.50-6.46 (m, 2H), 6.44 (s, 1H), 6.41 (t, J = 2.3 Hz, 
1H), 4.76 (d, J = 2.4 Hz, 2H), 4.61 (d, J = 2.5 Hz, 4H), 4.10 (t, J = 5.7 Hz, 2H), 3.97 (t, J = 5.2 
Hz, 2H), 3.72 (t, J = 5.6 Hz, 2H), 3.52 (t, J = 6.1 Hz, 2H), 3.50 (s, 2H), 3.45 (s, 2H), 2.97 (t, J 
= 2.4 Hz, 1H), 2.90 (t, J = 2.4 Hz, 2H); 13C-DEPT135 NMR (126 MHz, CD3OD) δ 128.77, 
114.29, 108.37, 108.23, 108.06, 100.52, 99.74, 78.34, 77.95, 75.87, 75.54, 66.13, 66.10, 
55.32, 42.56, 40.93, 39.27, 38.88. MS (MALDI): m/z calcd for [C36H35N2O9]+: 639.24 [M + H]+; 
found: 639.27 (DHB matrix); m/z calcd for [C36H34NaN2O9]+: 661.24 [M + Na]+; found: 661.27 
(DHB matrix); m/z calcd for [C36H34KN2O9]+: 677.24 [M + K]+; found: 677.27 (DHB matrix). 
Tris-alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118c) 
 
N-Fmoc-protected compound 93 (65 mg, 0.091 mmol, 1 equiv) was deprotected following 
General Procedure GP2. A solution of acid 89 (70 mg, 0.11 mmol, 1.2 equiv) in dry DMF (2 
mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (59 mg, 0.16 mmol, 1.7 equiv), 
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HOAt (22 mg, 0.16 mmol, 1.7 equiv) and iPr2NEt (64 µL, 0.364 mmol, 4 equiv) were added 
and the mixture was stirred for 20 min at 0 °C. A solution of 93-NH (45 mg, 0.091 mmol, 1 
equiv) in dry DMF (3 mL) was added to the stirred mixture. The reaction was allowed to slowly 
reach room temperature and stirred overnight. The mixture was diluted with AcOEt (100 mL) 
and washed with 1 M aqueous solution of KHSO4 (2 × 15 mL), a saturated aqueous solution of 
NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated. The crude was purified by flash chromatography [eluent: CH2Cl2/MeOH, 9:1] to 
afford amide 118c as a light-yellow solid (73 mg, 80% yield over two steps). 
Rf = 0.41 (9:1, CH2Cl2/MeOH); 1H NMR (400 MHz, [D]6DMSO) δ 9.77 (s, 1H), 8.39 (t, J = 5.5 
Hz, 1H), 8.10-8.00 (m, 2H), 7.89-7.81 (m, 3H), 7.55 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.3 Hz, 
2H), 7.03 (d, J = 8.9 Hz, 2H), 6.53 (d, J = 2.2 Hz, 2H), 6.50 (d, J = 2.2 Hz, 2H), 6.48 (s, 1H), 
6.40 (t, J = 2.3 Hz, 1H), 4.98 (s, 2H), 4.85 (d, J = 2.4 Hz, 2H), 4.72 (d, J = 2.4 Hz, 4H), 4.41 (p, 
J = 7.0 Hz, 1H), 4.20 (dd, J = 8.7, 6.6 Hz, 1H), 4.08 (t, J = 6.0 Hz, 2H), 3.97 (t, J = 5.8 Hz, 2H), 
3.60 (q, J = 5.8 Hz, 2H), 3.51-3.45 (m, 2H), 3.44-3.37 (m, 7H), 3.32 (dd, J = 12.3, 4.7 Hz, 4H), 
2.85 (s, 3H), 2.74 (s, 3H), 2.00 (h, J = 6.8 Hz, 1H), 1.37 (s, 9H), 1.30 (d, J = 7.1 Hz, 3H), 0.85 
(dd, J = 9.5, 6.8 Hz, 6H); 13C NMR (101 MHz, [D]6DMSO) δ 170.73, 170.53, 169.74, 165.80, 
159.27, 159.20, 159.12, 157.98, 155.18, 154.54, 138.44, 138.33, 138.26, 131.52, 128.68, 
127.93, 127.23, 118.93, 114.18, 108.69, 107.95, 100.04, 99.41, 78.91, 78.64, 78.24, 77.95, 
77.68, 66.19, 66.03, 65.75, 57.52, 55.44, 48.89, 45.92, 42.19, 38.66, 38.24, 33.73, 30.28, 
28.67, 27.78, 18.86, 17.81, 17.60. 
MS (MALDI): m/z calcd for [C61H74N7O14]+: 1128.52 [M + H]+; found: 1128.52 (DHB matrix); m/z 
calcd for [C61H73NaN7O14]+: 1150.54 [M + Na]+; found: 1150.55 (DHB matrix); m/z calcd for 
[C61H73KN7O14]+: 1166.24 [M + K]+; found: 1166.27 (DHB matrix). 
Tris-alkyne–Val–Ala–PTX (119c) 
 
A solution of Boc-protected compound 118c (40 mg, 0.035 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained TFA solid was dissolved in dry DMF (500 μL) 
and iPr2NEt (25 µL, 0.14 mmol, 4 equiv). The resulting solution was added at 0 °C to a stirred 
  
122 Experimental Section 
solution of 95 (54 mg, 0.052 mmol, 1.5 equiv) in dry DMF (700 μL), under a nitrogen 
atmosphere. The reaction was then allowed to reach room temperature and stirred overnight. 
AcOEt (60 mL) was added and the solution was washed with a 1 M aqueous solution of KHSO4 
(2 × 10 mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 and 
concentrated, then the crude was purified by a flash chromatography (eluent: CH2Cl2/MeOH 
from 100% to 95% of CH2Cl2) to afford carbamate 119c as a white solid (44 mg, 69% yield 
over two steps). 
Rf = 0.43 (9:1, CH2Cl2/MeOH); MS (ESI+): m/z calcd for [C104H114NaN8O27]+: 1930.03 [M + Na]+; 
found: 1930.04; MS (MALDI-TOF): m/z calcd for [C104H114NaN8O27]+: 1930.03 [M + Na]+; found: 
1930.03 (DHB matrix); m/z calcd for [C104H114KN8O27]+: 1946.07 [M + K]+; found: 1946.09 (DHB 
matrix);  HRMS (ESI+): m/z calcd for [C104H114NaN8O27]+: 1930.03 [M + Na]+; found: 1930.75; 
m/z calcd for [C104H114Na2N8O27]2+: 976.39 [M + 2Na]2+; found: 976.38. 
(cyclo[DKP-RGD]-PEG-4)3-Val-Ala-PTX (104) 
 
Tri-alkyne 119c (5 mg, 0.0026 mmol, 1 equiv) and azide 86 (9.5 mg, 0.0094 mmol, 3.6 equiv) 
were reacted following the General Procedure GP3. The solvent was removed under vacuum, 
and the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm 
column; gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% 
(CH3CN+0.1% CF3COOH) in 20 min; tR (product)=11.5 min]. The purified product was then 
freeze-dried to give the desired compound 104 as a white solid (6.9 mg, 62% yield). 
MS (ESI+): m/z calcd for [C215H281N47O66]2+: 2289.85, [M + 2H]2+; found: 2289.89; m/z calcd for 
[C215H282N47O66]3+: 1526.86 [M + 3H]3+; found: 1527.00; m/z calcd for [C215H283N47O66]4+: 
1145.86 [M + 4H]4+; found: 1145.51; m/z calcd for [C215H284N47O66]5+: 916.23 [M + 5H]5+; found: 
916.61; MS (MALDI-TOF): m/z calcd for [C215H280N47O66]+: 4577.01 [M + H]+; found: 4582.01 
(DHB matrix); HRMS (ESI+): m/z calcd for [C215H279Na3N47O66]3+: 1548.99 [M + 3Na]3+; found: 
1548.92; m/z calcd for [C215H279Na4N47O66]4+: 1167.43 [M + 4Na]4+; found: 1167.24. 
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(cyclo[DKP-RGD]-PEG-4)4-Val-Ala-PTX (105) 
Methyl 2-(3,5-bis(2-(2-(3,5-bis(prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)phenyl) 
acetate (117) 
 
A solution of Boc-protected compound 112 (200 mg, 0.43 mmol, 1 equiv) was deprotected 
following General Procedure GP1. Then, acid 88 (315 mg, 1.29 mmol, 3 equiv) was solubilized 
in dry DMF (15 mL) and cooled to 0 °C under a nitrogen atmosphere. HATU (556 mg, 1.46 
mmol, 3.6 equiv), HOAt (199 mg, 1.46 mmol, 3.6 equiv) and iPr2NEt (449 µL, 2.58 mmol, 6 
equiv) were added and the mixture was stirred for 20 min at 0 °C. Later, the salt 113 (200 mg, 
0.43 mmol, 1 equiv) was dissolved in dry DMF (9 mL) and slowly added (dropwise) the reaction 
mixture that was stirred overnight at r.t. The mixture was diluted with AcOEt (100 mL) and 
washed with 1 M aqueous solution of KHSO4 (2 × 15 mL), a saturated aqueous solution of 
NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated. The crude was purified by flash chromatography [eluent: CH2Cl2/MeOH, 9:1] to 
afford diamide 117 as a light orange solid (238 mg, 77% yield over two steps). 
Rf = 0.28 (99:1, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 6.50 (s, 6H), 6.37-6.34 (m, 
2H), 6.27 (s, 1H), 6.02 (t, J = 5.7 Hz, 2H), 4.63 (d, J = 2.3 Hz, 8H), 3.96 (t, J = 5.2 Hz, 4H), 
3.66 (s, 3H), 3.56 (q, J = 5.5 Hz, 4H), 3.52 (s, 2H), 3.48 (s, 4H), 2.56 (t, J = 2.5 Hz, 4H). 13C 
NMR (101 MHz, CD2Cl2-d2) δ 172.12, 170.86, 160.29, 159.47, 138.10, 137.11, 109.56, 108.93, 
101.54, 100.53, 78.91, 76.11, 67.30, 56.46, 52.50, 44.28, 41.62, 39.54. MS (ESI+): m/z calcd 
for [C41H40NaN2O10]+: 743.11 [M + Na]+; found: 743.10. 
2-(3,5-bis(2-(2-(3,5-bis(Prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)phenyl)acetic acid (90) 
 
Compound 117 (137 mg, 0.2 mmol, 1 equiv) was dissolved in THF (6.6 mL) under a nitrogen 
atmosphere. The solution was cooled to 0 °C, then a solution of LiOH∙H2O (21 mg, 0.5 mmol, 
2.5 equiv) in H2O (3.3 mL) was added. The mixture was stirred 1.5 h at 0 °C. The mixture was 
acidified to ca. pH = 2 with a 1 M KHSO4 aqueous solution and extracted with CH2Cl2 (4 × 20 
mL). The organic phase was dried over Na2SO4 and concentrated. The crude was purified by 
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flash chromatography [eluent: 9:1:0.1 CH2Cl2/MeOH/AcOH] affording 90 as a white solid (120 
mg, 85% yield). 
Rf = 0.2 (95:5, CH2Cl2/MeOH); 1H NMR (400 MHz, CD3OD) δ 6.56 (d, J = 2.3 Hz, 4H), 6.51 (t, 
J = 2.3 Hz, 2H), 6.47 (d, J = 2.2 Hz, 2H), 6.37 (d, J = 2.2 Hz, 1H), 4.64 (d, J = 2.4 Hz, 8H), 4.01 
(t, J = 5.4 Hz, 4H), 3.56 (t, J = 5.3 Hz, 4H), 3.52 (s, 2H), 3.48 (s, 4H), 2.91 (t, J = 2.4 Hz, 4H). 
13C NMR (101 MHz, CD3OD) δ 173.97, 161.21, 160.27, 139.04, 138.69, 109.77, 109.55, 
108.51, 101.94, 101.07, 79.71, 76.87, 67.50, 56.72, 43.95, 42.75, 40.26. MS (ESI+): m/z calcd 
for [C40H38NaN2O10]+: 729.42 [M +Na]+; found: 729.45. 
Tetra-alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118d) 
 
N-Fmoc-protected compound 93 (35 mg, 0.047 mmol, 1 equiv) was deprotected following 
General Procedure GP2. A solution of acid 90 (50 mg, 0.071 mmol, 1.5 equiv) in dry DMF (1 
mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (31 mg, 0.08 mmol, 1.7 equiv), 
HOAt (11 mg, 0.08 mmol, 1.7 equiv) and iPr2NEt (33 µL, 0.189 mmol, 4 equiv) were added 
and the mixture was stirred for 20 min at 0 °C. A solution of 93-NH (24 mg, 0.047 mmol, 1 
equiv) in dry DMF (1.6 mL) was added to the stirred mixture. The reaction was allowed to 
slowly reach room temperature and stirred overnight. The mixture was diluted with AcOEt (100 
mL) and washed with 1 M aqueous solution of KHSO4 (2 × 15 mL), a saturated aqueous 
solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic phase was dried over 
Na2SO4 and concentrated. The crude was purified by flash chromatography [eluent: 
CH2Cl2/MeO, 95:5 H] to afford amide 118d as a light-yellow solid (54 mg, 92% yield over two 
steps). 
Rf = 0.27 (95:5, CH2Cl2/MeOH); 1H NMR (400 MHz, [D]6DMSO) δ 9.82 (s, 1H), 8.18-8.07 (m, 
3H), 7.91 (d, J = 8.6 Hz, 1H), 7.56 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 6.54 (d, J = 2.3 
Hz, 2H), 6.51 (t, J = 2.2 Hz, 5H), 6.49 (d, J = 2.3 Hz, 2H), 4.99 (s, 2H), 4.73 (d, J = 2.4 Hz, 8H), 
4.41 (p, J = 6.9 Hz, 1H), 4.21 (dd, J = 8.7, 6.6 Hz, 1H), 3.97 (t, J = 5.9 Hz, 4H), 3.50-3.38 (m, 
14H), 3.33 (dd, J = 12.1, 4.6 Hz, 4H), 2.86 (s, 3H), 2.74 (s, 3H), 2.01 (h, J = 6.7 Hz, 1H), 1.38 
(s, 9H), 1.31 (d, J = 7.1 Hz, 3H), 0.86 (dd, J = 10.3, 6.8 Hz, 6H). 13C NMR (101 MHz, [D]6DMSO) 
δ 170.82, 170.61, 169.78, 159.29, 159.13, 158.00, 141.44, 138.52, 138.38, 138.31, 131.54, 
128.03, 108.67, 108.25, 107.94, 107.69, 107.44, 100.00, 99.65, 99.36, 78.96, 78.28, 77.81, 
66.21, 65.80, 57.45, 55.44, 48.91, 42.24, 40.42, 38.28, 30.41, 27.83, 18.93, 17.88, 17.68; MS 
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(MALDI-TOF): m/z calcd for [C65H77NaN7O15]+: 1218.03 [M + Na]+; found: 1218.2 (HCCA 
matrix). 
Tetra–alkyne–Val–Ala-PTX (119d) 
 
A solution of Boc-protected compound 118d (40 mg, 0.033 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained TFA solid was dissolved in dry DMF (500 μL) 
and iPr2NEt (24 µL, 0.13 mmol, 4 equiv). The resulting solution was added at 0 °C to a stirred 
solution of 95 (51 mg, 0.05 mmol, 1.5 equiv) in dry DMF (500 μL), under a nitrogen atmosphere. 
The reaction was then allowed to reach room temperature and stirred overnight. AcOEt (60 
mL) was added and the solution was washed with a 1 M aqueous solution of KHSO4 (2 × 10 
mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 and concentrated, then 
the crude was purified by a flash chromatography (eluent: AcOEt/MeOH from 100% to 95% of 
AcOEt) to afford carbamate 119d as a white solid (49 mg, 75% yield over two steps). 
Rf = 0.25 (95:5, CH2Cl2/MeOH); MS (MALDI-TOF): m/z calcd for [C108H119N8O28]+: 1976.01 [M 
+ H]+; found: 1976.2 (HCCA matrix); m/z calcd for [C108H118NaN8O28]+: 1997.9 [M + Na]+; found: 
1998.02 (HCCA matrix); HRMS (ESI+): m/z calcd for [C108H118NaN8O28]+: 1997.99, [M + Na]+; 
found 1997.79; m/z calcd for [C108H118Na2N8O28]2+: 1010.31, [M + 2Na]2+: found 1010.39. 
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(cyclo[DKP-RGD]-PEG-4)4-Val-Ala-PTX (105) 
 
Tetra-alkyne 119d (4 mg, 0.002 mmol, 1 equiv) and azide 86 (9.8 mg, 0.0097 mmol, 4.8 equiv) 
were reacted following the General Procedure GP3. The solvent was removed under vacuum, 
and the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm 
column; gradient: 90% (H2O + 0.1% CF3COOH)/10% (CH3CN + 0.1% CF3COOH) to 100% 
(CH3CN + 0.1% CF3COOH) in 20 min; tR (product)=10.9 min]. The purified product was then 
freeze-dried to give the desired compound 105 as a white solid (8 mg, 73% yield). 
MS (MALDI-TOF): m/z calcd for [C256H339N60O80]+: 5532.78 [M + H]+; found: 5532.90 (HCCA 
matrix); HRMS (ESI+): m/z calcd for [C256H338Na4N60O80]4+: 1406.93 [M + 4Na]4+; found: 
1406.84; m/z calcd for [C256H338Na5N60O80]5+: 1130.14 [M + 5Na]5+; found: 1130.07. 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-Val-PTX (121) 
Fmoc-Asn(Trt)-Pro-OH (126) 
 
Commercial Fmoc-Asn(Trt)-OH 125 (2 g, 3.35 mmol, 1 equiv) and EDC·HCl (1.9 g, 10.05 
mmol, 3 equiv) were dissolved in dry CH2Cl2 (33 mL) under nitrogen atmosphere. N-
hydroxysuccinimide (771 mg, 6.70 mmol, 2 equiv) was added thereto, and the mixture was 
stirred overnight at room temperature. The reaction mixture was diluted with CH2Cl2 (30 mL) 
and washed with HCl aq. 1 M (1 × 25 mL) and brine. The organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure. Then, the residue was purified 
by flash chromatography on a pad of silica gel (eluent: 8:2, CH2Cl2/AcOEt) affording the desired 
activated Fmoc-Asn(Trt)-OSu as a white solid. Later on, commercial H-Pro-OH (464 mg, 4.02 
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mmol, 1.2 equiv) was dissolved in H2O (20 mL) and NaHCO3 (563 mg, 6.70 mmol, 2 equiv) 
was added. The previously obtained Fmoc-Asn(Trt)-OSu was dissolved in THF (20 mL) and 
added to the stirred solution of H-Pro-OH and NaHCO3. The mixture was stirred overnight at 
room temperature. The solvent was concentrated, followed by addition of a 1 M aqueous 
solution of KHSO4 (40 mL). The suspension was extracted with CH2Cl2 (4 × 20 mL), and the 
collected organic phases were dried and concentrated. The crude was purified by flash 
chromatography [eluent: 8:2, CH2Cl2/AcOEt + 0.1% AcOH] affording Fmoc-Asn(Trt)-Pro-OH 
126 (1.2 g, 52% yield). 
Rf = 0.15 (8:2, CH2Cl2/AcOEt + 0.1% AcOH); 1H NMR (500 MHz, CD2Cl2-d2) δ 7.80 (d, J = 7.6 
Hz, 2H), 7.60 (t, J = 8.7 Hz, 2H), 7.42 (t, J = 7.7 Hz, 2H), 7.34 – 7.18 (m, 18H), 6.08 (s, 1H), 
4.83 – 4.74 (m, 1H), 4.37 (d, J = 7.0 Hz, 3H), 4.19 (t, J = 6.8 Hz, 1H), 3.64 – 3.53 (m, 1H), 3.43 
(s, 1H), 2.84 (dd, J = 15.4, 7.3 Hz, 1H), 2.72 (dd, J = 15.4, 5.8 Hz, 1H), 2.19 – 2.04 (m, 2H), 
1.95 – 1.82 (m, 2H); MS (MALDI-TOF): m/z calcd for [C43H40N3O6]+: 694.79 [M + H]+; found: 
694.81; m/z calcd [C43H39NaN3O6]+: 716.79 [M + Na]+; found: 716.80 (DHB matrix). 
Fmoc-Asn(Trt)-Pro-Val-OH (127) 
 
Fmoc-Asn(Trt)-Pro-OH 126 (1.18 g, 1.70 mmol, 1 equiv) and EDC·HCl (977 mg, 5.10 mmol, 3 
equiv) were dissolved in dry CH2Cl2 (17 mL) under nitrogen atmosphere. N-
hydroxysuccinimide (400 mg, 3.40 mmol, 2 equiv) was added thereto, and the mixture was 
stirred overnight at room temperature. The reaction mixture was diluted with CH2Cl2 (20 mL) 
and washed with HCl aq. 1 M (1 × 15 mL) and brine. The organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure affording the desired activated 
Fmoc-Asn(Trt)-Pro-OSu as a white solid. Later, commercial H-Val-OH (240 mg, 2.04 mmol, 
1.2 equiv) was dissolved in H2O (11 mL) and NaHCO3 (290 mg, 3.40 mmol, 2 equiv) was 
added. The previously obtained Fmoc-Asn(Trt)-Pro-OSu was dissolved in THF (11 mL) and 
added to the stirred solution of H-Val-OH and NaHCO3. The mixture was stirred overnight at 
room temperature. The solvent was concentrated, followed by addition of a 1 M aqueous 
solution of KHSO4 (20 mL). The suspension was extracted with CH2Cl2 (4 × 15 mL), then the 
collected organic phases were dried and concentrated. The crude was purified by flash 
chromatography [eluent: 95:5 CH2Cl2/MeOH + 0.1% AcOH] affording Fmoc-Asn(Trt)-Pro-Val-
OH 127 (1.10 g, 82% yield). 
Rf = 0.21 (95:5, CH2Cl2/MeOH + 0.1% AcOH); 1H NMR (500 MHz, CD2Cl2-d2) δ 7.85 (d, J = 
8.2 Hz, 1H), 7.66 (d, J = 6.9 Hz, 2H), 7.51 – 7.41 (m, 3H), 7.27 (td, J = 7.3, 3.5 Hz, 2H), 7.20 - 
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7.05 (m, 17H), 6.60 (d, J = 8.4 Hz, 1H), 4.44 (td, J = 9.5, 3.6 Hz, 1H), 4.21 – 4.08 (m, 3H), 4.04 
(t, J = 7.3 Hz, 1H), 3.85 (t, J = 8.3 Hz, 1H), 3.27 (q, J = 8.6 Hz, 1H), 2.95 – 2.82 (m, 1H), 2.71 
– 2.64 (m, 1H), 2.61 (dd, J = 14.0, 3.7 Hz, 1H), 1.92 – 1.76 (m, 2H), 1.70 – 1.58 (m, 2H), 1.47 
(p, J = 10.7, 9.8 Hz, 1H), 0.67 (d, J = 6.7 Hz, 3H), 0.44 (d, J = 6.6 Hz, 3H); 13C-DEPT45 NMR 
(126 MHz, CD2Cl2-d2) δ 128.87, 128.81, 127.99, 127.86, 127.80, 127.18, 127.05, 125.34, 
125.33, 120.02, 67.24, 61.55, 59.26, 49.72, 47.60, 47.15, 40.58, 29.81, 29.56, 29.15, 24.70, 
19.36, 18.87. MS (MALDI-TOF): m/z calcd for [C48H49N4O7]+: 793.92 [M + H]+; found: 793.99; 
m/z calcd [C48H48NaN4O7]+: 815.92 [M + Na]+; found: 816.01 (DHB matrix). 
Fmoc-Asn(Trt)-Pro-Val-PABC-PNP (128) 
 
Compound 127 (880 mg, 1.11 mmol, 1 equiv) was dissolved in dry CH2Cl2/MeOH (2:1, 11 mL) 
under a nitrogen atmosphere. EEDQ (686 mg, 2.77 mmol, 2.5 equiv) and 4-aminobenzyl 
alcohol (273 mg, 2.22 mmol, 2 equiv) were added at 0 °C, under a nitrogen atmosphere. Then, 
the mixture was allowed to reach room temperature and stirred overnight under nitrogen 
atmosphere. The solvent was removed under reduced pressure affording a yellow solid. The 
crude was diluted in Et2O (3 × 30 mL) and filtered in a fritz. The solid was purified by flash 
chromatography [gradient: from 0% MeOH / 100% CH2Cl2 to 5% MeOH / 95% CH2Cl2] to afford 
the Fmoc-Asn(Trt)-Pro-Val-PABA as a white solid (MS (MALDI-TOF): m/z calcd for 
[C55H55NaN5O7]+: 921.05 [M + Na]+; found: 921.23). Later on, a solution of Fmoc-Asn(Trt)-Pro-
Val-PABA in a mixture of dry THF (65 mL) under nitrogen atmosphere was cooled to 0 °C. 
Pyridine (224 μL, 2.77 mmol, 2.5 equiv) and 4-nitrophenylchloroformate (448 mg, 2.22 mmol, 
2 equiv) were added, then the mixture could reach room temperature and stirred for 2 h. The 
reaction mixture was concentrated under reduced pressure and AcOEt (150 mL) was added 
and the solution was washed with a 1 M aqueous solution of KHSO4 (3 × 20 mL) and brine (20 
mL). The organic phase was dried and concentrated, then the crude was purified by flash 
chromatography [eluent: 4:6, n-Hexane/EtOAc] affording compound 128 (640 mg, 54% yield) 
as a white solid. 
Rf = 0.28 (4:6, n-Hexane/EtOAc); 1H NMR (500 MHz, CD2Cl2-d2) δ 8.57 (s, 1H), 8.28 (d, J = 
8.9 Hz, 2H), 7.89 – 7.80 (m, 4H), 7.77 (d, J = 8.6 Hz, 1H), 7.62 (dd, J = 13.4, 7.5 Hz, 2H), 7.47 
– 7.40 (m, 6H), 7.37 – 7.17 (m, 18H), 5.86 (d, J = 8.4 Hz, 1H), 5.31 (s, 2H), 4.48 (t, J = 10.1 
Hz, 1H), 4.43 – 4.35 (m, 3H), 4.22 (t, J = 6.9 Hz, 1H), 4.10 (t, J = 8.2 Hz, 1H), 3.41 (q, J = 8.5 
Hz, 1H), 3.00 (t, J = 12.6 Hz, 1H), 2.73 – 2.66 (m, 1H), 2.62 (dd, J = 13.8, 3.0 Hz, 1H), 2.22 – 
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2.13 (m, 1H), 2.00 – 1.92 (m, 1H), 1.90 – 1.75 (m, 2H), 1.62 – 1.53 (m, 1H), 0.80 (d, J = 6.7 
Hz, 3H), 0.44 (d, J = 6.6 Hz, 3H). 13C-APT NMR (151 MHz, CD2Cl2-d2) δ 171.61, 171.25, 
169.93, 168.88, 155.64, 155.36, 152.49, 145.38, 143.83, 143.78, 143.69, 141.28, 141.24, 
139.61, 129.48, 128.59, 127.95, 127.73, 127.07, 127.02, 125.18, 124.97, 121.90, 120.04, 
119.98, 70.83, 70.77, 66.99, 61.85, 60.01, 49.41, 49.31, 47.62, 47.11, 40.68, 29.85, 29.67, 
28.45, 28.11, 24.62, 19.56, 19.05. MS (MALDI-TOF): m/z calcd for [C62H58NaN6O11]+: 1086.92 
[M + Na]+; found: 1087.03 (DHB matrix). 
Fmoc-Asn(Trt)-Pro-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (129)  
 
A solution of commercial N-(Boc)-N,N′-dimethylethylenediamine (208 μL, 1.03 mmol, 2 equiv) 
in dry THF (7 mL) and iPr2NEt (250 mg, 1.38 mmol, 2.5 equiv) were added under nitrogen to 
a solution of 128 (587 mg, 0.552 mmol, 1 equiv) in dry THF (15 mL) kept at 0 ºC. The mixture 
was stirred overnight at room temperature, then the solvent was removed at the rotavapor. 
AcOEt (100 mL) was added and the solution was washed with 1 M aqueous solution of KHSO4 
(3 × 20 mL), a saturated aqueous solution of NaHCO3 (2 × 20 mL) and brine (20 mL). The 
organic phase was dried and concentrated. The crude was purified by flash chromatography 
(gradient: 3:2, AcOEt/n-Hexane to 4:1, AcOEt/n-Hexane), affording 129 (490 mg, 80% yield) 
as white solid. 
Rf = 0.19 (1:4, n-Hexane/EtOAc); 1H NMR (500 MHz, CD2Cl2-d2) δ 8.47 (d, J = 11.0 Hz, 1H), 
7.86 – 7.76 (m, 4H), 7.72 (d, J = 7.0 Hz, 1H), 7.65 – 7.58 (m, 2H), 7.43 (s, 2H), 7.38 – 7.06 (m, 
21H), 5.11 (s, 2H), 4.48 (t, J = 10.2 Hz, 1H), 4.41 – 4.34 (m, 3H), 4.25 – 4.21 (m, 1H), 4.16 – 
4.06 (m, 1H), 3.51 – 3.25 (m, 5H), 3.06 – 2.93 (m, 4H), 2.86 (s, 2H), 2.75 (s, 1H), 2.70 – 2.62 
(m, 2H), 2.19 – 2.12 (m, 1H), 1.97 – 1.93 (m, 1H), 1.91 – 1.76 (m, 2H), 1.58 – 1.55 (m, 1H), 
1.46 (s, 9H), 0.77 (d, J = 6.8 Hz, 3H), 0.41 (d, J = 6.8 Hz, 3H). 13C NMR (151 MHz, CD2Cl2-d2) 
δ 171.53, 171.33, 171.24, 169.72, 168.94, 156.21, 155.97, 155.41, 143.80, 143.74, 141.27, 
141.24, 138.71, 138.58, 132.31, 132.19, 128.60, 127.93, 127.72, 127.04, 125.01, 119.96, 
119.77, 79.31, 70.74, 67.01, 66.72, 66.53, 61.85, 59.90, 59.68, 49.40, 47.57, 47.10, 46.98, 
46.68, 46.42, 40.70, 35.00, 34.46, 34.22, 29.87, 29.67, 28.59, 28.13, 24.61, 19.59, 18.98, 
18.90. MS (MALDI-TOF): m/z calcd for [C65H74N7O10]+: 1113.32 [M + H]+; found: 1113.87; calcd 
for [C65H73NaN7O10]+: 1135.32 [M + Na]+; found: 1135.75 (DHB matrix). 
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4-pentynamido-Asn(Trt)-Pro-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (130)  
 
N-Fmoc-protected compound 129 (90 mg, 0.081 mmol, 1 equiv) was deprotected following 
General Procedure GP2. Commercial 4-pentynoic acid (12 mg, 0.122 mmol, 1.5 equiv) in dry 
DMF (1.5 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (51 mg, 0.134 mmol, 
1.7 equiv), HOAt (18 mg, 0.134 mmol, 1.7 equiv) and iPr2NEt (56 µL, 0.324 mmol, 4 equiv) 
were added and the mixture was stirred for 20 min at 0 °C. A solution of 129-NH in dry DMF 
(3 mL) was added to the stirred mixture. The reaction was allowed to slowly reach room 
temperature and stirred overnight. The mixture was diluted with an AcOEt/CH2Cl2, 4:1 mixture 
(100 mL) and washed with 1 M aqueous solution of KHSO4 (2 × 15 mL), a saturated aqueous 
solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic phase was dried over 
Na2SO4 and concentrated. The solid was purified by flash chromatography [gradient: from 
CH2Cl2 100% to 99:1 CH2Cl2/MeOH] to afford amide 130 as a white solid (70 mg, 90% yield 
over two steps). 
Rf = 0.30 (95:5, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.46 (s, 1H), 7.84 – 7.69 (m, 
3H), 7.57 (s, 1H), 7.37 – 7.14 (m, 17H), 6.84 (s, 1H), 5.10 (s, 2H), 4.74 (t, J = 9.7 Hz, 1H), 4.33 
(dd, J = 9.0, 3.8 Hz, 1H), 4.09 (t, J = 8.8 Hz, 1H), 3.52 – 3.27 (m, 5H), 3.09 – 2.92 (m, 4H), 
2.81 – 2.66 (m, 5H), 2.56 – 2.35 (m, 4H), 2.23 – 2.09 (m, 1H), 2.03 (t, J = 2.7 Hz, 1H), 1.94 (p, 
J = 6.0, 5.4 Hz, 1H), 1.86 – 1.75 (m, 2H), 1.65 – 1.53 (m, 1H), 1.47 (s, 9H), 0.76 (d, J = 6.7 Hz, 
3H), 0.43 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CD2Cl2-d2) δ 171.57, 171.33, 170.32, 169.76, 
169.21, 143.85, 138.67, 138.53, 132.26, 132.17, 128.63, 128.07, 127.88, 127.77, 126.99, 
119.74, 82.86, 79.33, 79.08, 70.69, 68.98, 66.77, 66.63, 61.87, 60.09, 59.87, 47.75, 47.57, 
47.04, 46.68, 46.44, 40.33, 38.36, 34.98, 34.66, 34.46, 34.29, 29.91, 29.68, 28.68, 28.15, 
24.63, 19.59, 19.08, 14.47. MS (MALDI-TOF): m/z calcd for [C55H67NaN7O9]+: 993.16 [M + 
Na]+; found: 993.47. 
Aliphatic alkyne-Asn-Pro-Val-PTX (122) 
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A solution of Boc-protected compound 130 (58 mg, 0.060 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The obtained TFA salt was dissolved in dry DMF (900 μL) 
and iPr2NEt (42 µL, 0.240 mmol, 4 equiv). The resulting solution was added at 0 °C to a stirred 
solution of 95 (68 mg, 0.066 mmol, 1.1 equiv) in dry DMF (900 μL), under a nitrogen 
atmosphere. The reaction was then allowed to reach room temperature and stirred overnight. 
AcOEt (50 mL) was added and the solution was washed with a 1 M aqueous solution of KHSO4 
(2 × 10 mL) and brine (1 × 15 mL). The organic phase was dried over Na2SO4 and 
concentrated, then the crude was purified by flash chromatography [gradient: from 99:1 
CH2Cl2/MeOH to 95:5 CH2Cl2/MeOH] to afford carbamate 122 as a white solid (63 mg, 71% 
yield over two steps). 
Rf = 0.28 (CH2Cl2/MeOH, 9:1); MS (MALDI-TOF): m/z calcd for [C79H94NaN8O22]+: 1530.63 [M 
+ Na]+; found: 1530.03 (HCCA matrix), 1532.08 (SA matrix); HRMS (ESI+): m/z calcd for 
[C79H94NaN8O22]+: 1529.64 [M + Na]+; found: 1529.63; m/z calcd for [C79H94Na2N8O22]2+: 776.31 
[M + 2Na]2+; found: 776.31. 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-Val-PTX (121) 
 
Alkyne 122 (7.8 mg, 0.0052 mmol, 1.3 equiv) and azide 86 (4 mg, 0.004 mmol, 1 equiv) were 
reacted following General Procedure GP3. The solvent was removed under vacuum, and the 
crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
CF3COOH) in 20 min; tR (product)=12.5 min]. The purified product was then freeze-dried to 
give the desired compound 122 as a white solid (9 mg, 94% yield).  
MS (MALDI-TOF): m/z calcd for [C116H150N21O35]+: 2398.54 [M + H]+; found: 2398.99 (HCCA 
matrix), 2399.52 (SA matrix); HRMS (ESI+): m/z calcd for [C116H149Na2N21O35]2+: 1221.01 [M + 
2Na]2+; found: 1221.51. 
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cyclo[DKP-RGD]-PEG-4-Asn-Pro-[D]-Val-PTX (123) 
Fmoc-[D]-Val-PABA (132) 
 
Commercial Fmoc-[D]-Valine-OH 131 (150 mg, 0.442 mmol, 1 equiv) was dissolved in dry 
CH2Cl2/MeOH (2:1, 6 mL) under a nitrogen atmosphere. EEDQ and 4-aminobenzyl alcohol 
were added at 0 °C, under a nitrogen atmosphere. Then, the mixture was allowed to reach 
room temperature and stirred overnight under nitrogen atmosphere. The solvent was removed 
under reduced pressure affording a yellow solid. The crude was diluted in Et2O (3 × 25 mL) 
and filtered in a fritz affording compound 132 as white solid (165 mg, 84% yield). 
Rf = 0.18 (98:2, CH2Cl2/MeOH + 0.1% AcOH); 1H NMR (400 MHz, MeOD-d4) δ 7.79 (d, J = 7.6 
Hz, 2H), 7.67 (t, J = 7.4 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.34 – 7.26 
(m, 4H), 4.56 (s, 2H), 4.45 – 4.33 (m, 2H), 4.23 (t, J = 6.8 Hz, 1H), 4.03 (d, J = 7.6 Hz, 1H), 
2.10 (dq, J = 13.9, 6.9 Hz, 1H), 1.00 (d, J = 6.8 Hz, 3H); MS (ESI+) m/z calcd for [C27H29N2O4]+: 
445.20 [M + H]+; found: 445.34; m/z calcd for [C27H28NaN2O4]+: 467.52 [M + Na]+; found: 
467.71. 
Fmoc-Asn(Trt)-Pro-[D]-Val-PABC-PNP (135)  
 
N-Fmoc-protected compound 132 (163 mg, 0.367 mmol, 1 equiv) was deprotected following 
General Procedure GP2. The remaining crude was directly used at the next step. A solution 
commercial Fmoc-L-Proline-OH (186 mg, 0.550 mmol, 1.5 equiv) in dry DMF (5 mL) was 
cooled to 0 °C under a nitrogen atmosphere. HATU (238 mg, 0.624 mmol, 1.7 equiv), HOAt 
(85 mg, 0.624 mmol, 1.7 equiv) and iPr2NEt (256 µL, 1.47 mmol, 4 equiv) were added and the 
mixture was stirred for 20 min at 0 °C. A solution of 132-NH (82 mg, 0.367 mmol, 1 equiv) in 
dry DMF (2 mL) was added to the stirred mixture. The reaction was allowed to slowly reach 
room temperature and stirred overnight. The solvent was evaporated at rotavapor and the 
crude was purified by flash chromatography [gradient: from CH2Cl2 99:1 to 99:3 CH2Cl2/MeOH] 
to afford intermediate 133, of which isolation was not possible. Similar procedure was used to 
afford intermediate 134. A solution of Fmoc-Asn(Trt)-Pro-[D]-Val-PABA 134 in a mixture of dry 
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THF (21 mL) under nitrogen atmosphere was cooled to 0 °C. Pyridine (74 μL, 0.918 mmol, 2.5 
equiv) and 4-nitrophenylchloroformate (148 mg, 0.734 mmol, 2 equiv) were added, then the 
mixture could reach room temperature and stirred for 2 h. AcOEt (200 mL) was added and the 
solution was washed with a 1 M aqueous solution of KHSO4 (3 × 20 mL) and brine (20 mL). 
The organic phase was dried and concentrated, then the crude was purified by flash 
chromatography [gradient: from AcOEt/Hexane 1:1 to 7:3] affording compound 135 (185 mg, 
47% yield, after five steps). 
Rf = 0.36 (2:8, n-Hexane/EtOAc); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.40 (s, 1H), 8.24 (d, J = 
9.2 Hz, 2H), 7.77 (d, J = 7.6 Hz, 2H), 7.56 (d, J = 7.4 Hz, 2H), 7.47 – 7.12 (m, 27H), 5.93 (s, 
1H), 5.22 (s, 2H), 4.65 (s, 1H), 4.50 – 4.28 (m, 3H), 4.19 (t, J = 6.7 Hz, 1H), 3.89 (d, J = 8.3 
Hz, 1H), 3.49 (d, J = 8.9 Hz, 1H), 3.13 (s, 1H), 2.97 (t, J = 11.3 Hz, 1H), 2.63 (d, J = 14.0 Hz, 
1H), 2.14 – 2.01 (m, 2H), 1.91 – 1.70 (m, 3H), 0.80 (dd, J = 15.9, 6.6 Hz, 6H). 13C NMR (101 
MHz, CD2Cl2-d2) δ 171.67, 170.38, 169.87, 168.97, 155.61, 152.45, 145.41, 143.93, 143.72, 
141.27, 138.92, 129.80, 129.39, 128.59, 127.94, 127.73, 127.09, 125.20, 125.06, 121.86, 
120.11, 119.96, 70.82, 70.68, 67.14, 61.00, 60.24, 50.08, 47.39, 47.10, 40.21, 29.67, 28.91, 
24.75, 19.35, 18.65. MS (MALDI-TOF): m/z calcd for [C62H59N6O11]+: 1064.16 [M + H]+; found: 
1064.22 (HCCA matrix), 1065.25 (SA matrix). 
Fmoc-Asn(Trt)-Pro-[D]-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (136) 
 
A solution of N-(Boc)-N,N′-dimethylethylenediamine (64 µL, 0.339 mmol, 2 equiv) in dry THF 
(2 mL) and iPr2NEt (74 µL, 0.423 mmol, 2.5 equiv) were added under nitrogen to a solution of 
135 (180 mg, 0.169 mmol, 1 equiv) in dry THF (5 mL) kept at 0 ºC. The mixture was stirred 
overnight at room temperature, then the solvent was removed at the rotavapor. AcOEt (50 mL) 
was added and the solution was washed with 1 M aqueous solution of KHSO4 (3 × 20 mL), a 
saturated aqueous solution of NaHCO3 (2 × 20 mL) and brine (20 mL). The organic phase was 
dried and concentrated. The crude was purified by flash chromatography (8:2, AcOEt/n-
Hexane), affording 136 (140 mg, 87% yield) as a white solid. 
Rf = 0.19 (8:2 AcOEt/n-Hexane); 1H NMR (400 MHz, MeOD-d4) δ 7.80 (d, J = 7.6 Hz, 2H), 7.65 
(t, J = 7.2 Hz, 4H), 7.39 (t, J = 7.6 Hz, 2H), 7.33 – 7.16 (m, 19H), 5.05 (s, 2H), 4.61 (t, J = 7.0 
Hz, 1H), 4.51 – 4.32 (m, 3H), 4.24 – 4.15 (m, 2H), 3.63 (q, J = 6.9, 6.1 Hz, 1H), 3.42 – 3.35 
(m, 4H), 3.29 – 3.18 (m, 1H), 2.91 (s, 3H), 2.85 (s, 2H), 2.77 – 2.71 (m, 3H), 2.18 – 2.04 (m, 
2H), 2.01 – 1.85 (m, 3H), 1.42 (s, 9H), 0.91 (d, J = 5.9 Hz, 6H). 13C NMR (101 MHz, MeOD-
d4) δ 173.23, 171.26, 170.46, 169.59, 156.66, 156.03, 144.33, 143.75, 141.19, 138.15, 138.03, 
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132.42, 132.20, 128.64, 128.27, 127.42, 127.34, 126.82, 126.38, 124.77, 124.74, 120.08, 
119.56, 79.79, 79.50, 70.32, 66.88, 66.67, 60.68, 59.66, 50.09, 46.56, 46.15, 38.08, 34.18, 
33.87, 33.23, 29.43, 29.34, 29.14, 27.32, 24.54, 18.44, 17.34. MS (MALDI-TOF): m/z calcd for 
[C65H74N7O10]+: 1113.32 [M + H]+; found: 1113.54 (HCCA matrix), 1113.55 (SA matrix). 
4-pentynamido-Asn(Trt)-Pro-[D]-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (137)  
 
N-Fmoc-protected compound 136 (153 mg, 0.138 mmol, 1 equiv) was deprotected following 
General Procedure GP2. Commercial 4-pentynoic acid (25 mg, 0.235 mmol, 1.5 equiv) in dry 
DMF (2 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (80 mg, 0.207 mmol, 1.7 
equiv), HOAt (30 mg, 0.207 mmol, 1.7 equiv) and iPr2NEt (97 µL, 0.552 mmol, 4 equiv) were 
added and the mixture was stirred for 20 min at 0 °C. A solution of 136-NH (123 mg, 0.138 
mmol, 1 equiv) in dry DMF (5 mL) was added to the stirred mixture. The reaction was allowed 
to slowly reach room temperature and stirred overnight. The mixture was diluted with an 
AcOEt/CH2Cl2, 4:1 mixture (100 mL) and washed with 1 M aqueous solution of KHSO4 (2 × 15 
mL), a saturated aqueous solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The organic 
phase was dried over Na2SO4 and concentrated. The solid was purified by flash 
chromatography [gradient: from CH2Cl2 100% to 97:3 CH2Cl2/MeOH] to afford amide 137 as 
fade white solid (125 mg, 94% yield over two steps). 
Rf = 0.37 (95:5, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.26 – 8.16 (m, 1H), 7.62 – 
7.46 (m, 1H), 7.35 (s, 2H), 7.28 – 7.15 (m, 18H), 6.72 (s, 1H), 5.03 (s, 2H), 4.83 (td, J = 7.8, 
3.7 Hz, 1H), 4.46 (dd, J = 8.4, 3.4 Hz, 1H), 3.83 (s, 1H), 3.45 (s, 1H), 3.39 – 3.26 (m, 4H), 3.06 
(s, 1H), 2.91 (s, 4H), 2.83 (s, 2H), 2.75 (s, 1H), 2.70 (dd, J = 14.1, 3.7 Hz, 1H), 2.46 (td, J = 
7.6, 6.6, 2.4 Hz, 2H), 2.40 – 2.30 (m, 2H), 2.17 – 2.06 (m, 1H), 2.05 – 1.98 (m, 1H), 1.97 (t, J 
= 2.6 Hz, 1H), 1.88 – 1.76 (m, 2H), 1.71 (s, 1H), 1.42 (s, 9H), 0.79 (dd, J = 16.8, 6.6 Hz, 6H); 
13C NMR (101 MHz, CD2Cl2-d2) δ 171.59, 170.42, 170.30, 169.58, 169.01, 144.01, 138.08, 
132.47, 128.62, 128.37, 127.88, 127.01, 120.01, 70.70, 69.00, 66.68, 66.55, 60.98, 48.42, 
47.32, 40.10, 34.84, 28.95, 28.57, 28.11, 24.66, 19.49, 18.72, 14.44. MS (MALDI-TOF): m/z 
calcd for [C55H67NaN7O9]+: 993.16 [M + Na]+; found: 993.20 (HCCA matrix), 993.22 (SA matrix). 
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Aliphatic alkyne-Asn-Pro-[D]-Val-PTX (138) 
 
A solution of Boc-protected compound 137 (50 mg, 0.052 mmol, 1 equiv) in dry CH2Cl2 (1.8 
mL) was cooled to 0 °C under a nitrogen atmosphere and TFA (900 μL) was added. The 
mixture was then allowed to reach room temperature and stirred for 15 min. The solvent was 
removed affording the corresponding trifluoroacetate salt, without further purifications. The 
solid was dissolved in dry DMF (800 μL) and iPr2NEt (37 µL, 0.208 mmol, 4 equiv). The 
resulting solution was added at 0 °C to a stirred solution of 95 (55 mg, 0.057 mmol, 1.1 equiv) 
in dry DMF (800 μL), under a nitrogen atmosphere. The reaction was then allowed to reach 
room temperature and stirred overnight. AcOEt (100 mL) was added and the solution was 
washed with a 1 M aqueous solution of KHSO4 (2 × 10 mL) and brine (1 × 15 mL). The organic 
phase was dried over Na2SO4 and concentrated, then the crude was purified by flash 
chromatography [gradient: from CH2Cl2 100% to 95:5 CH2Cl2/MeOH] to afford carbamate 138 
as a light-yellow solid (41 mg, 54% yield over two steps). 
Rf = 0.19 (95:5, CH2Cl2/MeOH); MS (MALDI-TOF): m/z calcd for [C79H94NaN8O22]+: 1530.65 
[M + Na]+; found: 1530.08 (HCCA matrix), 1530.52 (SA matrix); HRMS (ESI+): m/z calcd for 
[C79H94NaN8O22]+: 1529.64 [M + Na]+: found 1529.63. 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-[D]-Val-PTX conjugate (123) 
 
Alkyne 138 (5.6 mg, 0.0036 mmol, 1.2 equiv) and azide 86 (3 mg, 0.003 mmol, 1 equiv) were 
reacted following General Procedure GP3. The solvent was removed under vacuum, and the 
crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
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CF3COOH) in 20 min; tR (product)=12.2 min]. The purified product was then freeze-dried to 
give the desired compound 123 as a white solid (5 mg, 70% yield). 
MS (MALDI-TOF): m/z calcd for [C116H150N21O35]+: 2398.52 [M + H]+; found: 2398.29 (HCCA 
matrix), 2399.52 (SA matrix); m/z calcd for [C116H149NaN21O35]+: 2420.22 [M + Na]+; found: 
2420.32 (HCCA matrix), 2420.52 (SA matrix); HRMS (ESI+): m/z calcd for 
[C116H150NaN21O35]2+: 1210.02 [M + H + Na]2+; found: 1210.03; m/z calcd for 
[C116H150Na2N21O35]3+: 814.34 [M + H + 2Na]3+; found: 814.35. 
cyclo[DKP-RGD]-Uncleavable-PTX (124) 
tert-butyl methyl(2-(N-methylpent-4-ynamido)ethyl)carbamate (140) 
 
Commercial 4-pentynoic acid (78 mg, 0.796 mmol, 1.5 equiv) in dry DMF (4 mL) was cooled 
to 0 °C under a nitrogen atmosphere. HATU (343 mg, 0.902 mmol, 1.7 equiv), HOAt (123 mg, 
0.902 mmol, 1.7 equiv) and iPr2NEt (370 µL, 2.124 mmol, 4 equiv) were added and the mixture 
was stirred for 20 min at 0 °C. A solution of N-(Boc)-N,N′-dimethylethylenediamine 139 (100 
mg, 0.531 mmol, 1 equiv) in dry DMF (5 mL) was added to the stirred mixture. The reaction 
was allowed to slowly reach room temperature and stirred overnight. The mixture was diluted 
with an AcOEt/CH2Cl2, 4:1 mixture (100 mL) and washed with 1 M aqueous solution of KHSO4 
(2 × 15 mL), a saturated aqueous solution of NaHCO3 (1 × 15 mL) and brine (1 × 20 mL). The 
organic phase was dried over Na2SO4 and concentrated. The solid was purified by flash 
chromatography [eluent: CH2Cl2 100%] to afford amide 140 as dark yellow oil (140 mg, 98%). 
Rf = 0.46 (95:5, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 3.43 – 3.31 (m, 2H), 3.24 (t, 
J = 6.2 Hz, 2H), 2.91 (s, rotamer A, 3H), 2.83 (s, rotamer B, 3H), 2.75 (s, rotamer A + B, 3H), 
2.49 – 2.36 (m, 4H), 1.90 (q, J = 2.2 Hz, 1H), 1.35 (s, rotamer A + B, 9H); 13C NMR (101 MHz, 
CD2Cl2-d2) δ 171.14, 156.27, 84.35, 79.57, 68.74, 48.30 (rotamer A), 48.09 (rotamer B), 47.72, 
46.95 (rotamer A), 46.60 (rotamer B), 46.22 (rotamer A), 45.72 (rotamer B), 36.35 (rotamer A), 
35.05, 34.24 (rotamer B), 33.08 (rotamer A), 32.20 (rotamer B), 28.71, 15.04 (rotamer A), 14.76 
(rotamer B). MS (ESI +): m/z calcd for [C14H25N2O3]+: 269.10 [M + H]+; found: 269.09. 
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Aliphatic alkyne-PTX (141) 
 
A solution of Boc-protected compound 140 (67 mg, 0.249 mmol, 1 equiv) was deprotected 
following General Procedure GP1. The resulting dark yellow oil was dissolved in dry DMF (0.5 
mL) and iPr2NEt (87 µL, 0.5 mmol, 10 equiv). The resulting solution was added at 0 °C to a 
stirred solution of 95 (50 mg, 0.05 mmol, 1 equiv) in dry DMF (1 mL), under a nitrogen 
atmosphere. The reaction was then allowed to reach room temperature and stirred overnight. 
AcOEt (50 mL) was added and the solution was washed with a 1 M aqueous solution of KHSO4 
(2 × 5 mL) and brine (1 × 5 mL). The organic phase was dried over Na2SO4 and concentrated, 
then the crude was purified by flash chromatography [gradient: from AcOEt/n-Hexane 1:1 to 
4:1] to afford carbamate 141 as a white solid (41 mg, 84% yield over two steps). 
Rf = 0.31 (4:1, AcOEt/n-Hexane 1:1); 1H NMR (400 MHz, CDCl3-d) δ 8.71 (d, J = 9.8 Hz, 1H), 
8.21 – 8.15 (m, 2H), 7.87 – 7.79 (m, 2H), 7.61 – 7.55 (m, 1H), 7.54 – 7.46 (m, 5H), 7.44 – 7.34 
(m, 5H), 7.33 – 7.27 (m, 2H), 6.35 – 6.28 (m, 2H), 6.19 (dd, J = 9.8, 3.0 Hz, 1H), 5.69 (d, J = 
7.3 Hz, 1H), 5.45 (d, J = 3.0 Hz, 1H), 5.00 (dd, J = 10.0, 2.3 Hz, 1H), 4.47 (td, J = 6.8, 3.3 Hz, 
1H), 4.35 – 4.29 (m, 1H), 4.24 (dd, J = 8.4, 1.0 Hz, 1H), 4.00 – 3.89 (m, 1H), 3.84 (d, J = 7.1 
Hz, 1H), 3.64 – 3.54 (m, 1H), 3.12 – 3.06 (m, 1H), 3.05 – 2.98 (m, 4H), 2.98 – 2.94 (m, 2H), 
2.90 (s, 3H), 2.63 – 2.52 (m, 5H), 2.51 – 2.46 (m, 3H), 2.24 – 2.21 (m, 3H), 1.99 (d, J = 1.4 Hz, 
3H), 1.93 (t, J = 2.6 Hz, 2H), 1.69 (s, 3H), 1.23 (s, 3H), 1.13 (s, 3H); 13C NMR (101 MHz, CDCl3-
d) δ 133.56, 131.28, 130.31, 128.75, 128.67, 127.97, 127.95, 127.75, 126.81, 84.51, 83.14, 
77.22, 76.48, 75.82, 75.71, 75.24, 72.14, 71.35, 52.73, 46.76, 45.80, 45.57, 36.78, 35.81, 
35.55, 35.52, 32.34, 30.32, 29.69, 26.78, 22.79, 22.69, 22.35, 20.82, 14.88, 14.25, 14.11, 9.66. 
MS (MALDI-TOF): m/z calcd for [C57H66N3O16]+: 1049.14 [M + H]+; found: 1049.22 (HCCA 
matrix); m/z calcd for [C57H65NaN3O16]+: 1071.14 [M + Na]+; found: 1071.26. 
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cyclo[DKP-RGD]-Uncleavable-PTX (124) 
 
Alkyne 141 (7 mg, 0.0065 mmol, 1.3 equiv) and azide 86 (5 mg, 0.005 mmol, 1 equiv) were 
reacted following General Procedure GP3. The solvent was removed under vacuum, and the 
crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
CF3COOH) in 20 min; tR (product)=12.1 min]. The purified product was then freeze-dried to 
give the desired compound 124 as a white solid (9.7 mg, 100% yield). 
MS (MALDI-TOF): m/z calcd for [C94H121N16O29]+: 1939.05 [M + H]+; found: 1939.70 (HCCA 
matrix); HRMS (ESI+): m/z calcd for [C94H121N16O29]+: 1937.85, [M + H]+; found 1937.85; m/z 
calcd for [C94H120NaN16O29]+: 1959.83 [M + Na]+; found 1959.83; m/z calcd for 
[C94H120Na2N16O29]2+: 991.41 [M + 2Na]2+ found: 991.41; m/z calcd for [C94H121NaN16O29]2+: 
980.41 [M + H + Na]2+; found: 980.42; m/z calcd for [C94H120Na3N16O29]2+: 1002.40 [M + 3Na]2+; 
found: 1002.41. 
Pro-PTX (142) 
PTX-N-(Boc)-N,N′-dimethylethylenediamine (143) 
 
Compound 95 (10 mg, 0.01 mmol, 1 equiv) was solubilized in dry DMF (150 µL) under nitrogen. 
A mixture of N-(Boc)-N,N′-dimethylethylenediamine 139 (3 mg, 0.015 mmol, 1.5 equiv) in dry 
DMF (150 µL mL) and iPr2NEt (6 µL, 0.03 mmol, 3 equiv) were added to 95 at 0 ºC under 
nitrogen. The mixture was stirred overnight at room temperature. AcOEt (20 mL) was added 
and the solution was washed with 1 M aqueous solution of KHSO4 (2 × 10 mL) and brine (20 
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mL). The organic phase was dried and concentrated. The crude was purified by preparative 
TLC (gradient: 65:35 AcOEt/n-Hexane), affording 143 (10 mg, 95% yield) as a fade white solid. 
Rf = 0.29 (3:2 AcOEt/n-Hexane); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.65 (d, J = 9.7 Hz, 1H), 
8.21 – 8.09 (m, 2H), 7.82 – 7.73 (m, 2H), 7.63 (t, J = 7.2 Hz, 1H), 7.55 (q, J = 8.1, 7.6 Hz, 4H), 
7.47 – 7.25 (m, 6H), 6.31 – 6.20 (m, 2H), 6.13 (dd, J = 9.9, 2.8 Hz, 1H), 5.64 (d, J = 7.1 Hz, 
1H), 5.31 (dd, J = 10.2, 2.3 Hz, 1H), 5.00 (dd, J = 9.8, 2.3 Hz, 1H), 4.46 (dd, J = 11.1, 6.6 Hz, 
1H), 4.33 – 4.26 (m, 1H), 4.22 – 4.13 (m, 1H), 4.11 – 4.00 (m, 1H), 3.80 (dd, J = 15.0, 7.0 Hz, 
1H), 3.64 – 3.46 (m, 2H), 2.88 (d, J = 8.3 Hz, 6H), 2.59 (s, 3H), 2.55 – 2.49 (m, 1H), 2.41 (t, J 
= 7.5 Hz, 1H), 2.20 (s, 3H), 2.12 (dd, J = 15.5, 9.2 Hz, 1H), 1.96 (s, 3H), 1.89 (s, 2H), 1.81 
(ddd, J = 14.0, 10.8, 2.3 Hz, 2H), 1.63 (s, 3H), 1.27 (s, 9H), 1.19 (s, 3H), 1.10 (s, 3H); 13C NMR 
(101 MHz, CD2Cl2-d2) δ 204.57, 171.92, 170.62, 169.58, 168.77, 167.34, 156.24, 155.40, 
143.96, 138.24, 135.14, 134.22, 134.10, 133.05, 131.71, 130.78, 130.07, 129.26, 129.08, 
128.68, 128.33, 127.63, 84.90, 81.49, 80.49, 79.64, 76.87, 76.53, 76.27, 75.74, 72.75, 72.18, 
71.85, 59.00, 53.36, 46.92, 46.77, 46.25, 43.71, 36.32, 36.25, 36.14, 35.81, 30.26, 28.54, 
27.10, 23.34, 22.62, 21.21, 15.15, 10.02. MS (MALDI-TOF): m/z calcd for [C57H70N3O17]+: 
1069.17 [M + H]+; found: 1069.00 (HCCA matrix); m/z calcd for [C57H69NaN3O17]+: 1091.17 [M 
+ Na]+; found: 1091.36 (HCCA matrix). 
Pro-PTX·TFA (142) 
 
To a solution of CH2Cl2/TFA (1:1, 300 µL), compound 143 (10 mg, 0.0095 mmol, 1 equiv) in 
dry CH2Cl2 (200 µL) was added, under nitrogen, at 0 ºC. The mixture was stirred for 20 minutes 
at room temperature. The solvent was removed under reduced pressure and the crude was 
purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; gradient: 90% 
(H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% CF3COOH) 
in 20 min; tR (product)=13 min]. The purified product was then freeze-dried to give the desired 
compound 142 as a white solid (7 mg, 68% yield).  
MS (MALDI-TOF): m/z calcd for [C52H62N3O15]+: 969.05 [M + H]+; found: 969.20 (HCCA matrix); 
m/z calcd for [C52H61NaN3O15]+: 991.05 [M + Na]+; found: 991.23; HRMS (ESI+): m/z calcd for 
[C52H62N3O15]+: 968.41 [M + H]+; found: 968.42. 
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cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAE (145) 
Aliphatic alkyne-Val-Ala-PABA (152) 
 
The previously synthesized Fmoc-Val-Ala-PABA 151[130] (800 mg, 1.55 mmol, 1 equiv) was 
deprotected following General Procedure GP2. Commercial 4-pentynoic acid (228 mg, 2.325 
mmol, 1.5 equiv) in dry DMF (5 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU 
(999 mg, 2.635 mmol, 1.7 equiv), HOAt (359 mg, 2.635 mmol, 1.7 equiv) and iPr2NEt (1.1 mL, 
6.20 mmol, 4 equiv) were added and the mixture was stirred for 20 min at 0 °C. A solution of 
151-NH in dry DMF (15 mL) was added to the stirred mixture. The reaction was allowed to 
slowly reach room temperature and stirred overnight. The mixture was dried at rotavapor under 
reduced pressure. The remained oil was purified by flash chromatography [gradient: from 
CH2Cl2/MeOH (98:2) to CH2Cl2/MeOH (90:10)] to afford amide 152 as a white solid (550 mg, 
90% yield over two steps).  
Rf = 0.21 (9:1, CH2Cl2/AcOEt); 1H NMR (400 MHz, MeOD-d4) δ 7.55 (d, J = 8.5 Hz, 2H), 7.30 
(d, J = 8.5 Hz, 2H), 4.55 (s, 2H), 4.48 (q, J = 7.1 Hz, 1H), 4.21 (d, J = 7.0 Hz, 1H), 2.58 – 2.42 
(m, 4H), 2.26 (t, J = 2.5 Hz, 1H), 2.09 (hept, J = 6.8 Hz, 1H), 1.43 (d, J = 7.1 Hz, 3H), 0.99 (d, 
J = 7.0 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, MeOD-d4) δ 174.37, 173.57, 
172.93, 138.73, 138.65, 128.58, 121.17, 83.65, 70.39, 64.83, 60.39, 51.06, 35.76, 31.81, 
19.72, 18.71, 18.00, 15.64. MS (ESI+): m/z calcd for [C20H28N3O4]+: 373.20 [M + H]+: found: 
373.41. 
Aliphatic alkyne-Val-Ala-PABC-PNP (153)  
 
A solution of compound 152 in a mixture of dry THF (78 mL) under nitrogen atmosphere was 
cooled to 0 °C. Pyridine (270 μL, 3.33 mmol, 2.5 equiv) and 4-nitrophenylchloroformate (537 
mg, 2.66 mmol, 2 equiv) were added, then the mixture could reach room temperature and 
stirred for 2 h. The reaction mixture was concentrated under reduced pressure and AcOEt (50 
mL) was added and the solution was washed with a 1 M aqueous solution of KHSO4 (3 × 20 
mL) and brine (20 mL). The organic phase was dried and concentrated, then the crude was 
purified by flash chromatography [eluent: 2:8, n-Hexane/EtOAc] affording compound 153 (460 
mg, 65% yield) as a white solid. 
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Rf = 0.19 (2:8, n-Hexane/EtOAc); 1H NMR (400 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.31 (d, J = 
9.1 Hz, 2H), 8.21 (d, J = 6.9 Hz, 1H), 7.94 (d, J = 8.6 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.57 
(d, J = 9.1 Hz, 2H), 7.41 (d, J = 8.7 Hz, 2H), 5.24 (s, 2H), 4.39 (p, J = 7.0 Hz, 1H), 4.21 (dd, J 
= 8.6, 6.7 Hz, 1H), 2.74 (t, J = 2.2 Hz, 1H), 2.48 – 2.30 (m, 4H), 1.97 (h, J = 6.8 Hz, 1H), 1.31 
(d, J = 7.1 Hz, 3H), 0.87 (dd, J = 15.7, 6.7 Hz, 6H); 13C NMR (101 MHz, DMSO-d6) δ 171.23, 
170.86, 170.52, 155.26, 151.91, 145.15, 139.42, 129.44, 125.37, 122.58, 119.00, 83.78, 71.21, 
70.23, 57.53, 49.06, 33.96, 30.49, 19.14, 18.13, 17.82, 14.25. MS (ESI+): m/z calcd for 
[C27H31N4O8]+: 538.21 [M + H]+; found: 538.22. 
Aliphatic alkyne-Val-Ala-PABC-MMAE (154)  
 
Compound 153 (20 mg, 0.037 mmol, 1 equiv) and HOBt (3 mg, 0.019 mmol, 0.5 equiv) were 
dissolved in dry DMF under argon atmosphere. Commercial MMAE (32 mg, 0.044 mmol, 1.2 
equiv) was solubilized in dry DMF:Pyridine (4:1, 600 µL, reaction total volume) and DIPEA (6 
µL, 0.033 mmol, 0.9 equiv) and added to the starting material solution at 0 ºC, under argon 
atmosphere. Then, the mixture was allowed to reach room temperature and stirred over 
weekend under argon atmosphere. The reaction mixture was diluted with AcOEt (150 mL) the 
solution was washed with a 1 M aqueous solution of KHSO4 (3 × 20 mL) and brine (20 mL). 
The organic phase was dried with Na2SO4 and concentrated, then the crude was purified by 
flash chromatography [gradient: from 99:1, CH2Cl2/MeOH to 95:5, CH2Cl2/MeOH] affording 
compound 154 (40 mg, 95% yield) as a white solid. 
Rf = 0.35 (95:5, CH2Cl2/MeOH); MS (ESI+): m/z calcd for [C60H93N8O12]+: 1117.68 [M + H]+; 
found: 1118.01. HRMS (ESI+): m/z calcd for [C60H92NaN8O12]+: 1139.67 [M + Na]+; found 
1139.67. 
cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAE (145) 
 
Alkyne 154 (7 mg, 0.006 mmol, 1.2 equiv) and azide 86 (5 mg, 0.005 mmol, 1 equiv) were 
reacted following General Procedure GP3. The solvent was removed under vacuum, and the 
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crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
CF3COOH) in 20 min; tR (product)=12 min]. The purified product was then freeze-dried to give 
the desired compound 145as a white solid (6.7 mg, 65% yield). 
MS (MALDI-TOF): m/z calcd for [C97H148N21O25]+: 2007.33 [M + H]+; found: 2007.77; (HCCA 
matrix), 2009.6 (SA matrix); HRMS (ESI+): m/z calcd for [C97H148N21O25]+: 2007.096 [M + H ]+; 
found: 2007.093; m/z calcd for [C97H148NaN21O25]2+: 1015.045 [M + H + Na]2+; found 1015.042; 
m/z calcd for [C97H148Na2N21O25]3+: 684.363 [M + H + 2Na]3+; found: 684.360. 
HOOC-PEG-4-Val-Ala-MMAE (147) 
 
Alkyne 154 (5 mg, 0.006 mmol, 1 equiv) and azide-COOH 91 (1.7 mg, 0.006 mmol, 1 equiv) 
were reacted following General Procedure GP3. The solvent was removed under vacuum, and 
the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm 
column; gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% 
(CH3CN+0.1% CF3COOH) in 20 min; tR (product)=13 min]. The purified product was then 
freeze-dried to give the desired compound 147 as a white solid (2.6 mg, 30% yield). 
MS (MALDI-TOF): m/z calcd for [C70H112N11O18]+: 1395.69 [M + H]+; found: 1395.70; (HCCA 
matrix), 1395.85 (SA matrix); HRMS (ESI+): m/z calcd for [C70H112N11O18]+: 1394.82 [M + H]+; 
found 1394.82; m/z calcd for [C70H111Na2N11O18]2+: 719.91 [M + 2Na]2+; found: 719.89; m/z 
calcd for [C70H110Na3N11O18]2+: 730.90 [M + 3Na - H]2+; found: 730.88. 
cyclo[DKP-RGD]-Uncleavable-MMAE (148) 
Aliphatic alkyne-MMAE (155)  
 
Commercial 4-pentynoic acid (4.2 mg, 0.042 mmol, 1.5 equiv) in dry DMF (0.5 mL) was cooled 
to 0 °C under a nitrogen atmosphere. HATU (19 mg, 0.048 mmol, 1.7 equiv), HOAt (7 mg, 
0.048 mmol, 1.7 equiv) and iPr2NEt (20 µL, 0.112 mmol, 4 equiv) were added and the mixture 
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was stirred for 20 min at 0 °C. A solution of commercial MMAE in dry DMF (1 mL) was added 
to the stirred mixture. The reaction was allowed to slowly reach room temperature and stirred 
overnight. The mixture was diluted with AcOEt (30 mL), washed with 1 M aqueous solution of 
KHSO4 (2 × 10 mL) and brine (1 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated. The solid was purified by flash chromatography [gradient: from 
CH2Cl2/MeOH 97:2 to 97:] to afford amide 155 as white solid (20 mg, 90% yield). 
Rf = 0.30 (97:3, CH2Cl2/MeOH); MS (ESI+) m/z calcd for [C44H72N5O8]+: 798.06 [M + H]+; found: 
798.09; HRMS (ESI+): m/z calcd for [C44H71NaN5O8]+: 820.52 [M + Na]+; found: 820.51. 
cyclo[DKP-RGD]-Uncleavable-MMAE (148) 
 
Alkyne 155 (4 mg, 0.004 mmol, 1.2 equiv) and azide 86 (5 mg, 0.004 mmol, 1 equiv) were 
reacted following the General Procedure GP3. The solvent was removed under vacuum, and 
the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm 
column; gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% 
(CH3CN+0.1% CF3COOH) in 20 min; tR (product)=10.8 min]. The purified product was then 
freeze-dried to give the desired compound 148 as a white solid (5.5 mg, 83% yield). 
MS (MALDI-TOF): m/z calcd for [C81H127N18O21]+: 1688.98 [M + H]+; found: 1688.90; (SA 
matrix), 1688.00 (HCCA matrix); HRMS (ESI+): m/z calcd for [C81H127N18O21]+: 1687.94 [M + 
H]+; found: 1687.94; m/z calcd for [C81H127NaN18O21]2+: 855.47 [M + Na + H]2+; found: 855.46. 
HOOC-Uncleavable-MMAE (156) 
 
Alkyne 155 (4 mg, 0.005 mmol, 1 equiv) and azide-COOH 91 (1.4 mg, 0.004 mmol, 1 equiv) 
were reacted following the General Procedure GP3. The solvent was removed under vacuum, 
and the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm 
column; gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% 
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(CH3CN+0.1% CF3COOH) in 20 min; tR (product)=12 min]. The purified product was then 
freeze-dried to give the desired compound 156 as a white solid (2.4 mg, 45% yield). 
MS (MALDI-TOF): m/z calcd for [C54H91N8O14]+: 1075.34 [M + H]+; found: 1075.35; (SA matrix), 
1075.55 (HCCA matrix); HRMS (ESI+): m/z calcd for [C54H91N8O14]+: 1075.670 [M + H]+; found: 
1075.665; m/z calcd for [C54H90NaN8O14]+: 1097.65 [M + Na]+; found: 1097.64; m/z calcd for 
[C54H90Na2N8O14]2+: 560.33 [M + 2Na]2+; found: 560.32. 
cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAF (146) 
Aliphatic alkyne-Val-Ala-PABC-MMAF (157)  
 
Compound 153 (20 mg, 0.037 mmol, 1 equiv) and HOBt (3 mg, 0.019 mmol, 0.5 equiv) were 
dissolved in dry DMF under argon atmosphere. Commercial MMAF·TFA (37 mg, 0.044 mmol, 
1.2 equiv) is solubilized in dry DMF:Pyridine (4:1, 600 µL, reaction total volume) and DIPEA 
(12 µL, 0.066 mmol, 1.8 equiv) and added to the starting material solution at 0 ºC, under argon 
atmosphere. Then, the mixture was allowed to reach room temperature and stirred over 
weekend under argon atmosphere. The reaction mixture was concentrated at the rotavapor 
and the crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm 
column; gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% 
(CH3CN+0.1% CF3COOH) in 20 min; tR (product)=10.0 min]. The purified product was then 
freeze-dried to give the desired compound 157 as a white solid (23 mg, 55% yield). 
MS (MALDI-TOF): m/z calcd for [C60H91N8O13]+: 1131.40 [M + H]+; found: 1132.00; (SA matrix), 
1132.01 (HCCA matrix); m/z calcd for [C60H90N8O13]+: 1153.02 [M + Na]+; found: 1153.00; (SA 
matrix), 1153.01 (HCCA matrix). 
cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAF (146) 
 
Alkyne 157 (5.5 mg, 0.0048 mmol, 1.2 equiv) and azide 86 (4 mg, 0.004 mmol, 1 equiv) were 
reacted according General Procedure GP3. The solvent was removed under vacuum, and the 
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crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
CF3COOH) in 20 min; tR (product)=12 min]. The purified product was then freeze-dried to give 
the desired compound 146 as a white solid (7.6 mg, 95% yield). 
MS (MALDI-TOF): m/z calcd for [C97H146N21O26]+: 2022.31 [M + H]+; found: 2022.35; (SA 
matrix), 2022.85 (HCCA matrix); HRMS (ESI+): m/z calcd for [C97H146N21O26]+: 2021.07 [M + 
H]+; found: 2021.07; m/z calcd for [C97H146NaN21O26]2+: 1022.04 [M + Na + H]2+; found: 1022.03. 
 cyclo[DKP-RGD]-Uncleavable-MMAF (149) 
Aliphatic alkyne-MMAF (158)  
 
Commercial 4-pentynoic acid (3.5 mg, 0.036 mmol, 1.5 equiv) in dry DMF (0.4 mL) was cooled 
to 0 °C under a nitrogen atmosphere. HATU (16 mg, 0.041 mmol, 1.7 equiv), HOAt (6 mg, 
0.041 mmol, 1.7 equiv) and iPr2NEt (21 µL, 0.120 mmol, 5 equiv) were added and the mixture 
was stirred for 20 min at 0 °C. A solution of commercial MMAF·TFA in dry DMF (1 mL) was 
added to the stirred mixture. The reaction was allowed to slowly reach room temperature and 
stirred overnight. The reaction mixture was concentrated at the rotavapor and the crude 
residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
CF3COOH) in 20 min; tR (product)=10.2 min]. The purified product was then freeze-dried to 
give the desired compound 158 as a white solid (16 mg, 82% yield). 
MS (MALDI-TOF): m/z calcd for [C44H70N5O9]+: 812.05 [M + H]+; found: 812.05; (SA matrix), 
812.05 (HCCA matrix); m/z calcd for [C44H69NaN5O9]+: 835.05 [M + Na]+; found: 835.20; (SA 
matrix), 835.18 (HCCA matrix). 
cyclo[DKP-RGD]-Uncleavable-MMAF (149) 
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Alkyne 158 (4 mg, 0.0048 mmol, 1.2 equiv) and azide 86 (4 mg, 0.004 mmol, 1 equiv) were 
reacted following General Procedure GP3. The solvent was removed under vacuum, and the 
crude residue was purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; 
gradient: 90% (H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% 
CF3COOH) in 20 min; tR (product)=11.0 min]. The purified product was then freeze-dried to 
give the desired compound 149 as a white solid (6.3 mg, 95% yield). 
MS (MALDI-TOF): m/z calcd for [C81H125N18O22]+: 1701.96 [M + H]+; found: 1702.01; (SA 
matrix), 1701.91; HRMS (ESI+): m/z calcd for [C81H125N18O22]+: 1701.92 [M + H]+; found: 
1701.92; m/z calcd for [C81H125NaN18O22]2+: 862.95 [M + Na + H]2+; found: 862.96. 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-Val-MMAE (150) 
Aliphatic alkyne-Asn(Trt)-Pro-Val-PABA (160) 
 
Fmoc-Asn(Trt)-Pro-Val-PABA 159 (425 mg, 0.473 mmol, 1 equiv) was deprotected following 
General Procedure GP2. Commercial 4-pentynoic acid (70 mg, 0.709 mmol, 1.5 equiv) in dry 
DMF (4 mL) was cooled to 0 °C under a nitrogen atmosphere. HATU (310 mg, 0.804 mmol, 
1.7 equiv), HOAt (110 mg, 0.804 mmol, 1.7 equiv) and iPr2NEt (330 µL, 1.892 mmol, 4 equiv) 
were added and the mixture was stirred for 20 min at 0 °C. A solution of 159-NH in dry DMF 
(8 mL) was added to the stirred mixture. The reaction was allowed to slowly reach room 
temperature and stirred overnight. The mixture was dried at rotavapor under reduced pressure. 
The remained oil was purified by flash chromatography (gradient: from CH2Cl2 100% to 
CH2Cl2/MeOH, 95:5) to afford amide 160 as fade white solid (227 mg, 65% yield over two 
steps). Rf = 0.26 (97:3, CH2Cl2/MeOH); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.62 (s, 1H), 7.90 (d, 
J = 8.5 Hz, 2H), 7.74 (s, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.33 – 7.16 (m, 18H), 4.61 – 4.49 (m, 
2H), 4.43 (td, J = 11.4, 7.9 Hz, 1H), 4.27 (dd, J = 9.1, 3.5 Hz, 1H), 3.97 (t, J = 8.7 Hz, 1H), 3.25 
(q, J = 8.7 Hz, 1H), 2.76 (t, J = 13.0 Hz, 1H), 2.50 (td, J = 10.1, 8.9, 3.4 Hz, 1H), 2.46 – 2.39 
(m, 2H), 2.33 – 2.20 (m, 3H), 2.14 – 2.04 (m, 1H), 1.99 (t, J = 2.6 Hz, 1H), 1.92 – 1.80 (m, 2H), 
1.78 – 1.69 (m, 1H), 1.51 – 1.40 (m, 1H), 0.78 (d, J = 6.6 Hz, 3H), 0.38 (d, J = 6.6 Hz, 3H); 13C 
NMR (101 MHz, CD2Cl2-d2) δ 172.85, 171.93, 170.88, 170.38, 169.71, 144.56, 138.31, 137.76, 
129.33, 128.51, 128.45, 127.52, 121.16, 71.33, 69.52, 65.41, 62.30, 60.58, 48.00, 47.88, 
40.27, 35.25, 30.40, 30.26, 28.09, 25.13, 20.18, 19.44, 14.86. MS (MALDI-TOF): m/z calcd for 
[C45H49NaN5O6]+: 778.90 [M + Na]+: found 778.30. 
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Aliphatic alkyne-Asn(Trt)-Pro-Val-PABC-PNP (161) 
 
A solution of compound 160 (210 mg, 0.278 mmol, 1 equiv) in dry THF (16 mL) under nitrogen 
atmosphere was cooled to 0 °C. Pyridine (60 μL, 0.695 mmol, 2.5 equiv) and 4-
nitrophenylchloroformate (115 mg, 0.556 mmol, 2 equiv) were added, then the mixture could 
reach room temperature and stirred for 2 h. The reaction mixture was concentrated under 
reduced pressure and AcOEt (100 mL) was added and the solution was washed with a 1 M 
aqueous solution of KHSO4 (3 × 30 mL) and brine (20 mL). The organic phase was dried and 
concentrated, then the crude was purified by flash chromatography (eluent: 1:9, n-
Hexane/EtOAc) affording compound 161 (160 mg, 64% yield) as a white solid. 
Rf = 0.29 (1:9, n-Hexane/EtOAc); 1H NMR (400 MHz, CD2Cl2-d2) δ 8.45 (s, 1H), 8.25 (d, J = 
9.2 Hz, 2H), 7.78 – 7.71 (m, 3H), 7.43 – 7.36 (m, 4H), 7.29 (s, 1H), 7.27 – 7.20 (m, 9H), 7.18 
– 7.13 (m, 6H), 6.58 (d, J = 8.0 Hz, 1H), 5.24 (d, J = 2.0 Hz, 2H), 4.72 (ddd, J = 11.3, 8.1, 3.0 
Hz, 1H), 4.13 (dd, J = 8.7, 3.8 Hz, 1H), 3.93 (t, J = 8.1 Hz, 1H), 3.29 (q, J = 8.6 Hz, 1H), 2.97 
(d, J = 13.7 Hz, 1H), 2.65 (dd, J = 13.7, 2.8 Hz, 1H), 2.61 – 2.53 (m, 1H), 2.49 – 2.44 (m, 2H), 
2.43 – 2.38 (m, 2H), 1.98 (t, J = 2.5 Hz, 1H), 1.78 – 1.63 (m, 4H), 1.51 – 1.39 (m, 1H), 0.71 (d, 
J = 6.8 Hz, 3H), 0.40 (d, J = 6.6 Hz, 3H); 13C NMR (101 MHz, CD2Cl2-d2) δ 172.40, 171.69, 
170.98, 170.92, 169.63, 156.16, 153.09, 146.03, 144.28, 139.84, 130.21, 130.14, 129.13, 
128.51, 127.66, 125.80, 122.54, 120.40, 83.43, 71.35, 71.29, 69.57, 62.26, 61.20, 48.32, 
48.14, 41.17, 35.25, 30.26, 29.42, 25.12, 19.96, 19.91, 15.00; MS (MALDI-TOF): m/z calcd for 
[C52H52NaN6O10]+: 944.00 [M + Na]+: found 944.21. 
Aliphatic alkyne-Asn(Trt)-Pro-Val-PABC-MMAE (162)  
 
Compound 161 (20 mg, 0.022 mmol, 1 equiv) and HOBt (2 mg, 0.011 mmol, 0.5 equiv) were 
dissolved in dry DMF under argon atmosphere. Commercial MMAE (19 mg, 0.026 mmol, 1.2 
equiv) was solubilized in dry DMF:Pyridine (4:1, 400 µL, reaction total volume) and DIPEA (4 
µL, 0.020 mmol, 0.9 equiv) and added to the starting material solution at 0 ºC, under argon 
atmosphere. Then, the mixture was allowed to reach room temperature and stirred over 
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weekend under argon atmosphere. The reaction mixture was diluted with AcOEt (100 mL) the 
solution was washed with a 1 M aqueous solution of KHSO4 (3 × 20 mL) and brine (20 mL). 
The organic phase was dried with Na2SO4 and concentrated, then the crude was purified by 
flash chromatography [gradient: from 98:2, CH2Cl2/MeOH to 95:5, CH2Cl2/MeOH] affording 
compound 162 (26 mg, 80% yield) as a white solid. 
Rf = 0.30 (95:5, CH2Cl2/MeOH); MS (ESI+): m/z calcd for [C85H115N10O14]+: 1499.85 [M + H]+; 
found: 1499.75; HRMS (ESI+): m/z calcd for [C85H114NaN10O14]+: 1521.84 [M + Na]+; found: 
1521.84; m/z calcd for [C85H114Na2N10O14]2+: 772.41 [M + 2Na]2+; found: 772.41. 
 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-Val-MMAE (150) 
 
Alkyne 162 (15 mg, 0.01 mmol, 1 equiv) was solubilized in dry CH2Cl2 (0.75 mL) under nitrogen 
atmosphere. Et3SiH (75 µL) and TFA (375 µL) were added at 0 ºC. The reaction mixture stirred 
for 45 min at room temperature and then CH2Cl2 (10 mL) was added. The organic layer was 
washed with H2O (5 mL) and dried with Na2SO4. The CH2Cl2 was evaporated at rotavapor 
affording a white solid, which was used directly without purification. Resulting alkyne (13 mg, 
0.00952 mmol, 1.4 equiv) and azide 86 (6.9 mg, 0.0068 mmol, 1 equiv) were reacted following 
General Procedure GP3. The solvent was removed under vacuum, and the crude residue was 
purified by semipreparative HPLC [Waters Atlantis 21 mm x 10 cm column; gradient: 90% 
(H2O+0.1% CF3COOH)/10% (CH3CN+0.1% CF3COOH) to 100% (CH3CN+0.1% CF3COOH) 
in 20 min; tR (product)=11.5 min]. The purified product was then freeze-dried to give the desired 
compound 150 as a white solid (9.5 mg, 45% yield). 
MS (MALDI-TOF): m/z calcd for [C103H156N23O27]+: 2148.45 [M + H]+; found: 2148.44; (SA 
matrix), 2148.51; HRMS (ESI+): m/z calcd for [C103H156N23O27]+: 2147.15 [M + H]+; found: 
2147.15; m/z calcd for [C103H156NaN23O27]2+: 1085.08 [M + Na + H]2+; found: 1085.07; m/z calcd 
for [C103H156Na2N23O27]3+: 731.05 [M + 2Na + H]3+; found: 731.04. 
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HPLC Traces of the Final Products 
cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX aliphatic scaffold (97) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: 98% 
 
cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX aromatic scaffold (102) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: 98% 
 
(cyclo[DKP-RGD]-PEG-4)2-Val-Ala-PTX (103) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 26 min. Purity: >99% 
 
(cyclo[DKP-RGD]-PEG-4)3-Val-Ala-PTX (104) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
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(cyclo[DKP-RGD]-PEG-4)4-Val-Ala-PTX (105) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-Val-PTX (121) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: 98% 
 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-[D]-Val-PTX (123) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
cyclo[DKP-RGD]-Uncleavable-PTX (124) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: 96% 
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Pro-PTX (142) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAE (145) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
HOOC-PEG-4-Val-Ala-MMAE (147) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
cyclo[DKP-RGD]-Uncleavable-MMAE (148) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
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HOOC-Uncleavable-MMAE (156) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
cyclo[DKP-RGD]-PEG-4-Val-Ala-MMAF (146) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
 
cyclo[DKP-RGD]-Uncleavable-MMAF (149) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: 97% 
 
cyclo[DKP-RGD]-PEG-4-Asn-Pro-Val-MMAE (150) 
Waters Atlantis 21 mm  10 cm column, gradient from 90% (H2O + 0.1% CF3COOH) / 10% (CH3CN + 
0.1% CF3COOH) to 100% (CH3CN + 0.1% CF3COOH) in 20 min. Purity: >99% 
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14-Azido-3,6,9,12-tetraoxatetradecanoic acid (91) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
Azido-tetraethylene glycol-N-hydroxysuccinimidyl ester (92) 
1H NMR (400 MHz, CD2Cl2-d2) 
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cyclo[DKP-RGD]-PEG-4-N3 (86) 
1H NMR (400 MHz, D2O) 
  
13C NMR (101 MHz, D2O) 
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Aliphatic alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (94) 
1H NMR (500 MHz, [D]6DMSO), T= 70º C 
 
13C NMR (126 MHz, [D]6DMSO), T = 70 ºC 
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Methyl 4-hydroxybenzoate (107) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
Methyl 4-(prop-2-yn-1-yloxy)benzoate (108) 
1H NMR (400 MHz, CD2Cl2-d2) 
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4-(Prop-2-yn-1-yloxy)benzoic acid (109) 
1H NMR (400 MHz, CD3OD) 
 
Aromatic alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118a) 
1H NMR (400 MHz, CD2Cl2-d2) 
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13C NMR (101 MHz, CD2Cl2-d2) 
 
Methyl 3,5-bis(propynyloxy)phenyl acetate (111) 
1H NMR (400 MHz, CDCl3) 
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13C NMR (101 MHz, CDCl3) 
 
3,5-bis(Propynyloxy)phenyl acetic acid (88) 
1H NMR (400 MHz, CD3OD) 
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Bis-alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118b) 
1H NMR (400 MHz, CD3OD + [D]6DMSO) 
  
13C NMR (101 MHz, CD3OD + [D]6DMSO) 
  
  
163 Appendix of NMR Data 
Methyl 2-(3,5-bis(2-((tert-butoxycarbonyl)amino)ethoxy)phenyl)acetate (112) 
1H NMR (400 MHz, CDCl3) 
 
13C NMR (101 MHz, CDCl3) 
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Methyl 2-(3-(2-(2-(3,5-bis(prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)-5-(2-(4-(prop-2-
yn-1-yloxy)benzamido)ethoxy)phenyl)acetate (116) 
1H NMR (600 MHz, CD2Cl2-d2) 
 
13C NMR (151 MHz, CD2Cl2-d2) 
 
  
165 Appendix of NMR Data 
2-(3-(2-(2-(3,5-bis(Prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)-5-(2-(4-(prop-2-yn-1-
yloxy)benzamido)ethoxy)phenyl)acetic acid (89) 
1H NMR (500 MHz, CD3OD)
 
NMR (126 MHz, CD3OD), 13C-DEPT135 
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Tris-alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118c) 
1H NMR (400 MHz, [D]6DMSO) 
 
13C NMR (101 MHz, [D]6DMSO) 
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Methyl 2-(3,5-bis(2-(2-(3,5-bis(prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)phenyl) 
acetate (117) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C NMR (101 MHz, CD2Cl2-d2) 
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2-(3,5-bis(2-(2-(3,5-bis(Prop-2-yn-1-yloxy)phenyl)acetamido)ethoxy)phenyl)acetic acid (90) 
1H NMR (400 MHz, CD3OD)  
 
13C NMR (101 MHz, CD3OD) 
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Tetra-alkyne-Val-Ala-PABC-N-(Boc)-N,N′-dimethylethylenediamine (118d) 
1H NMR (400 MHz, [D]6DMSO)  
 
13C NMR (101 MHz, [D]6DMSO)  
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Fmoc-Asn(Trt)-Pro-OH (126) 
1H NMR (500 MHz, CD2Cl2-d2) 
 
Fmoc-Asn(Trt)-Pro-Val-OH (127) 
1H NMR (500 MHz, CD2Cl2-d2) 
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13C-DEPT45 NMR (126 MHz, CD2Cl2-d2) 
 
Fmoc-Asn(Trt)-Pro-Val-PABC-PNP (128) 
1H NMR (500 MHz, CD2Cl2-d2) 
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13C-APT NMR (126 MHz, CD2Cl2-d2) 
 
Fmoc-Asn(Trt)-Pro-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (129)  
1H NMR (500 MHz, CD2Cl2-d2) 
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13C-APT NMR (126 MHz, CD2Cl2-d2) 
 
4-pentynamido-Asn(Trt)-Pro-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (130)  
1H NMR (500 MHz, CD2Cl2-d2) 
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13C-APT NMR (126 MHz, CD2Cl2-d2) 
 
Fmoc-[D]-Val-PABA (132) 
1H NMR (400 MHz, MeOD-d4) 
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Fmoc-Asn(Trt)-Pro-[D]-Val-PABC-PNP (135)  
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
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Fmoc-Asn(Trt)-Pro-[D]-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (136) 
1H NMR (400 MHz, MeOD-d4) 
 
13C-APT NMR (101 MHz, MeOD-d4) 
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4-pentynamido-Asn(Trt)-Pro-[D]-Val-PABC-N-(Boc)-N,N′-dimethylethylenediamine (137)  
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
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tert-Butyl methyl(2-(N-methylpent-4-ynamido)ethyl)carbamate (140) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
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Aliphatic alkyne-PTX (141) 
1H NMR (400 MHz, CDCl3-d) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
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PTX-N-(Boc)-N,N′-dimethylethylenediamine (143) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
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Aliphatic alkyne-Val-Ala-PABA (152) 
1H NMR (400 MHz, MeOD-d4) 
 
13C-TOTAL NMR (101 MHz, MeOD-d4) 
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Aliphatic alkyne-Val-Ala-PABC-PNP (153)  
1H NMR (400 MHz, DMSO-d6) 
 
13C-TOTAL NMR (101 MHz, DMSO-d6) 
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Aliphatic alkyne-Asn(Trt)-Pro-Val-PABA (160) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
 
  
184 Appendix of NMR Data 
Aliphatic alkyne-Asn(Trt)-Pro-Val-PABC-PNP (161) 
1H NMR (400 MHz, CD2Cl2-d2) 
 
13C-APT NMR (101 MHz, CD2Cl2-d2) 
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